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ABSTRACT 
The reaction of α–toluenesulphonyl chloride with various readily available amino acids 
in basic medium afforded α–toluenesulphonamides (1a-k) which had their acid function 
subsequently amidated with diethyl amine to obtain their corresponding new N,N-
diethylalkanamido substituted α–toluenesulphonamide derivatives (2a-k). The 
electrophilic addition of p-toluenesulphonyl chloride with various amino acids' nitrogen 
gave p-tolylsulphonamide derivatives (4a-k) which upon further reaction of the 
corresponding acid chloride with diethylamine afforded N, N-diethylamido substituted 
moieties (5a-k). Sulphonylation of the amino acids with benzenesulphonyl chloride 
yielded benzenesulphonamides derivatives, (7a-k) which were used as the intermediate 
for the synthesis of the N′, N′-diethylated alkanamido benzenesulphonamide derivatives, 
(8a-k). The chemical structures of synthesized compounds were confirmed using 
elemental analysis and spectroscopic tools which include Fourier Transform-Infrared 
(FT-IR), Mass Spectra, proton and carbon-13 Nuclear Magnetic Resonance (1H- and 13C-
NMR). The antimicrobial properties of the synthesized sulphonamides (fifty five 
compounds) were determined on Staphylococcus aureus and Escherichia coli using agar 
diffusion method where 1-(benzylsulphonyl)pyrrolidine-2-carboxylic acid, (1a) was the 
most active compound against Staphylococcus aureus at MIC value of 1.8 µg/mL while 
4-(3-(diethylamino)-3-oxo-2-(phenylmethylsulphonamido)propyl)phenyl phenyl methane 
sulphonate (2k) and N,N-diethyl-2-(4-methylphenylsulphonamido)-3-phenyl 
propanamide (5j) were the most active on Escherichia coli at MIC of 12.5 µg/mL.    
 
 
 
 
 
 
 
 
CHAPTER ONE 
INTRODUCTION 
1.1. Background of the Study 
 Sulphonamide is a very important class of compounds in the pharmaceutical 
industry that has been attracting a lot of attention (Behmadi et al., 2009; Hopper et al., 
2009). Sulphonamide is one of the most widely used classes of antibiotics in the world 
(Connor, 1998). They contain the functional group (-SO2NH2) which are the amides of 
sulphonic acids. They are obtained by chemical conversion of hydroxyl of sulphonic acid 
into amino group (Connor, 1998). They have been in clinical use since 1968 (Connor, 
1998) and are known to represent a class of medicinally important compounds which are 
extensively used as antibacterial agents (Chohan et al., 2010a). Domagk's discovery of 
antibacterial activity for the azo dye, prontosil led to the first effective chemotherapeutic 
agent, sulphanilamide (Anand and Remer, 2010). The development of sulphonamides is a 
fascinating and informative area in medicinal chemistry, highlighting the role of skillful 
planning and serendipity in drug research (Gadad et al., 2000).  
 In primary care medicine, sulphonamides are widely used in various conditions 
including gastrointestinal (Gadad et al., 2000) and urinary tract infections (Giguere et al., 
2006; Chambers and Jawetz, 1998). Sulphonamide is the organic framework of main 
focus in this research and it belongs to the family of sulphur-containing compounds 
(LaMarche et al., 2011), which are earlier referred to as the sulpha drugs. Some of these 
sulpha drugs that have performed ‘’healing magic’’ in the world of chemotherapy include; 
sulphanilamide (1), sulphadiazine (2), sulphacetamide (3), sulphamonomethoxine (4), 
sulphasalazine (5), sulphadoxin (6) among others. Sulphonamides have long been the 
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subject of pharmaceutical interest as a result of their potent biological activities 
(Purushottamachar et al., 2008; Stranix et al., 2006; Harter et al., 2004; Reddy et al., 
2004). 
 
 Furthermore, the sulphonamide group has been proven to have remarkable utility 
in medicinal chemistry and features in the structure of a number of clinically relevant 
small molecules (Njardarson, 2008; Supuran, 2008). For instance, some currently 
approved drugs with sulphonamide structural skeletons include; the antihypertensive 
agent bosentan (7) (Ueda et al., 2011; Wu et al., 2001), the antiviral HIV protease 
inhibitor amprenavir (8) (Shen et al., 2010; De Clercq, 2001), the phophodiesterase-5 
inhibitor sildenafil (9) (Masson et al., 2005; Setter et al., 2005; Rotella, 2002), 
antidiabetic drug glibenclamide (10) (Gianotto et al., 2007; Gribble and Reimann, 2003), 
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antidiabetic nonantibiotic glimepiride (11) and the diuretic drug torasemide (12) (Lopez 
et al., 2009; Knauf and Mutschler, 1998).  
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 In addition, sulphonamides are also highly relevant both in the animal world and 
the plant life cycle. In fact, the breakdown of cyclic guanosine monophosphate is retarded 
by sildenafil, a substituted guanine analog, which indeed keeps cut flowers fresh for 
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another week and also strengthens plant stem to stand straight even in the midst of storm 
and wind (Bergmann, 2010). A preserving effect on fruit and vegetables was also found, 
making sildenafil (9), a promising agent (Bergmann, 2010). Today, it is marketed under 
the trade name Viagra (Bergmann, 2010; Siegel-Itzkovich, 1999) which is a potent drug 
used in the treatment of erectile dysfunction in man (Blonde, 2006; Fink et al., 2002), an 
illness that affects 34 million men in the United States (Seftel et al., 2004) and more than 
150 million men worldwide (Hellstrom et al., 2003). In another discovery, sulphonamide 
has been documented as highly efficient candidate with high HDAC inhibitory activity 
(Oh et al., 2007).  
 Similarly, some sulphonamides have been established as potent drugs in treatment 
of insomnia and other sleepless challenges in man by antagonizing orexin neural activity. 
Activation of orexin neurons contributes to the promotion and maintenance of 
wakefulness (Brisbare-Roch et al., 2007). Conversely, relative inactivity of orexin 
neurons allows the onset of sleep (Lee et al., 2005; Estrabrooke et al., 2001). 
Consequently, blocking orexin signaling with receptor antagonists may provide a new 
mechanism for decreasing wakefulness. Thus, a novel therapeutic opportunity for the 
treatment of insomnia was reported using a dual OX1R and OX2R receptor antagonist 
almorexant (13) (Brisbare-Roch et al., 2007). Also, low molecular weight aryl containing 
N-glycine-sulphonamide (2-[(4-tert-butyl-benzenesulphonyl)-p-tolyl-amino]-N,N-diethyl-
acetamide) (14) was discovered as a potent and selective OX2R antagonist with very poor 
oral bioavailability (F = 1%) in Wistar rats while recently discovered optimized orexin 
antagonist but with good oral bioavailabilty is compound (15) which was prepared based 
on N-glycine-sulphonamide core (Aissaoui et al., 2008).  
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 The mode of action of sulphonamide is by mimicking p-aminobenzoic acid 
(PABA) (Evanthia et al., 2010). Their molecular structures are similar to p-aminobenzoic 
acid (PABA), which is needed in bacteria as a substrate of the enzyme dihydropteroate 
synthetase for the synthesis of tetrahydrofolic acid which is a basic growth factor 
essential for the metabolic process of bacteria (Evanthia et al., 2010). They are preferred 
due to the ease of administration (Fehintola et al., 2004), wide spectrum of antimicrobial 
activity (Moylett et al., 2003), noninterference with the host defense mechanism and 
relative freedom from problems of super-infection (Gadad et al., 2000). Sulphonamide 
function is the basis of several groups of drugs (More, 2010). The original antibacterial 
sulphonamides (sometimes called sulpha drugs) are synthetic antimicrobial agents that 
contain the sulphonamide functional group (More, 2010).  
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 Moreover, sulphonamides have been classified using various parameters. For 
instance, by using the antibiotic properties, it can be classified into antibiotic or 
antimicrobial sulphonamide and nonantibiotic or nonantimicrobial sulphonamides (Ponka, 
2006). Although, almost all therapeutically useful sulphonamides are aromatic linked Ar-
SO2NH2 or Ar-SO2NHR (Supuran, 2008; Anand, 1996), yet, there are important 
distinctions between sulphonylarylamines (antimicrobial/sulphonamides), nonarylamine 
(nonantimicrobial) sulphonamides, and sulphones, with regard to allergic and other 
adverse drug reactions (Dibbern and Montanaro, 2008). Sulphone (16), unlike the 
sulphonamide, has its SO2 unit incorporated between two carbon systems which may be 
from either aliphatic or aromatic moieties (Dibbern and Montanaro, 2008).   
 Most reactions to sulphonylarylamines probably result from multifactorial 
immunologic and toxic metabolic mechanisms, whereas less is known about the precise 
mechanisms of reactions to other sulphur-containing drugs. Some sulphonamides such as 
the anticonvulsant, sultiames are also devoid of antibacterial activity. The sulphonylurea 
and thiazide diuretics are newer drug groups based on the antibacterial sulphonamides 
(Kourlas and Morey, 2007). One of the sulphonamides of paramount importance in this 
study is benzenesulphonamide derivatives. Benzenesulphonamide moiety is an integral 
part of many drugs and drug-like scaffolds (Bhat et al., 2005; Supuran et al., 2004). 
Many derivatives of benzenesulphonamide have been explored as important starting 
materials and reactive intermediates in various organic syntheses. For example, 2-
hydroxyalkylbenzene sulphonamides (17) and (18) have been reported as the important 
starting materials produced in large quantities (Singh et al., 2007), for the structure-
activity relationship (SAR) study during the search of cyclooxygenase-2 (COX-2) 
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inhibitors as analgesic (Zebardast et al., 2009) and anti-inflammatory agents (Singh et al., 
2005; Singh et al., 2004a, Singh et al., 2004b).  
 
 The chemistry of sulphonamides has recently shown them to be highly efficient 
synthons in the preparation of various valuable biologically active compounds (Bahrami 
et al., 2009; Yuan et al., 2001). In view of the versatile chemistry of sulphonamides as 
ligands, various researchers have attempted and embarked upon designing and 
synthesizing various novel metal based sulphonamides (Chohan et al., 2006a; Puccetti et 
al., 2005; Bregman et al., 2004; Hassan et al., 2002). The chiral ligands with an 
isoborneol-10-sulphonamide structure has been discovered as 10 years odyssey, designed 
as first (19), second (20) and third generation (21) ligands for catalyzing and 
stereoselective synthesis of highly relevant asymmetric compounds (Ramon and Yus, 
2007). In a similar manner, a new series of sulphonamide derived Schiff bases has been 
synthesized by a condensation reaction of various sulphonamides with aromatic 
aldehydes (Chohan et al., 2010b). The sulphonamides obtained were further investigated 
for their metal complexes potential in terms of chelation (Aoki et al., 2009) and 
biological properties (Chohan et al., 2010b). 
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 Based on the side effect factor, it is important to make a distinction between 
sulpha drugs and other sulphur-containing drugs and additives, such as sulphates and 
sulphites, which are chemically unrelated to the sulphonamide group, and do not cause 
the same hypersensitivity reactions seen in the sulphonamides. Although, there are 
reported cases of allergy to sulphonamide drug, but the term sulpha allergy is imprecise 
and misleading and therefore, should be discouraged (Dibbern and Montanaro, 2008). 
Sulpha allergies are commonly reported as the side effect of sulphonamide drugs (More, 
2010); hence, medications containing sulphonamides are prescribed carefully. In fact, 
issues in understanding the clinical evidence and drug market dynamics as they relate to 
individuals and populations have been explored (Mamdani, 2005). Statistics have shown 
that approximately 3% of the general population show sulpha drugs allergy, when treated 
with sulphonamide and other similar antibiotics (Srivastava, 2011). 
 Furthermore, the potential utilization of sulpha drug compounds as corrosion 
inhibitors has been established (El-Naggar, 2007). The inhibitory effect of four sulpha 
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drugs compounds namely: sulphamethazine (22), sulphaguanidine (23), 
sulphamethoxazole (24) and sulphadiazine (2), on mild steel corrosion in 1.0 M HCl 
solutions was evaluated using both galvanostatic polarization and weight loss techniques 
(El-Naggar, 2007). All the examined sulpha drug compounds were reported to reduce the 
corrosion of mild steel indicating their high potency as anti-corrosion agents. Among the 
compounds studied, sulphadiazine (2) was claimed to have the best inhibition efficiency 
(El-Naggar, 2007). Sulphonamide derivatives of azo dyes achieve improved light stability, 
water solubility and fixation to fiber (Hansch et al., 1990).  
 
 Some quantum mechanical studies have successfully linked the corrosion 
inhibition efficiency with molecular properties for different kinds of organic compounds 
(Khalil, 2003; Bereket et al., 2001). In fact, quantum chemical calculations using the 
density functional theory (DFT) and some semi-empirical methods (Arslan et al., 2009) 
were performed on four sulphonamides in order to determine the relationship between 
molecular structure and their inhibition efficiencies (Arslan et al., 2009). The 
sulphonamide dyes, especially secondary sulphonamide dyes, exhibited superior dye 
exhaustion and color fastnesses to washing, sublimation, and rubbing on fine denier PP 
fabrics (Cui et al., 2009). They have been used as protecting groups of hydroxyl, OH or 
amino, NH functionalities for easy removal under mild conditions (Chandrasekhar and 
Mohapatra, 1998; O’Connell and Rapoport, 1992). 
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 Even though many synthetic methods have been reported for the preparation of 
sulphonamides (Wright and Hallstrom, 2006; Katritzky et al., 2005; Caddick et al., 2004), 
the sulphonylation of ammonia (Behmadi et al., 2009) or primary and secondary amines 
with sulphonyl chlorides in the presence of a base is still being used as the method of 
choice because of high efficiency and simplicity of the reaction (Meshram and Patil, 
2009). Nevertheless, various acceptable techniques involve the need to reduce the amount 
of toxic waste and by-product arising from chemical processes required thereby 
increasing emphasis on the use of less toxic and environmentally compatible materials in 
the design of new synthetic methods (Li, 2005). One of the most promising approaches is 
using water as the reaction media (Shi et al., 2010) while others include microwave 
irradiation technique, heterogeneous catalytic approach, solvent free media usage, 
nontoxic solid support resin etc. Sulphonamides, ionizable, polar antimicrobial 
compounds, may reach the environment in substantial amounts by the spreading of 
manure (Kahle and Stamm, 2007) or other means.  
 Adsorption of three sulphonamide antimicrobials to clay minerals was 
investigated as a function of pH, ionic strength, and type of exchangeable cation. 
Sulphonamide antimicrobial adsorption exhibited pronounced pH dependence consistent 
with sorbate speciation and clay properties (Gao and Pedersen, 2005). In a similar 
manner, amide formation is a fundamental reaction of great interest in organic chemistry 
(Naik et al., 2004; Katritzky et al., 2000). The development of efficient methods for the 
synthesis of amides remains a great challenge because of their importance in chemistry 
and biology, with a wide range of industrial and pharmaceutical applications and as 
valuable intermediates in organic synthesis (Theodorou et al., 2009; Katritzky et al., 
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2006). Hence, it is conceivable to design the synthetic route in such a way to have amide 
functionality, being incorporated within the framework of the synthesized sulphonamides. 
This will help in the comparative study of the antimicrobial activity of the ordinary 
sulphonamide with amide bearing sulphonamide derivatives.    
 Despite the various hazardous effects posed by deadly microbes (Zabransky, 
2002), it is highly pathetic to know that no new antimicrobial drug has been discovered in 
the last few years. Therefore, there is a continuous need for the design and synthetic 
formulation of new class of antimicrobial drugs in order to control rapid spread of 
harmful microbes. Biofilm effect is the mechanism responsible for the frequent failure of 
antibiotic treatment to cure infections of medical devices and other prosthetic materials 
(Ceri et al., 2001). In the biofilm stage, a phenotypic change occurs in which the bacteria 
require generally much higher concentrations of antibiotics to inhibit their growth. In fact, 
it has been recently discovered that the comparative study of the minimum inhibitory 
concentration (MIC) and minimum biofilm eliminating concentration (MBEC) is a 
potential factor for determining the changes in the pattern of antibiotic sensitivity of 
Gram negative bacilli from planktonic to the biofilm stage of growth (Sepandj et al., 
2004). In addition, the rapid emergence of drug resistance has become the most urgent 
concern because it renders current treatments ineffective and therefore compels the 
scientific community to continue efforts in the design of inhibitory agents that can 
efficiently combat drug resistance (Ghosh et al., 2008).  
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1.2. Objectives of the Study 
The specific objectives of the study are: 
• to synthesize aryl sulphonamides and alkylaryl sulphonamides as reactive 
intermediates and subsequently use them to synthesize various novel N,N-diethyl 
alkanamide substituted sulphonamides and characterize using elemental analysis 
and spectroscopic means, especially FT-IR, Mass Spectra, 1H- and 13C-NMR.    
• to investigate the antimicrobial activities of the series of new sulphonamide 
compounds on Escherichia coli and Staphylococcus aureus by comparing their 
inhibitory activity and antimicrobial efficiency with streptomycin clinical 
reference.    
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CHAPTER TWO 
LITERATURE REVIEW 
2.1. History of Sulphonamide Drug Discovery 
 Sulphonamide drugs were the first antimicrobial drugs which paved way for the 
unprecedented revolution in the world of antibiotics in medicine (Domagk, 1986). The 
first of such sulphonamide was actually a prodrug with the trade name Prontosil (25) 
(Domagk, 1986). Experiments with Prontosil (25) began in 1932 in the laboratories 
of Bayer AG where the Bayer team believed that coal-tar dyes’ ability to preferentially 
bind to bacteria and parasites might be used to target harmful organisms in the body. 
After years of fruitless efforts, a team led by Gerhard Domagk finally found one that 
worked. It was a red dye synthesized by Bayer chemist Josef Klarer that had remarkable 
effects on stopping some bacterial infections in mice (Domagk, 1986).  
 The first official communication about the breakthrough discovery was not 
published until 1935, more than two years after the drug was patented by Klarer and his 
research partner Fritz Mietzsch. Later, at the Pasteur Institute, it was accidentally 
discovered by a French research team, led by Ernest Fourneau, who also established that 
the drug was metabolized into two pieces inside the body, releasing from the inactive dye 
portion a smaller, colourless, active compound called sulphanilamide. 
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 For several years in the late 1930s, hundreds of manufacturers produced tens of 
thousands of tons of myriad forms of sulpha. This phenomenon coupled with a 
nonexistent testing requirement led to the Elixir Sulphanilamide disaster in the fall of 
1937, during which at least 100 people were poisoned with diethylene glycol (Kent, 
2011). This led to the passage of the Federal Food, Drug, and Cosmetic Act in United 
State (US) in 1938. However, as the first and only effective antibiotic available in the 
years before penicillin, sulpha drugs continued to thrive through the early years of World 
War II (Kent, 2011). They are credited with saving the lives of tens of thousands of 
patients including Franklin Delano Roosevelt, Jr. (son of President Franklin Delano 
Roosevelt) in 1936 and Winston Churchill (Hager, 2010). Sulpha had a central role in 
preventing wound infections during the war. American soldiers were issued a first-aid kit 
containing sulpha pills and powder and were told to sprinkle it on any open wound. 
During the years 1942 to 1943, Nazi doctors conducted sulphanilamide experiments on 
prisoners in concentration camps (USHMM, 2011; Tyson, 2011). Many thousands of 
molecules containing the sulphanilamide structure have been created since its discovery 
(by one account, over 5,400 permutations by 1945), yielding improved formulations with 
greater effectiveness and less toxicity. Sulpha drugs are still widely used for conditions 
such as acne and urinary tract infections. They are also receiving renewed interest for the 
treatment of infections caused by bacteria resistant to other antibiotics (Kent, 2011). 
2.2. Structure of Sulphonamide 
 Sulphonamides or sulpha drugs have the following general structure represented 
by (26). In this structure (26), R may be alkyl, aromatic or heteroaromatic and R1, R2 may 
be hydrogen, alkyl aromatic or heteroaromatic group. However, sulphanilamide which 
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was the first compound used of this type has the sulphonamide base structure (27) in 
which R1 and R4 are hydrogen (Ophardt, 2003). To date about 15,000 sulphonamide 
derivatives, analogues and related compounds have been synthesized (Ophardt, 2003). 
This has led to the discovery of many useful drugs which are effective as diuretics (28), 
antimalarial (29), antileprosy agents (30), antithyroid agents and so on (Ophardt, 2003).                              
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 The basic structure of sulphonamide cannot be modified if it is to be an effective 
competitive "mimic" for p-aminobenzoic acid (Levin et al., 2007). Essential structural 
features are the benzene ring with two substituents para to each other; an amino group in 
the fourth position; and the singly substituted 1-sulphonamido group. The chemical 
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structure of sulphonamide antibiotics and sulphonamide nonantibiotics can affect the 
potential for adverse drug reactions (Verdel et al., 2006). 
2.3. Synthesis of Sulphonamide Derivatives 
 Sulphonamide is widely used in medicine and has been tagged an essential 
functional group in drug design (Kalgutkar et al., 2010). Hence, due to its versatility, 
numerous derivatives have been synthesized in order to obtain biologically active 
scaffolds. Some of the synthtetic approaches for the formation of sulphonamides were 
discussed below: 
2.3.1. Sulphonylation of 2-Amino-1-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)ethanone 
 The 2-amino-1-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)ethanone (33) (Al-Soud et 
al., 2008a) which was prepared by transformation of 2-(piperazin-1-yl)benzo[d]thiazole 
(31) via the chloro derivative (32), has been recently utilized in the synthesis of some 
sulphonamide derivatives (34a-k). This was achieved by the reaction of the amino end of 
compound (33) with various substituted arylsulphonyl chlorides in triethylamine base for 
20 h at room temperature in the presence of dichloromethane (Al-Soud et al., 2008b).  
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(f) 3-CF3-Ph;(g) 4-MeO-Ph; (h) quinolin-8-yl; (i) thiophen-2-yl;
(j) 2,5-dichloro thiophen-3-yl; (k) 3-bromo-5-chlorothiophen-2-yl
(34a-k)
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(33)
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2.3.2. Synthesis from Amination of Chalcones  
 Treatment of 4-methoxychalcone (35) with chlorosulphonic acid at room 
temperature for one week afforded the sulphonyl chloride derivative (36) which was 
subsequently reacted with secondary amines in the presence of methanol to afford 
sulphonamide derivatives (37a-i) (Andrighetti-Fröhner et al., 2009). The 4-
methoxychalcone used as the versatile precursor in the synthetic pathway to obtain the 
sulphonamide, was itself prepared by a standard procedure (Bhattacharya et al., 2002).      
 
2.3.3. Synthesis from 4-Azidomethyl Coumarin  
 A series of new and novel coumarin-6-sulphonamides with a free C4-azidomethyl 
group (41a-y) have been synthesized as antimicrobials in three steps starting from 7-
methyl-4-bromomethylcoumarin (38) (Basanagouda et al., 2010). The reaction of (38) 
with chlorosulphonic acid was found to yield the corresponding 6-sulphonylchloride (39), 
which when treated with sodium azide led to intermediate (40). The titled sulphonamides 
(401a–y) were finally obtained from the reaction of (40) with aromatic amines in 
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refluxing benzene. 
 
 
2.3.4. Microwave-Assisted Synthesis for Sulphonamide 
 An easy and handy synthesis of sulphonamides (42a-e) directly from sulphonic 
acids or its sodium salts is performed under microwave irradiation. This approach was 
reported to show a good functional group tolerance and the products were formed in 
excellent yield (Luca and Giacomelli, 2008). 
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 2.3.5. Synthesis from Solid Phase Combinatorial Technique 
 Solid phase technique, with the aid of different resin linker, has been utilized to 
synthesize series of potentially active sulphonamides (Maclean et al., 2001; Wagman et 
al., 2000; Yan et al., 2000). In fact, the resin-bound sulphonamide (44) which was 
synthesized by reaction of the 3-bromopropylsulphonyl chloride (43) with the rink amide 
resin, was reported to react with a 2 M solution of the amino heterocycle (HetNH2) or 
other amine in dimethyl sulphoxide at 75° C for 16 h to form (45) (Millan and Prager, 
2000). Finally, the desired hetero-aminopropyl sulphonamide (46) was achieved by 
cleaving away the resin from (45) with the help of equimolar mixture of trifluoroacetic 
acid/dichloromethane (Millan and Prager, 2000). 
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2.3.6. Chloromethylsulphonylation of S-Benzylisothiourea 
 Sulphonamide analogues of creatinine have been conveniently synthesized by 
chloromethylsulphonylation of substituted benzylisothiourea as reported by Fares and co-
workers (1997). The treatment of a mixture of chloromethylsuphonyl chloride (47) and 
benzylisothiourea (48) in the presence of anhydrous sodium carbonate and anhydrous 
ethyl acetate at room temperature for 2 days gave the sulphonamide  (E)-1-(benzylthio)-
2-(chloromethylsulphonyl)ethenamine (49) in good yield. They also demonstrated the 
effectiveness of base-induced cyclization of (49) with 2 molar equivalent of sodium 
hydroxide in the presence of 2-(t-butoxycarbonyloxyimino)-2-phenylacetonitrile (50) in 
sodium hydroxide to afford thiadiazole 1,1-dioxide derivative  (51) in 61% yield (Fares et 
al., 1997). 
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  2.3.7. Synthesis via Ring Opening Aminolysis of N-Tosylaziridines 
 Bisai and co-workers reported that the ring-opening of N-tosylaziridines (52) with 
chiral benzylamine derivative can be efficiently catalyzed by lithium perchlorate to 
provide derivatives of the trans-1,2-diamine and (S,S,R)-(53) in high yields. Alkylation 
of (R,R,R)-(53) intermediate with 2-methoxybenzyl bromide gave sulphonamide 
(R,R,R)-(54) in 72% yield. The reaction was used in desymmetrization of several cyclic 
N-tosylaziridines using chiral amines. Using this strategy, an efficient synthesis was 
developed of chiral vicinal C2 symmetric bis-(sulphonamides), unsymmetrical 
bis(sulphonamides) and other symmetric and unsymmetric ligands based on trans- 1,2-
cyclohexanediamine (Bisai et al., 2007).  
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2.3.8. Synthesis from Diprotected Glutamic Acid  
 Diprotected glutamic acid (55) was directly conjugated with commercially 
available sulphonyl chlorides to obtain sulphonamides (56) which were then deprotected 
with TFA to produce the library of sulphonamide inhibitors (57a-o). Alternatively, 
compound (55) was conjugated with sulphonyl chlorides and then treated with 
iodomethane to afford N-methylsulphonamide analogs (58), which thereafter, were 
deprotected to give the final N-methylsulphonamide inhibitor library (59a-d) (Blank et al., 
2011).  
 
2.3.9. Synthesis from Structural Modification of Paracetamol Derivative 
 The 4-(acetylamine)benzenesulphonyl chloride (60), a derivative of paracetamol 
earlier prepared by several interconversion of functional group  of aniline (Bastos et al., 
2008) was condensed with functionalized amines in DCM to give the desired N-phenyl-
acetamide sulphonamide derivatives (61a-g) in 50 – 70% yield (Barbosa et al., 2009).   
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2.3.10. Copper II Oxide Catalytic Sulphonylation Method 
 The catalytic activity of cupric oxide for the sulphonylation of p-anisidine (2 
mmol), other aromatic amines as well as some aliphatic amines with p-toluene sulphonyl 
chloride (2 mmol) at room temperature were studied (Meshram and Patil, 2009). It was 
found that the application of less than 0.1 mmol of cupric oxide in acetonitrile (5 ml) 
gave a moderate yield of the corresponding sulphonamide (62), whereas the use of more 
than 0.1 mmol of cupric oxide gave an excellent yield (Meshram and Patil, 2009). 
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2.3.11. Indium Catalyzed Sulphonylation 
 A facile and efficient indium-catalyzed sulphonylation of amines with p-
toluenesulphonyl chloride allows the synthesis of a wide range of sulphonamides in 
excellent yields. The method showed a generality for substrates including less 
nucleophilic and sterically hindered anilines, and it is also applicable for preparing 
sulphonic esters from sulphonyl chlorides and alcohols (Kim and Jang, 2007). 
O OR
N
R'
N
R
+ S
O
0.1 eq. In
MeCN, rt, 6-16 h
Cl S
O
CH3H CH3
R'
R   : alkyl, Ar
R ' : H, alkyl  
2.3.12. Sequential Mitsunobu Condensation Reaction 
  
 Chen and co-workers reported recently that bis(sulphonamide) analogues could be 
assembled by two sequential Mitsunobu reactions which linked protected mycophenolic 
and adenosine derivative through a properly protected methylene bis(sulphonamide) (65)  
linker intermediate. The intermediate was prepared by treating methanedisulphonyl 
dichloride (63) with 2,4-dimethoxybenzyl amine (DMB) (64) in THF at 0oC for 30 min 
and later stirred at room temperature for 5 h (Chen et al., 2008). 
 
2.3.13. Synthesis from Condensation Reaction of Indole-3-Carbaldehyde 
 A rapid condensation of indole-3-carbaldehyde (66) with various existing 
sulphonamides under reflux has successfully led to a new series of sulphonamides, 
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containing indole moiety (67a-g) in good yield (80–86%). These synthesized compounds 
were used as potential ligands for complexation with some selected divalent transition 
metals ions (Chohan et al., 2010a). 
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2.3.14. Synthesis from Sulphonylation of Benzo[d]thiazol-2-amine 
 Subsituted N-(benzo[d]thiazol-2-yl)benzenesulphonamides (69) were prepared by 
heating the appropriate heteroarylamine (benzo[d]thiazol-2-amine) (68) with the selected 
benzenesulphonyl chlorides in pyridine for several hours. Nucleophilic addition of the 
NH2 group to the sulphonyl function of the benzenesulphonyl chlorides takes place at 60 
oC (Argyropoulou et al., 2009). 
 
 
 
 32
2.3.15. Amination of (+)-10-Camphorsulphonic Acid Chloride   
 New chiral sulphonamides from (+)-camphor derivative (72), with different 
substituents on camphor C2 and sulphonamide N, were synthesized (Kozakiewicz et al., 
2010). This was achieved by first stirring a DCM solution of (+)-10-camphorsulphonic 
acid chloride (70) in cooled solution of various amines for 2.5 h to form 
ketosulphonamide (71), which consecutively underwent L-selectride reduction to produce 
hydroxysulphonamide (72). The catalytic activity of these new chiral sulphonamides was 
also investigated by Kozakiewicz and coworkers in 2010.  
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 In recent years, a large variety of amino-alcohols starting from camphor (Parrott 
and Hitchcock, 2008; Martinez et al., 2002; Chen et al., 2001; Dimitrov et al., 2001), 
camphor-10-sulphonamides (Hui et al., 2008; Hui et al., 2006; Ramon and Yus, 2007; 
Forrat et al., 2006) and similar chiral compounds (Binder et al., 2009; Szakonyi et al., 
2008; Tanyeli et al., 2007; Martins et al., 2006; Soki et al., 2005) were prepared and used 
as catalysts. The commercially available (+)-camphor-10-sulphonyl chloride was also 
reported to be easily transformed into the dimethylsulphonamide through a reaction 
almost similar to the one above but using diethyl ether as the solvent (Kamenova-
Nacheva et al., 2009).  
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2.3.16. Iodine-Catalyzed Hydrophosphonylation Method 
 Treatment of N-tosyl aldimines (73) with dialkyl trimethylsilyl phosphites (74) at 
0 °C in the presence of iodine as a catalyst afforded the corresponding sulphonamide 
phosphonates (75) in excellent yields within 1.5 to 2.5 h (Das et al., 2009). 
R1 H
N
Ts
RO
P
OR
OSiMe3
I2 (20 mol %)
CH2Cl2, 0oC, rt
1.5-2.5 h R1
HN
O2
S
RO
P
OR
O
CH3
86-94%
(73) (74)
(75)
+
 
2.3.17. Synthesis from Ionic Liquid Mediated Approach 
 The coupling of pyrrole with aryl- or alkylsulphonyl chloride in 2 h by reflux in 
the presence of KOH and ionic liquid gave the corresponding heteroaromatic 
sulphonamide (76) in excellent yield. Generally speaking, in ionic liquids [Bmim][PF6] 
or [Bmim][BF4], a highly regioselective N-substitution of pyrrole with alkyl halides, 
sulphonyl chlorides, and benzoyl chloride gave substituted pyrrole in excellent yields. 
Michael addition of pyrrole with electrophilic olefins was completed in a highly 
regioselective manner to afford N-alkylpyrroles (Lea et al., 2004). 
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2.3.18. Synthesis from Heteroaryl Thiols 
 Since direct oxidative conversion of thiols (Bahrami et al., 2009) and disulphide 
to sulphonamide was achieved by Prakash and co-workers (2007), pyrimidine-2-thiol was 
conveniently converted to sulphonyl chloride at low temperature (-25 oC) by using 3.3 
equiv. of aqueous sodium hypochlorite. The treatment of such sulphonyl chloride with 
amine afforded corresponding sulphonamide (77) (Wright and Hallstrom, 2006). In 
addition, the method allowed the preparation of sulphonyl fluorides (78), which are stable 
enough to be purified and stored, making them to be potentially useful monomers in 
parallel chemistry efforts (Wright and Hallstrom, 2006).  
 
 
2.3.19. Aminolysis of p-Nitrophenoxysulphonylphenylxanthine  
 
 A large variety of amines, including aniline, benzylamine, phenethylamine, 
propylamine, butylamine, 2-hydroxyethylamine, aminoacetic acid and N-
benzylpiperazine reacted with p-nitrophenoxysulphonylphenylxanthine derivative (79) to 
yield the desired sulphonamide products (80) in satisfying to very good yields (Yan et al., 
2006). It was also reported that the resulting sulphonamides were much more potent at 
A2B receptor than the parent sulphonates.  
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The most active compound of the series was 8-[4-(4-benzylpiperazide-1-sulphonyl) 
phenyl]-1-propylxanthine (81) with kinase inhibition (ki) value of 3.6 nM for the human 
A2B receptor combined with high selectivity versus the other human adenosine receptor 
subtypes (575-fold versus A1, 134-fold versus A2A, and > 278-fold versus A3). 
 
2.4. Pharmacokinetic Properties of Sulphonamides 
 Pharmacokinetic was first introduced to describe the characteristics of drug after 
the application. It is the study of time course of the administered drug and xenobiotic 
concentration in the body. The sulphonamides were reported to constitute a series of 
weak organic acids with pKa values ranging from 10.4 for sulphanilamides to 5.0 for 
sulphisoxazole (Giguere et al., 2006). The result of an investigation indicated that the 
moieties corresponding to specific pKa’s were identified based on chemical structures of 
antibiotics (Qiang and Adams, 2004) and the co-solvent effect (Ebead, 2010). 
 Sulphonamides exist predominantly in nonionized form in biologic fluids of pH 
lower than their pKa. It is the nonionized moiety that diffuses through cell membranes 
and penetrates cellular barriers. Sulphonamides are eliminated by a combination of renal 
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excretion and biotransformation (Dwight et al., 2004). This combination contributes to 
species variations in the half-life of individual drug which also play a major role in the 
classification of sulphonamides (Giguere et al., 2006). Sulphadimethoxine, for example, 
has half-life of 12.5 hours in cattle (Giguere et al., 2006), 8.6 hours in goats, 11.3 hours 
in horses (Oukessou and Alsouss, 1998), 15.5 hours in swines, 13.2 hours in dogs and 
10.2 hours in cats (Giguere et al., 2006). A quantitative method was developed and 
validated to measure the concentration of sulphadimethoxine (SDM) and its major 
metabolite (Li et al., 2009).      
 
2.5. Classification of Sulphonamides 
 Sulphonamides have been classified based on several parameters. These 
parameters include; chemical structure, duration of action, spectrum of activity and 
therapeutic application (Aschenbrenner and Venable, 2008). The commonest one is based 
on therapeutic usage in term of the duration of action. This has to do with observation 
according to plasma concentration and time profile which is essentially the rapidity with 
which compounds are absorbed and excreted (Paige and Tollefson, 2003). There are three 
groups of sulphonamide based on their duration of action. They are short acting, 
intermediate acting and long acting (Wiholm, 2001).   
2.5.1. Short Acting Sulphonamide 
 The sulphonamides are considered short acting if the blood concentration levels 
remain higher than 50 g/mL for less than 12 h after a single therapeutic dose (Paige and 
Tollefson, 2003). They have been preferred for systemic infections as they are rapidly 
absorbed and rapidly excreted (Yasuda, 2005). Some examples of sulphonamides with 
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short acting character are sulphisoxazole (82), sulphathiazole (83), trisulphapyrimidine 
(84), sulphadimidine (85) and sulphisomidine also unknown as sulphaisodimidine (86). 
For instance, sulphamethoxazole is classified as a short acting sulphonamide because its 
half-life is estimated at 11 h (Derouin et al., 2000) and sulphamethazine has been used 
effectively and conveniently for the treatment of urinary tract infections. 
 
 
2.5.2. Intermediate Acting Sulphonamide 
 The sulphonamides are considered intermediate acting if the blood plasma levels 
concentration of higher than 50 g/ml are obtained between 12 and 24 h (Paige and 
Tollefson, 2003). They have been used for infections requiring prolonged treatment. For 
instance, sulphamethoxazole (24) in combination with trimethoprim (87) commonly 
known as septran (Korolkovas, 1998a) has been used for various infections such as 
recurrent urinary tract infections and especially active against invasive aspergillosis in 
AIDS patients. Other examples are sulphamimethoxine and sulphamethazine (22).  
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2.5.3. Long Acting Sulphonamide 
 The sulphonamides are considered long acting if the blood plasma levels 
concentration of higher than 50 g/ml are obtained 24 h after dosing (Paige and Tollefson, 
2003). They are rapidly absorbed and slowly excreted. Sulphasalazine (5), which has 
been used as antihypertensive agent, is an example of this category. In addition, there are 
different types of sulphonamide which have been used in various types of infections 
(Kovolkovas, 1998b) such as mucous membranes sulphabenzamide (88); superficial 
ocular infection sulphacetamide sodium (89); urinary infections sulphadiazine (2) and 
anticancer sulphamethizole (90). Other examples are sulphadoxine (6), sulphamethoxy-
pyridazine (91), sulphaphenazole (92) and veterinary product sulphadimethoxine (93).  It 
is noteworthy that long acting sulphonamides are not available for use in the United 
States because of their ability to cause Stevens-Johnson syndrome (Aschenbrenner and 
Venable, 2008).   
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2.6. Sulphonamide as Antimicrobial Agents 
 The sulphonamides are synthetic antimicrobial agents with a wide spectrum 
encompassing most gram-positive and many gram-negative organisms (Shei, 2010). 
These drugs are bacteriostatic in action and were the first efficient treatment to be 
employed systematically for the prevention and cure of bacterial infections (Vicente and 
Pérez-Trallero, 2010). Their use introduced and substantiated the concept of metabolic 
antagonism. Sulphonamides, as antimetabolites, compete with para-aminobenzoic acid 
(PABA) for incorporation into folic acid. The substrate similarity resulted in site 
competition. The action of sulphonamides illustrates the principle of selective toxicity 
where some differences between mammalian cells and bacterial cells are exploited. All 
cells require folic acid for growth. Folic acid (as a vitamin is in food) diffuses or is 
transported into human cells. However, folic acid cannot cross bacterial cell walls by 
diffusion or active transport. For this reason, bacteria must synthesize folic acid from p-
aminobenzoic acid. In order to have a greater insight into the world of antimicrobial 
efficacy of sulphonamide (Shoji et al., 2009), it is expedient to look into the mechanism 
of action of such drugs and the mechanism of resistance of microbes to them.  
2.6.1. Mechanism of Action of Sulphonamides 
 Sulphonamides are synthetic, broad-spectrum bacteriostatic antibiotics. They 
were the first effective systemic antimicrobial agents. Their mode of action is based on 
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the inhibition of DNA synthesis (Pérez-Trallero and Iglesias, 2003). Sulphonamides 
interfere with the biosynthesis of folic acid in bacterial cells by competitively preventing 
para-aminobenzoic acid (PABA) incorporation into the folic (pteroylglutamic) acid 
molecule (Fig. 2.1). Specifically, sulphonamides compete with PABA for the enzyme 
dihydropteroate synthetase (Levin et al., 2007). Their selective bacteriostatic action 
depends on the difference between bacterial and mammalian cells in the source of folic 
acid. Susceptible microorganisms must synthesize folic acid, whereas mammalian cells 
use preformed folic acid. The bacteriostatic action can be reversed by an excess of PABA, 
so that tissue exudates and necrotic tissue should be removed if animals are to be treated 
with sulphonamides (Giguere et al., 2006).  
 
 
Fig. 2.1: Antimetabolite Action of Sulpha Drug 
Source: Ophardt, 2003. 
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 In detail, normally folic acid is synthesized in two steps in bacteria by the top 
reaction on the left. If a sulpha drug is used, the first enzyme is not too specific and can 
use the sulphonamide in the first reaction. This reaction produces the product containing 
pteridine and the sulpha drug. The next and final step is the reaction of PABA with 
glutamic acid to make folic acid. If the sulpha drug has been substituted for the PABA, 
then the final enzyme is inhibited and no folic acid is produced as shown in the Fig. 2.1 
above (Ophardt, 2003). Recent studies indicate that substituents on the N(1) nitrogen may 
play the role of competing for a site on the enzyme surface reserved for the glutamate 
residue in p-aminobenzoic acid-glutamate through one of the following two ways: (a) 
Direct competition in the linking of PABA-glutamate with the pteridine derivative (b) 
Indirect interference with the coupling of glutamate to dihydropteroic acid (Shei, 2010). 
2.6.2. Mechanism of Metabolic Resistance in Sulphonamide 
 Widespread resistance has been reported and there is complete cross-resistance 
among sulphonamides (Greenwood, 2003). Bacteria either have preexisting resistance to 
drugs, or they develop resistance. Human activity has contributed greatly to the increase 
in resistant strains of bacteria. Often, when bacteria acquire resistance to a certain drug 
from a particular class (e.g., the penicillins), the bacteria also acquire resistance to all 
other drugs in that class. There are various types of mechanisms of resistance that have 
been established for different type of antibiotic usage. Some of these mechanisms include 
efflux of antibiotics from the cell (Wright, 2005), ribosomal modifications (Yan et al., 
2010; Triinu et al., 2009; Weisblum, 1995), protein modifications (Smith and Mankin, 
2008; Wright, 2005), enzyme-based resistance (Yin, 2010), metabolic resistance (Li et al., 
2007; Claudianos et al., 2002). However, the mechanism of resistance that is prevalent in 
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sulphonamide is metabolic resistance. Sulphonamide resistance is due to the metabolic 
bypass they acquired (Greenwood, 2003). 
 In the case of sulphonamides, which operate by mimicking p-aminobenzoic acid 
(PABA) and competing for an enzyme that synthesizes folic acid, an increase in the 
amount of PABA can out-compete the sulphonamide and render it ineffective. In addition, 
an alteration in the code for the enzyme itself can prevent its sulphonamide binding 
thereby resulting in resistance. For example, multiple levels of sulphonamide resistance 
have been reported in pneumococci (Wolstenholme et al., 2008). In the recent time, it has 
been documented that resistance is found in 20-45% of strains of Escherichia coli and 
enterobacteria infecting the urinary tracts (Aschenbrenner and Venable, 2008). In fact, 
plasmid-mediated resistance is common among the enterobacteria (Gosh et al., 2008; 
Greenwood, 2003; Claudianos et al., 2002; Dyatkina et al., 2002). 
 
Fig. 2.2: Metabolic Bypass Experienced in Folic Acid Synthesis 
Source: Greenwood, 2003 
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2.7. Sulphonamide Ligand in Metal Complexes Preparation 
 Transition metals have an important place within medicinal biochemistry 
(Rafique et al., 2010). The rational design and synthesis of metal–organic frameworks, 
also known as coordination polymers, has attracted considerable attention because of 
their interesting supramolecular architectures (Fang et al., 2011). Various sulphonamide 
ligands are highly versatile precursors in the synthesis of numerous metal complexes of 
great medicinal properties (Mondelli et al., 2008; Borras et al., 2004). In order to find 
better compounds, some metal sulphonamides have attracted much attention due to the 
fact that complexes showed more activities than both free ligands and the corresponding 
metallic salts (Chohan et al., 2006b). It is well documented that toxicological (Chohan 
and Supuran, 2008; Torre et al., 2003) and pharmacological properties are enhanced 
when sulphonamides are administered in the form of their metal complexes (Chohan, 
2008; Cejudo-Marin et al., 2004).  
 In particular, Ag-sulphadiazine has proved to be an effective topical antimicrobial 
agent, of significance in burn therapy, better than the free ligand or than AgNO3 
(Reynolds, 1996). Moreover, several Cu(II), Ce(III), Bi(III), Cd(II) and Hg(II) 
sulphonamide complexes have shown antibacterial activity (Chohan et al., 2006c; Bellu 
et al., 2003). Specially, a series of copper complexes with heterocyclic sulphonamides 
was studied and a plausible explanation of their activities was presented (Kremer et al., 
2006). However, Nickel-sulphonamide complexes have not been well studied and only a 
few complexes are described in the literature. Some of them presented lower 
antimicrobial activity than the free ligands (Yang et al., 2003) and others higher activity 
(Chohan et al., 2005). Similarly, complexes of sulphamethoxydiazine with Cu(II), Zn(II), 
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Ni(II), Cd(II), Cr(III) and Fe(III) have been synthesized and showed that 
sulphamethoxydiazine behaved as a bidentate ligand, binding the metal ion through the 
sulphonyl oxygen and sulphonamide nitrogen (Yang et al., 2003).   
 
2.8. Classification of Immune Responses to Sulphonamide Antibiotics 
In the recent time, issues about cross-allergenicity between sulphonamide antibiotics and 
nonantibiotic sulphonamide-containing drugs continue to complicate pharmacotherapy 
(Brackett, 2007). There is an association between hypersensitivity after the receipt of 
sulphonamide antibiotics and a subsequent allergic reaction after the receipt of a 
sulphonamide nonantibiotic, but this association appears to be due to a predisposition to 
allergic reactions rather than to cross-reactivity with sulphonamide-based drugs (Strom et 
al., 2003). In fact, several elegant investigations have demonstrated unequivocal lack of 
interaction between the sulphonamide group and either cellular or humoral immunity. 
 
Fig. 2.3: The Role and Effect of Antigen and Hypersensitivity  
Source: Moore, 2008 
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 In hypersensitivity, the immune system is ineffective, erratically targeting 
innocent proteins. Hypersensitivity is caused by a defect in the immune system's 
functional properties similar to the defect seen in acquired and other immune deficiency 
syndromes (Turgeon, 2003). However, in hypersensitivity reactions, the immune system 
overreacts while in immune deficiency syndromes, the immune system under-reacts 
(Moore, 2008). Nevertheless, the immunologically mediated reactions caused by 
sulphonamide antibiotics encompass the entire Gell-Coombs spectrum (Cribb et al., 
1996). These reactions can be classified into four major categories which are: type I, type 
II, type III and type IV hypersensitive immune response or reactions. 
2.8.1. The Type I Reactions: 
 The type I reactions are also known as the antibody-mediated anaphylactic or 
immediate hypersensitivity reactions. These are the most feared types which underlie 
immunoglobulin E-mediated reactions such as anaphylaxis (Ben-Shoshan and Clarke, 
2011), urticaria, angioedema and hypotension with attendant cardiovascular collapse 
(Butani, 2002). Type I reactions usually occur within 30 minutes of drug administration 
and are more common with parenteral than with oral administration. The immunologic 
determinant of type I immunologic response to sulphonamide antibiotics is the N1 
heterocyclic ring, and nonantibiotic sulphonamides lack this structural feature (Brackett, 
2007). 
2.8.2. The Type II (Cytolytic) Hypersensitivity Reactions  
 These involve antibody-mediated destruction of cells. Both IgG and IgM 
antibodies may participate in these reactions. Type II hypersensitivity reactions are 
responsible for immune-mediated hemolytic anemias, neutropenias, thrombocytopenias, 
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and vasculitis caused by sulphonamide antibiotics. In these reactions, mature circulating 
or marrow progenitor cells are affected either directly or as "innocent bystanders" as 
antigenic drug or drug-antibody complexes adhere to them (Bergfeld and DeClerck, 2010; 
Brackett et al., 2004). Activated complement subsequently lyses the immunologically 
marked cells, resulting in drug-induced cytopenias. The cytopenias generally become 
evident within 7-14 days and are often dose dependent (Klinker et al., 2002).  
2.8.3. Type III (Immune Complex) Reactions  
 These also involve IgG and IgM antibodies, but they differ from type II reactions 
in that antibodies are directed against widely distributed soluble antigens in serum. Thus, 
whereas damage caused by type II reactions tends to be localized to a tissue or cell type, 
type III reactions affect entire organs in which antigen-antibody complexes are deposited. 
Skin, joints, and kidneys are commonly involved (Silbernagl and Lang, 2009). Clinical 
manifestations of these reactions result from complement activation by immune 
complexes. Complement split products are anaphylatoxins that can cause localized mast 
cell degranulation with subsequent localized histamine release and urticaria. In addition, 
deposition of large immune complexes in joint spaces and in the basement membranes of 
blood vessels or glomeruli is responsible for vasculitis, glomerulonephritis, and arthritis. 
These reactions underlie development of classic serum sickness syndromes that occur 
several days to a few weeks after exposure to an offending drug. Symptoms of serum 
sickness usually include constellations of fever, vasculitis, lymphadenopathy, and rashes 
or urticaria. 
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2.8.4. The Type IV (Cell-Mediated Immunity) Reactions  
 Type IV (cell-mediated immunity or delayed hypersensitivity) reactions are 
mediated by cytokines released by sensitized T cells. Cytokines attract and activate 
macrophages that subsequently elaborate lytic enzymes. The tissue damage caused by 
type IV reactions typically requires 48-72 hours to develop and may be responsible for 
such cutaneous reactions as maculopapular rashes, Stevens-Johnson syndrome, and toxic 
epidermal necrolysis (Fritsch and Sidoroff, 2000; Leyva et al., 2000). An example is the 
delayed rash that can occur 2 days after receiving an inoculation of tuberculin in the 
tuberculosis skin test (Moore, 2008). 
2.9.  Biological Activities of Sulphonamide Derivatives 
In the past few years, considerable evidence has been accumulated concerning the 
efficiency of sulphonamide in antibacterial, antimalarial, anticonvulsant, antitubercular, 
antifungal, antiviral (Chen et al., 2010), antihypertensive, analgesic among others.  
2.9.1. Anticancer and Antitumor 
 Cancer is a class of diseases characterized by out-of-control cell growth. There 
are over 100 different types of cancer, and each is classified by the type of cell that is 
initially affected. Cancers happen when cells that are not normal, grow and spread very 
fast. Normal body cells grow and divide and know to stop growing. Over time, they also 
die. Unlike these normal cells, cancer cells just continue to grow and divide out of control 
and don't die when they're supposed to.  
 According to the National Cancer Institute, smoking causes 30% of all cancer 
deaths in the U.S. and is responsible for 87% of cases of lung cancer. Not only does it 
affect the lungs, it can cause kidney, pancreatic, cervical and stomach cancers and acute 
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myeloid leukemia (Fayed, 2010). Sulphonamides have attracted great attention, as many 
sulphonamide derivatives were reported to have interesting antitumor activity (Rostom, 
2006; Ghorab et al., 2004).  
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 Several mechanisms have been reported for the anticancer activity of the 
sulphonamide compounds. It has been known that aryl/heteroaryl sulphonamides may act 
as antitumor agents through a variety of mechanisms such as cell cycle perturbation in the 
G1 phase, disruption of microtubule assembly, angiogenesis inhibition, and functional 
suppression of the transcriptional activator NF-Y (Ghorab et al., 2010). However, the 
most prominent of mechanism was through the inhibition of the carbonic anhydrase 
isozymes (Bertucci et al., 2009; Supuran and Scozzafava, 2007; Kivela et al., 2005). 
Some novel quinolines and pyrimido[4,5-b]quinolines bearing sulphonamide moieties 
have been synthesized and evaluated for antitumoral activity. Out of them all, compounds 
(94), (95), and (96) were reported to have higher activity with IC50 value of 5.5, 6.9 and 7 
µg/mL respectively (Alqasoumi et al., 2010). 
2.9.2.  Antiplatelet Aggregation Inhibitory Activity 
 It is accepted that platelets play a vital role in the progress and development of 
thrombotic disorder such as cerebral vascular diseases (Maguire et al., 2008; Sonoda et 
al., 2000). Thromboxane A2 (TXA2) is known to exhibit the activity of stimulation of 
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platelet function and smooth muscle contraction, including platelet aggregation (Joachim 
et al., 2001), vasoconstriction, and bronchoconstriction. It has been reported that 
arylsulphonamide and arylamide derivatives have the activity of thromboxane synthase 
inhibitor and thromboxane receptor antagonist. There are examples from using compound 
(97), HN-11 500, DT-TX30, EK112, (Jose et al., 2000; Wang et al., 2003). Centrally 
constrained thieno[2,3-b]thiophene sulphonamides have provided a potent, selective, 
orally active series of platelet aggregation inhibitors. Compound (98) showed excellent 
activity in the dog after a single oral dose of 200 µg/Kg (Prugh et al., 1997).  
 
In addition, a series of arylsulphonamide and arylamide derivatives have been prepared 
and evaluated for platelet aggregation inhibition with (99) having the highest activity 
with % inhibition of 79.16 (Wang et al., 2003).     
2.9.3.  Calmodulin (CaM) Antagonist 
 Calmodulin (CaM) is an 18-kd multifunctional protein and is the major 
intracellular Ca2+-binding protein. The molecule consists of two globular lobes connected 
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by a long exposed α-helix. Two calcium ions bind to each lobe through helix-loop-helix 
domains similar to those of other calcium-binding proteins. CaM is a Ca2+ binding 
protein that is a key component of the Ca2+ second-messenger system and is involved in 
controlling many of the biochemical processes of cells (Ahn et al., 2003). N-(6-
aminohexyl)-5-chloro-1-naphthalene-sulphonamide (100) (Bariwal et al., 2008) and N-
(5-aminopentyl)-5-chloro-1-naphthalene-sulphonamide hydrochloride (101) have been 
reported as calmodulin antagonist sulphonamide which showed dose dependant 
inhibitory action with the potencies comparable to that of calmodulin antagonist.  
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 Furthermore, N-(2-methylaminoethyl)-5-isoquinolinesulphonamide H8 (102) 
selectively inhibits several cAMP-dependent protein kinases while a newly synthesized 
isoquinoline sulphonamide, designated H89 (103) is even more potent than H8 in 
inhibiting cAMP-dependent protein kinases (Cope, 2011). In many instances, calcium 
exerts its regulatory role by activation of a family of related, high-affinity calcium 
binding proteins (i.e., calmodulin, troponin C, and parvalbumin) which are present in 
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eukaryotes (Veigl et al., 1984). Within this class of regulatory proteins, calmodulin 
appears to be the major intracellular receptor for Ca2+ (Veigl et al., 1986). 
2.9.4.  Anti-inflammatory Activity   
 Non-steroidal anti-inflammatory drugs (NSAIDs) are very widely used to treat a 
variety of acute and chronic inflammatory diseases. Today these drugs are being 
increasingly used for the treatment of postoperative pain (Ong et al., 2005). Since COX-2 
is involved in inflammation and pain, molecules that inhibit it’s enzymatic activity would 
be of therapeutic value. Many non-steroidal anti-inflammatory drugs (NSAIDs) were 
found to interact with these enzymes and inhibit their enzymatic activity (Ratish et al., 
2009). The synthesis and anti-inflammatory activity of new N-phenyl-phthalimide 
sulphonamides (104a–e) has been reported (Lima et al., 2002). Compound (104e) 
(LASSBio-468), having a sulphonyl-thiomorpholine unit, showed potent inhibitory 
activity on neutrophil recruitment with ED50 2.5 mg kg–1, which was correlated with its 
inhibitory effect on TNF-α level. Out of 19 new pyrazoline bearing sulphonamide 
synthesized by Ratish and coworkers, (104k) and (104i) were found to be more active 
than celecoxib (Ratish et al., 2009). 
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 In another study, N-acetyl-2-carboxylbenzenesulphonamide regioisomers 
possessing a N-difluoromethyl-1,2-dihydropyrid-2-one moiety (i.e. N-acetyl 4- (105) and 
5-(N-difluoro methyl-1,2-dihydropyrid-2-one-4-yl)carboxybenzenesulphonamides (106) 
were reported to exhibit weak to moderate in vitro COX-2 isozyme inhibitory potency 
and good COX-2 selectivity in conjunction with potent inhibition of the 5-LOX enzyme 
(Chowdhury et al., 2009).  
2.9.5. Carbonic Anhydrase Inhibitory Activity 
 The carbonic anhydrase program started in the Legacy Pharmacia Company with 
a screening effort of proprietary compounds that identified pyrazole 
benzenesulphonamides as inhibitors of CAII (Vernier et al., 2010). There was also 
collaboration at Pharmacia with C. Supuran that identified celecoxib as an inhibitor of 
CAII (Weber et al., 2004). For existing assays, esterase activity for the CAIV isozyme 
was much weaker than for the CAII isozyme (Landolfi et al., 1997). To improve 
sensitivity as well as throughput, a new assay for CAIV was developed (Maren et al., 
1983). Glaucoma is a disease characterized by increased intraocular pressure (IOP) 
(Libby et al., 2005). Carbonic anhydrase (CA) inhibition has been demonstrated to 
reduce fluid flow into the eye and alleviate high IOP (Supuran, 2008; Maren et al., 1983). 
For over 40 years, CA inhibitors (CAIs) were available only as pills, and these were 
intended for other therapies. A novel series of potent thioether benzenesulphonamide 
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inhibitors of carbonic anhydrases II and IV was discovered using structure-based drug 
design.  
 
 It was reported that 5-(aminosulphonyl)-N-ethyl-3-fluoro-2-(isobutylthio)-
benzamide (107), 6-[(2,3,5,6-tetrafluorophenyl)thio]pyridine-3-sulphonamide (108), 5-
(aminosulphonyl)-N-(3-methoxypropyl)-2-[(2,3,5,6-tetrafluorophenyl)thio]nicotinamide 
(109) exhibited very high CAII inhibition with IC50 of 2.79, 8.29 and 10.6 nM 
respectively. However, they are not as high as that of clinical reference dorzolamine (110) 
(IC50 < 2 nM). Synthesis, structure–activity relationship, and optimization of 
physicochemical properties of such templates are also described. Low nanomolar potency 
was achieved (Vernier et al., 2010). 
2.9.6. Antimicrobial Activity 
 Sulphonamides are a class of broad-spectrum synthetic bacteriostatic antibiotics. 
They inhibit multiplication of bacterial but do not actively kill bacteria. Although the 
sulphonamide therapy has been reduced, owing to development of more effective 
antimicrobial agents and to the gradual increase in the resistance of bacterial species, 
clinical treatment with sulphonamides has undergone a revival by the combination of 
sulphamethoxazole and trimethoprim (Genç et al., 2008). Antimicrobial activity of some 
sulphonamides against clinical isolates of Staphylococcus aureus has been investigated 
(Genç et al., 2008). The strongest inhibition was observed in the screening of [N-(2-
 54
hydroxy-4-nitrophenyl)-4-methylbenzenesulphonamide] (111) and [N-(2-hydroxy-5-
nitro-phenyl)-4-methylbenzene sulphonamide] (112) agai st S. aureus. n fact, compound 
(111) showed higher effect on twenty one S. aureus MRSA isolates than oxacillin 
antibiotic. Introduction of an electron withdrawing group on the ring increased the 
antimicrobial activity remarkably. 
n  I
 
2.9.7.  Anti-Human Immunodeficiency Virus (Anti-HIV) 
linical syndrome caused by  Acquired immunodeficiency syndrome (AIDS) is a c
the infection with human immunodeficiency virus-1 (HIV-1), which results in profound 
immunosuppression (Chauthe et al., 2010). The present line of research focuses on the 
presumption that an inhibitor that can maximize interactions in the HIV-1 protease active 
site, particularly with the enzyme backbone atoms, will likely retain these interactions 
with mutant enzymes (Ghosh et al., 2008). Human immunodeficiency virus type 1 (HIV-
1) infection remains a major global health problem due to the emergence of drug-resistant 
strains (Sorbera et al., 2005). It has been a serious, life-threatening health problem which 
has claimed 25 million lives world wide in the last 25 years (Chauthe et al., 2010). 
 Human immunodeficiency virus type 1 (HIV-1) integrase (IN) is not only a key 
molecule for HIV genomic integration but also is important in other steps of HIV-1 
replication, including reverse transcription, nuclear import, chromatin targeting, virus 
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release and maturation (Ao et al., 2010). Recently, a series of cyclotriazadisulphonamide 
analogues (113) and (114) derived from computer-aided prediction (Pinheiro et al., 2008) 
as well as sulphonamide marketed as darunavir (115) were reported as potent anti-HIV 
agent (Temesgen, 2007; Koh et al., 2003). Sulphonamide derivative amprenavir, (116) 
has also been designed and identified as a novel nonpeptidic human immunodeficiency 
virus type I (Ray et al., 2005). 
 
 
2.9.8. Antimalarial Activity 
infectious disease which poses serious problem to man’s 
health (Lee et al., 2010; Hay et al., 2005). It is caused primarily by a protozoan 
Plasmodium falciparum, which is responsible for the death of over 1 million individuals 
every year with more than 40% of the global population at risk (WHO, 2005). During the 
past 10 years, real progress has been made in scaling up malaria control and prevention 
Malarial is a tropical 
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efforts. Since resistance to currently used antimalarials is spreading rapidly, there is a 
great need for new drugs. Thus, there is a compelling and urgent necessity for new 
antimalarials, with mechanisms of action different from the existing ones and to identify 
new drug targets (Miller et al., 2002). An array of sixteen 2,4-diamino-6-quinazoline 
sulphonamide derivatives (117a-p) were evaluated for antimalarial activity and were 
shown to have promising activity (Agrawal et al., 2001). In like manner, sulphonamide 
(118), was identified as an important compound with potent antimalarial activity (Miller 
et al., 2002). 
 
 
.10 Justification for the Study 
e of the major immediate threats to human health today 
2
 Multi-drug resistance is on
(Dyatkina et al., 2002). This is because the upsurge of the antibiotic resistant bacteria in 
the recent years has contributed much towards the increased mortality and morbidity 
associated with systemic infectious diseases like pneumonia, tuberculosis and meningitis 
(Kanamaru et al., 2001). For instance, methicillin is a good antibacterial agent, yet, 
methicillin resistance among Staphylococcus aureus (Kaatz et al., 2005) and 
Staphylococcus epidermidis (Nayak et al., 2007; Masunari et al., 2007) had been 
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identified to be of great concern in public health, especially if the control of the spread is 
not quickly initiated. Likewise, ampicillin and fluoroquinolone derivatives (e.g. 
norfloxacin and ciprofloxacin) have been commonly prescribed for the treatment of 
bacteria caused infection because of their broad spectrum activities (Pecoul et al., 1991; 
Smolyakov et al., 2001). Nevertheless, the loss of potency of these antibiotics has 
occurred due to issues of drug resistance. The expression for the loss of potency as a 
result of development of resistance by the bacterial organism is as shown in Fig. 2.4  
Fig. 2.4: Selection of Resistant Bacteria  
05 
biotics has led to emergence of multidrug-
resistan
Source: Clatworthy et al., 2007; Wright, 20
However, the intensive use of these anti
t strains of Pseudomonas aeruginosa (Jensen et al., 2001; Wong and Hancock, 
2000). In these cases, the cells which were originally susceptible to a particular drug, 
over the time may acquire a tolerance (resistance) to that drug (Clatworthy et al., 2007). 
In other cases, it was found that the drug actually reversed its original action by 
stimulating instead of inhibiting the microorganisms activity (Finar, 1986). 
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Epidemiological studies have also revealed that emergence of new diseases is at the 
alarming rates in the recent time (WHO, 2005), while occurrence of side effects during 
the administration of some of these antimicrobial agents cannot be overemphasized. 
Phlebitis occurs consistently with the intravenous administration of vancomycin, 
erythromycin and amphotericin B (Lamb et al., 2002).  
 Furthermore, other side effects include itching of the body, gut irritation among 
s, animals and plants emerge regularly (Sekkides, 2010; 
others. This is why some of those drugs have to be constantly replaced by synthetic drugs 
with less toxicity for animal tissues. Sulphonamides are a very important class of 
compounds in the pharmaceutical industry, being widely used as antimicrobial (Eshghi et 
al., 2011; Santosh et al., 2010; Gao and Pedersen, 2009), anticancer, anti-inflammatory 
and antiviral agents (Supuran et al., 2003; Scozzafava et al., 2003). Over 30 drugs 
containing this functionality are in clinical use (Behmadi et al., 2009), including, anti-
bacterials, diuretics, anticonvulsants, hypoglycemic and HIV protease inhibitors (Hansch 
et al., 1990).  As a class; the sulpha drugs have a veritable history of application for the 
treatment of bacterial infection (Korbila et al., 2009; Hughes et al., 2005). 
Sulphonamides are among the most widely used antibacterial agents in the world, chiefly 
because of their low cost, low toxicity and excellent activity against common bacterial 
diseases (Özbek et al., 2007).   
 New diseases of human
Friesen et al., 2006). As at 2008, mankind is confronted by 346 generic infectious 
diseases, distributed in a seemingly haphazard fashion across 220 countries. An average 
of three new diseases is described every two years and a new infecting organism is 
published every week! Over 1,600 human pathogens have been reported, each with a 
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specific set of phenotypic, genomic and susceptibility characteristics which must be 
confronted by diagnostic laboratories and clinicians. The pathogens are in turn confronted 
by 276 generic anti-infective agents and 67 vaccines – marketed under 10,493 proprietary 
names (Gideon, 2008). The examples of some emerging pathogens and major infectious 
diseases reported since 1972 are presented in Table 1.1 (Gideon, 2008). 
Table 2.1: Major Infectious Diseases Reported Since 1972 
Year Agent Disease 
1973 Rotavirus Rotavirus disease 
1975 Parvovirus Fifth diseaseB19  
1976 Cryptosporidium parvum Cryptosporidiosis 
1977 Ebola virus Ebola 
1977 Legionella pneumophila Legionellosis 
1977 Hantavirus Hemorrhagic fevers 
1977 Campylobacter jejuni Campylobacteriosis 
1980 T-lymphotrophic virus T-cell leukemia 
1981 Toxigenic S. aureus Toxic shock syndrome 
1982 E. coli O157:H7 Hemorrhagic colitis, HUS 
1982 HTLV-II Hairy cell leukemia 
1982 Borrelia burgdorferi Lyme disease 
1983 HIV AIDS 
1983 Helicobacter pylori Peptic ulcer disease 
1985 Enterocytozoon bieneusi poridiosis Micros
1986 Cyclospora cayatenensis Cyclosporidiosis 
1988 Human Herpes 6 Roseola infantum 
1988 Hepatitis E virus Hepatitis E 
1989 Ehrlichia chaffeensis Ehrlichiosis 
1989 Hepatitis C virus Hepatitis C 
1989 Guanarito virus Venezuelan hemorrhagic fever 
1992 Bartonella henselae isease Cat scratch d
1993 Sin nombre virus  Hantavirus pulmonary syndrome
1994 Sabia virus Brazilian hemorrhagic fever 
1995 Human herpesvirus 8 Kaposi sarcoma 
1999 Nipah virus Nipah virus disease 
2003 SARS Coronavirus SARS 
So Gid
 
lphonamides are clinically important drugs (sulphamethazine, 
sulphanilamide, sulphaguanidine and sulphadoxin) in treating various gastrointestinal 
urce: eon, 2008 
 Furthermore, su
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diseases and other forms of infections (Bornholdt et al., 2009). Starting with the 
antibacterial sulpha drugs and later incorporated into launched drugs such as argatroban 
(Thrombin inhibitor), udenafil (PDE5 inhibitor), sumatriptan (5-HT agonist) and 
tipranavir (HIV protease inhibitor) with a variety of different pharmacological effects 
(Bornholdt et al., 2009). The mode of action of sulphonamide drug is based on the 
inhibition of DNA synthesis (Pérez-Trallero and Iglesias, 2003) by interfering with para-
aminobenzoic acid (PABA) in biosynthesis of folic acid which is essential for growth of 
bacterial cells (Levin et al., 2007). 
Sulphonamides were reported to be less toxic when compared with other 
antibiotics such as atovaquone and azithromycin (Chohan, 2008; Hughes et al., 2005). In 
fact, su
 
 
lphonamide-based compound E7070 successfully underwent phase II clinical 
trials because of its tolerable toxicity profile (Owa et al., 2002). Methicillin-resistant 
staphylococci are resistant to many antibiotics such as penicillin, carbapenems, cephems 
and beta-lactam, quinolone, amino glycosides and tetracycline (Jain et al., 2004; Knauer 
et al., 2004; Huang et al., 2003), whereas sulphonamides and their combination therapies 
are gaining more attention by the day in antimicrobial drug research (Genç et al., 2008). 
Based on the various challenges mentioned above, there is a continuous need for the 
synthesis of new organic sulphonamide compounds as potential antimicrobial agents for 
the replacement of the old existing ones currently available in the market or to enhance 
the potency of the former ones. Thus, it is conceivable to develop a series of 
functionalized sulphonamides and benzothiazepine compounds with different substituents 
on their fused phenyl framework (for structure-activity relationship purpose).  
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CHAPTER THREE 
MATERIALS AND METHODS 
.1. General Conditions  
The 1H-NMR and 13C-NMR spectra were recorded in CDCl3 or DMSO-d6, unless 
PX 400 spectrometer operating at 400 MHz and 100 
MHz respectively. TMS was used as interna  signal of the 
solvent as the lock and chem elting points were 
elting point apparatus manufactured by Beijing 
f) values were duly calculated. Column 
a
3
 
otherwise stated, on NMR Bruker D
l standard with the deuterium
ical shifts δ recorded in ppm. The m
determined on X-4 Digital Microscopic m
Technical Instrument Co. Ltd. and were uncorrected. IR spectra were run on Varian 
Excalibur HE 3100 FT-IR Spectrometer while the Mass Spectra were obtained using 
Waters GCT Premier Spectrometer. The elemental analysis (C, H, N) of the compounds 
were performed at the Institute of Chemistry, Chinese Academy of Sciences, Beijing, 
using Flash EA 1112 Elemental Analyzer. Lyophilization was carried out with the FD-1 
Freeze Drier while the concentration and removal of solvents was achieved with the RE-
2000B Rotary Evaporator.  
 In addition, the pH was monitored and confirmed during acidification with a 
Portable pH Meter Model PHB4. All drying were conducted at reduced pressure with 
DHG-9023A Vacuum Oven. The reaction progress was monitored with TLC using 
CHCl3/CH3OH solvent system; developed plates were visualized under UV lamp where 
necessary and the retention factor (R
chrom tographic purifications were carried out on Merck silica gel F (Mesh 200-300). 
Organic solutions were dried over anhydrous sodium sulphate (Na2SO4) and concentrated 
with a Buchi rotary evaporator at reduced pressure. At all stage of the experiments, the 
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synthetic protocols were effected in bone dried solvents under nitrogen atmosphere in 
dried glassware which were flushed with stream flow of nitrogen gas prior to use and 
thionyl chloride (SOCl2) was freshly distilled prior to use. p-Toluenesulphonyl chloride 
(p-TsCl) was purified by recrystallization from chloroform/pet ether before use while 
other reagents were used directly after ascertaining the purity condition. All the amino 
acids used as well as anthranilic acid, n-butyllithium (2.2M in hexane), carbon 
tetrachloride and potassium phthalate were obtained from Aladdin Chemical Co. Ltd., 
Shanghai. The benzenesulphonyl chloride and p-toluenesulphonyl chloride were supplied 
by Huaxueshiji China while oxalyl chloride and α–toluenesulphonyl chloride were 
obtained from Zur Synthese and Alfa Aesar Chemicals respectively. All other chemicals 
were obtained from Beijing Chemical Works, China. 
3.2. General Procedure for Synthesis of α-Toluenesulphonamides (1a-k) 
 Sodium caebonate (Na2CO3) (1.113 g, 10.5 mmol) was added to a solution of the 
amino acid (5 mmol) in H2O (6 mL) with continuous stirring until all the solutes had 
dissolved. The clear solution was cooled to -10 oC and α-toluenesulphonyl chloride (α-
TsCl) (1.144 g, 6 mmol) was added in three batches over a period of 1 h. It was warmed 
mixture was up to 0 oC and stirred at the same temperature for 1 h. Finally, the reacting 
then warmed up to room temperature and allowed to stir for 48 h. The reaction mixture 
was transferred into a separatory funnel where the excess of α-TsCl was removed by 
extraction with DCM. The aqueous layer was then worked up by addition of 2M HCl 
until pH 2.2 was attained. The clear liquid was then lyophilized at -52 oC under reduced 
pressure (1pa, 0.00750 mmHg) for 12 h to obtain the crude solid product which was 
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purified by column chromatography (CHCl3/CH3OH, 3:1) to afford α-
toluenesulphonamides (1a-k) in excellent yields (87.7 - 98.8%).   
3.2.1. 1-(Benzylsulphonyl)pyrrolidine-2-carboxylic acid (1a). The amino acid was L-
proline; yield 1.24 g (92.0%); mp 161 oC; Rf = 0.84 (CHCl3/CH3OH, 3:1, at RT). 1H-
NMR (D2O) δ: 7.47 (s, 5H, Ar-H), 4.46-4.43 (dd, J1 = 7.20 Hz, J2 = 15.76 Hz, 1H, 
HOOC-CH-CH2(a,b)), 4.24 (s, 2H, CH2-SO2), 3.48-3.45 (t, J = 7.28 Hz, 2H, N-CH2-
CH2), 2.46-2.45 (m, 1H, CHa of CH2), 2.22-2.21 (m, 1H, CHb of CH2), 2.15-2.09 
(quintet, J = 6.80 Hz, 2H, CH2-CH2-CH2(a,b)) ppm. 13C-NMR (Dioxane) δ: 173.1 (CO), 
132.6, 131.2 (2 × CH aromatic), 129.5 (2 × CH aromatic), 128.9, 60.6, 57.7, 47.1, 29.2, 
24.3 ppm. IR (KBr) cm-1: 3441 (OH of acid), 2980 (CH aromatic), 2828 (CH aliphatic), 
1728 (C=O of COOH), 1620 (C=C), 1219, 1151 (SO2 two bands), 700 (Ar-H). MS: in 
m/z [rel. %]: 270.1 [MH+, 6.5%], 269.1 [M+, 9%], 179.1 [18.4%], 178.1 [M+ - PhCH2·, 
100%], 176.1 [32.4%], 122.0 [49%], 105.0 [32%]. Anal. calcd. for C12H15NO4S (269.32): 
C, 53.52; H, 5.61; N, 5.20. Found: C, 53.77; H, 5.49; N, 5.34. 
N
O OH
S
O
O
1-(Benzylsulphonyl)pyrrolidine
-2-carboxylic acid
(1a)
                                              
3.2.2. 1-(Benzylsulphonyl)piperidine-2-carboxylic acid (1b). The amino acid was 
pipecolic acid; yield 1.38 g (98.0%); mp 248 oC (dec); Rf = 0.87 (CHCl3/CH3OH, 3:1, at 
RT). 1H-NMR (D2O) δ: 7.52 (s, 5H, Ar-H), 4.28 (s, 2H, CH2-SO2), 4.08-4.03 (dd, J1 = 
 HOOC-CH3.44 Hz, J2 = 15.12 Hz, 1H, -CH2), 3.57-3.53 (m, 1H, CHa of CH2-N), 3.16-
3.10 (m, 1H, CHb of CH2-N), 2.40-2.36 (m, 1H, CH), 2.01-1.92 (m, 2H, 2 × CH), 1.81-
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1.68 (m, 3H, CH & CH2) ppm. 13C-NMR (Dioxane) δ: 172.5 (CO), 132.5, 131.2 (2 × CH 
aromatic), 129.5 (2 × CH aromatic), 128.9, 57.7, 57.6, 44.8, 26.5, 22.1 (2 × CH2) ppm. IR 
(KBr) cm-1: 3422 (OH of acid), 2974 (CH aromatic), 2822 (CH aliphatic), 1736 (C=O of 
COOH), 1603 (C=C), 1238, 1159 (SO2 two bands), 700 (Ar-H). MS: in m/z [rel. %]: 
269.1 [M+ - CH2·, 3.2%], 180.1 [55%], 179.1 [65%], 178.1 [M+ - PhCH2, 100%], 165.1 
[30%], 121.0 [42%], 77.0 [Ph+, 13%], 64.0 [SO2+, 31.7%]. Anal. calcd. for C13H17NO4S 
(283.35): C, 55.11; H, 6.05; N, 4.94. Found: C, 55.29; H, 5.94; N, 4.86. 
                                             
N
O OH
S
O
O
1-(Benzylsulphonyl)piperidine
-2-carboxylic acid
(1b)
 
3.2.3. 2-(Phenylmethylsulphonamido)acetic acid (1c). The amino acid was glycine; 
yield 1.08 g (94.0%); mp 142-143 oC; Rf = 0.51 (CHCl3/CH3OH, 3:1, at RT). 1H-NMR 
(D2O) δ: 7.45 (s, 5H, Ar-H), 4.19 (s, 2H, CH2-SO2), 3.76 (s, 2H, CH2-COOH) ppm. 13C-
NMR (Dioxane) δ: 170.6 (CO), 132.7, 131.2 (2 × CH aromatic), 129.5 (2 × CH aromatic), 
(KBr) cm-1: 3433 (OH of acid), 3030 (N-H), 2990 (CH 128.9, 57.7, 40.8 ppm. IR 
aromatic), 2832 (CH aliphatic), 1736 (C=O of COOH), 1616 (C=C), 1215, 1171 (SO2 
two bands), 702 (Ar-H). MS: in m/z [rel. %]: 212.1 [M+ - OH, 7.9%], 180.1 [73%], 179.1 
[88%], 178.1 [M+ - PhCH2, 100%], 91.1 [PhCH2+, 48%], 64 [26%] 45 [+COOH, 2.4%]. 
Anal. calcd. for C9H11NO4S (229.26): C, 47.15; H, 4.84; N, 6.11. Found: C, 46.90; H, 
5.01; N, 5.97. 
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OHO S
O
ONH
2-(Phenylmethylsulphon
amido)acetic acid
(1c)
                                                     
3.2.4. 2-(Phenylmethylsulphonamido)propanoic acid (1d). The amino acid was alanine; 
yield 1.18 g (97.0%); mp 220-224 oC; Rf = 0.81 (CHCl3/CH3OH, 3:1, at RT). 1H-NMR 
2 (s, 2H, CH(D2O) δ: 7.47 (s, 5H, Ar-H), 4.2 2-SO2), 4.14-4.08 (q, J = 7.28 Hz, 1H, CH-
CH3), 1.60-1.58 (d, J = 7.28 Hz, 3H, CH3-CH) ppm. 13C-NMR (Dioxane) δ: 176.8 (CO), 
131.0, 130.6 (2 × CH aromatic), 129.3 (2 × CH aromatic), 129.1, 60.4, 52.1, 19.6 ppm. 
IR (KBr) cm-1: 3424 (OH of acid), 2974 (CH aromatic), 2822 (CH aliphatic), 1751 (C=O 
of COOH), 1599 (C=C), 1213, 1169 (SO2 two bands), 698 (Ar-H). MS: in m/z [rel. %]: 
212.1 [22%], 180.1 [81.5%], 179.1 [91%], 178.1 [85%], 165.1 [M+ – PhCH3, 55%], 
122.0 [80%], 121.0 [100%], 77.0 [Ph+, 71.4%], 64.0 [SO2+, 54.6%], 51.0 [28%]. Anal. 
calcd. for C10H13NO4S (243.28): C, 49.37; H, 5.39; N, 5.76. Found: C, 49.29; H, 5.28; N, 
5.94. 
OHS
O HN
CH3
O
O
2-(Phenylmethylsulphon
amido)propanoic acid
(1d)
                                             
3.2.5. 3-Mercapto-2-(phenylmethylsulphonamido)propanoic acid (1e). The amino 
acid was cysteine; yield 1.22 g (89.0%); mp 183-186 oC; Rf = 0.49 (CHCl3/CH3OH, 3:1, 
.49 (s, 5H, Ar-H), 4.50-4 7 (dd, J1 = 4.24 Hz, J2 = 7.92 Hz, at RT). 1H-NMR (D2O) δ: 7 .4
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1H, CH2-CH-COOH), 4.24 (s, 2H, CH2-SO2), 3.55-3.50 (dd, J1 = 4.24 Hz,  J2 = 20.00 Hz, 
1H, CHa of CH2-CH), 3.39-3.33 (dd, J1 = 7.92 Hz, J2 = 20 Hz, 1H, CHb of CH2-CH) 
ppm. 13C-NMR (Dioxane) δ: 171.5 (CO), 132.6, 131.3 (2 × CH aromatic), 129.5 (2 × CH 
aromatic), 128.7, 57.8, 52.7, 37.2 ppm. IR (KBr) cm-1: 3439 (OH of acid), 2978 (CH 
aromatic), 2832 (CH aliphatic), 1728 (C=O of COOH), 1618 (C=C), 1207, 1159 (SO2 
two bands), 810 (Ar-H). MS: in m/z [rel. %]: 214.1 [31.7%], 123.0 [100%], 122.0 [90%], 
92.1 [PhCH3+, 33%], 91.0 [PhCH2+, 88%], 77.0 [Ph+, 8%], 65.0 [HSO2+, 34%], 45.0 
[+COOH, 28%], 36.0 [34%]. Anal. calcd. for C10H13NO4S2 (275.35): C, 43.62; H, 4.76; N, 
5.09. Found: C, 43.45; H, 4.94; N, 5.07. 
O
OHS
N
                                    
O
O H
3-Mercapto-2-(phenylmethylsulphon
amido)propanoic acid
SH
(1e)
                                       
3.2.6. 4-(Methylthio)-2-(phenylmethylsulphonamido)butanoic acid (1f). The amino 
acid was methionine; yield 1.33 g (87.7%); mp 138-140 oC; Rf = 0.68 (CHCl3/CH3OH, 
D2O) δ: 7.47 (s, 5H, Ar-H), 4.23 (s, 3:1, at RT). 1H-NMR ( 2H, CH2-SO2), 4.01-3.97 (t, J 
= 8.84 Hz, 1H, CH-CH2), 2.76-2.72 (t, J = 7.40 Hz, 2H, CH2-CH2-S), 2.33-2.29 (m, 1H, 
CH), 2.28-2.21 (m, 1H, CH), 2.19 (s, 3H, CH3-S) ppm. 13C-NMR (Dioxane) δ: 172.9 
(CO), 132.6, 131.2 (2 × CH aromatic), 129.5 (2 × CH aromatic), 128.7, 57.9, 52.8, 29.8, 
29.4, 14.7 ppm. IR (KBr) cm-1: 3442 (OH of acid), 2974 (CH aromatic), 2833 (CH 
aliphatic), 2774 (CH aliphatic), 1742 (C=O of COOH), 1590 (C=C), 1211, 1161 (SO2 two 
bands), 698 (Ar-H). Anal. calcd. for C12H17NO4S2 (303.40): C, 47.51; H, 5.65; N, 4.62. 
Found: C, 47.49; H, 5.64; N, 4.66. 
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OOHS
N
O
O H
S
CH3
4-(Methylthio)-2-(phenylmethyl
sulphonamido)butanoic acid
(1f)
                                                      
3.2.7. 3-Methyl-2-(phenylmethylsulphonamido)butanoic acid (1g). The amino acid 
was valine; yield 1.34 g (98.7%); mp 197-200 oC; Rf = 0.83 (CHCl3/CH3OH, 3:1, at RT). 
Ar-H), 4.25 (s, 2H, CH1H-NMR (D2O) δ: 7.49 (s, 5H, 2-SO2), 4.04-4.03 (d, J = 4.40 Hz, 
1H, CH-CH-COOH), 2.47-2.38 (m, 1H, CH-CH-(CH3)2), 1.15-1.13 (d, J = 7.04 Hz, 
3H, CH3-CH), 1.13-1.11 (d, J = 7.08 Hz, 3H, CH3-CH) ppm. 13C-NMR (Dioxane) δ: 
172.4 (CO), 132.5, 131.2 (2 × CH aromatic), 129.5 (2 × CH aromatic), 128.9, 59.2, 57.7, 
29.8, 18.1, 17.8 ppm. IR (KBr) cm-1: 3447 (OH of acid), 2974 (CH aromatic), 2833 (CH 
aliphatic), 2783 (CH aliphatic), 1730 (C=O of COOH), 1618 (C=C), 1225, 1165 (SO2 two 
bands), 700 (Ar-H). MS: in m/z [rel. %]: 271.1 [M+, 14%], 91.0 [PhCH2+, 30%], 75.0 
[65%], 72.1 [100%], 55.0 [79%], 29.0 [50%]. Anal. calcd. for C12H17NO4S (271.34): C, 
53.12; H, 6.32; N, 5.16. Found: C, 53.31; H, 6.50; N, 5.20. 
CH3
S
O
O H
CH3
O OH
N
3-Methyl-2-(phenylmethylsulphon
amido)butanoic acid
(1g)
                                       
  3.2.8. 3-Hydroxy-2-(phenylmethylsulphonamido)butanoic acid (1h). The amino acid 
was threonine; yield 1.25 g (91.5%); mp 194-195 oC; Rf = 0.48 (CHCl3/CH3OH, 3:1, at 
, 1H, CH), 4.24 (s, 2H, CHRT). 1H-NMR (D2O) δ: 7.49 (s, 5H, Ar-H), 4.48-4.46 (m 2-
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SO2), 4.05-4.04 (d, J = 4.40 Hz, 1H, CH-CH-COOH), 1.42-1.41 (d, J = 6.64 Hz, 
3H, CH3-CH) ppm. 13C-NMR (Dioxane) δ: 171.5 (CO), 132.5, 131.2 (2 × CH aromatic), 
129.5 (2 × CH aromatic), 128.9, 66.1, 59.4, 57.7, 19.8 ppm. IR (KBr) cm-1: 3404 (OH of 
acid), 2976 (CH aromatic), 2824 (CH aliphatic), 1740 (C=O of COOH), 1601 (C=C), 
1219, 1157 (SO2 two bands), 700 (Ar-H). Anal. calcd. for C11H15NO5S (273.31): C, 48.34; 
H, 5.53; N, 5.12. Found: C, 48.29; H, 5.61; N, 4.98. 
CH3
O OH
S
N
OH
                                         
O
O H
3-Hydroxy-2-(phenylmethylsulphon
amido)butanoic acid
(1h)
 
3.2.9. 5-Amino-5-oxo-2-(phenylmethylsulphonamido)pentanoic acid (1i). The amino 
acid was glutamine; yield 1.41 g (94.1%); mp 211-214 oC; Rf = 0.38 (CHCl3/CH3OH, 3:1, 
J  = 5.04 Hz, J2 = 14.32 Hz, at RT). 1H-NMR (D2O) δ: 7.48 (s, 5H, Ar-H), 4.47-4.43 (dd, 1
1H, HOOC-CH-CH2), 4.23 (s, 2H, CH2-SO2), 2.62-2.55 (m, 1H, CH), 2.49-2.44 (dd, J1 = 
9.20 Hz, J2 = 18.72 Hz, 2H, CH2-CH2-CON), 2.27-2.20 (m, 1H, CH) ppm. 13C-NMR 
(Dioxane) δ: 181.1 (CO of acid), 163.2 (CO of amide), 132.5, 131.2 (2 × CH aromatic), 
129.5 (2 × CH aromatic), 128.9, 59.2, 57.7, 30.5, 26.2 ppm. IR (KBr) cm-1: 3246 (OH of 
acid), 3075, 3053 (NH two bands), 2983 (CH aromatic), 2951 (CH aliphatic), 1703 (C=O 
of COOH), 1659 (C=O amide), 1412 (OH bending in-plane), 1221, 1193 (SO2 two bands), 
696 (Ar-H), 631 (N-H bending with wagging). Anal. calcd. for C12H16N2O5S (300.34): C, 
47.99; H, 5.37; N, 9.33. Found: C, 48.03; H, 5.56; N, 9.41. 
 84
O
HO
O HN
S
O O
H2N
5-Amino-5-oxo-2-(phenylmethylsulphonamido)pentanoic acid
(1i)
                                 
3.2.10. 3-Phenyl-2-(phenylmethylsulphonamido)propanoic acid (1j). The amino acid 
yield 1.58 g (98.8%); mp 218 oC (dec); Rf = 0.84 (CHCl3 H3OH, was phenylalanine; /C
3:1, at RT). 1H-NMR (D2O) δ: 7.46 (s, 10H, 2 × Ar-H), 4.34-4.31 (dd, J1 = 5.60 Hz, J2 = 
13.28 Hz, 1H, PhCH2-CH-COOH), 4.22 (s, 2H, CH2-SO2), 3.41-3.36 (dd, J1 = 5.60 Hz, 
J2 = 20.00 Hz, CHa of CH2-Ph), 3.28-3.22 (dd, J1 = 7.60 Hz, J2 = 20.00 Hz, 1H, CHb of 
CH2-Ph) ppm. 13C-NMR (Dioxane) δ: 172.3 (CO of acid), 134.8, 132.6, 131.2 (2 × CH 
aromatic), 130.3 (2 × CH aromatic), 130.1 (2 × CH aromatic), 129.5 (2 × CH aromatic), 
128.9 (2 × CH aromatic), 57.7, 55.0, 36.4 ppm. IR (KBr) cm-1: 3441 (OH of acid), 2974 
(NH), 2822 (CH aromatic), 2776 (CH aliphatic), 1740 (C=O of COOH), 1609 (C=C), 
1221, 1171 (SO2 two bands), 702 (Ar-H), 623 (N-H bending). MS: in m/z [rel. %]: 270.1 
[4%], 212.1 [12%], 180.1 [90%], 179.1 [95%], 178.1 [100%], 165.1 [60%], 122.0 [34%], 
121.0 [67%], 64 [SO2+, 70%]. Anal. calcd. for C16H17NO4S (319.38): C, 60.17; H, 5.37; 
N, 4.39. Found: C, 59.98; H, 5.21; N, 4.42. 
S
O
O OH
O HN
3-Phenyl-2-(phenylmethyl
sulphonamido)propanoic acid
(1j)
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3.2.11. 3-(4-(Benz lsulphonamido)propanoic 
acid (1k). Th  258-260 oC; Rf = 0.82 
(CHCl3/CH3 : 7.43 (s, 10H, 2 × Ar-H), 7.22-7.20 (d, J 
J  = 5.60 
J
ylsulphonyloxy)phenyl)-2-(phenylmethy
e amino acid was tyrosine; yield 2.19 g (89.6%); mp
OH, 3:1, at RT). 1H-NMR (D2O) δ
= 8.40 Hz, 2H, OTs-H), 6.93-6.91 (d, J = 8.40 Hz, 2H, OTs-H), 4.31-4.28 (dd, 1
Hz, 2 = 13.08 Hz, 1H, PhCH2-CH-COOH), 4.19 (s, 4H, 2 × CH2-SO2), 3.31-3.26 (dd, 1 
= 5.60 Hz, 2 2 1 2
CHb of CH2-Ph) ppm. C-NMR (Dioxane) : 172.8 (CO of acid), 156.5, 140.9, 132.0, 
aromatic), 126.6, 123.6 (2 × CH aromatic), 117.1 (2 × CH aromatic), 111.8 (2 × CH 
2 
2
2 23 23 7 2 
OHO
O
OHN
O
S
O
J
J  = 20.00 Hz, CHa of CH -Ph), 3.19-3.14 (dd, J  7.52 Hz, J  = 20.00 Hz, 1H, 
13 δ
131.8 (2CH aromatic), 131.3 (2 × CH aromatic), 129.6 (2 × CH aromatic), 129.0 (2 × CH 
aromatic), 58.4, 55.4, 36.1 ppm. IR (KBr) cm-1: 3435 (OH of acid), 3167 (NH), 3028 (CH 
aromatic), 2949 (CH aliphatic), 1724 (C=O of COOH), 1597 (C=C), 1194, 1148 (SO
two bands), 789 (S-OR ester), 694 (Ar-H), 631 (N-H bending). MS: in m/z [rel. %]: 
180.1 [74%], 179.1 [90%], 178.1 [100%], 165.1 [30%], 122.0 [10%], 91.1 [PhCH +, 
47%], 64 [SO +, 24%]. Anal. calcd. for C H NO S (489.57): C, 56.43; H, 4.76; N, 2.86. 
Found: C, 56.38; H, 4.79; N, 2.69. 
                        
SO
3-(4-(benzylsulphon
sulphonam
yloxy)phenyl)-2-(phenylmethyl 
ido)propanoic acid
(1k)
 
3.3. General Procedure for N,N-Diethylalkanamide of α-Toluenesulphonamide (2a-k) 
Oxalyl chloride (0.34 mL, 3.85 mmol, 1.30 equiv.) was added via dropping pipette to a 
solution of α-toluenesulphonamides 1a-k (2.96 mmol) in H2O (10 mL) in a streaming 
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flow of nitrogen gas, followed by addition of 1 drop of DMF. The resulting mixture was 
stirred at room temperature for 2 h to obtain the crude acid chloride which was kept air-
tighted prior to use. In a separate 250 mL three-necked round bottom flask, equipped with 
a magnetic stirring bar, was added Na2CO3 (0.628 g, 5.92 mmol, 2 equiv.) and H2O (10 
y diethyl amine DEA (0.4 mL, 3.85 mmol, 1.3 equiv.) in continuous mL) followed b
stirring and cooled to -15 oC. Then, earlier kept acid chloride was added in such a way to 
maintain the internal temperature of the reaction mixture at around -10 oC. The reacting 
mixture was then stirred at -10 oC for 1 h; at 0 oC for 1 h and finally at room temperature 
for 1 h. The reaction was terminated, worked up by acidifying with 2M HCl and 
concentrated in rotary evaporator. The clear solution obtained was freeze-dried to obtain 
the crude solid product which was purified by column chromatography (CHCl3 / CH3OH, 
3:1) to afford N,N-diethylalkanamide of α-toluenesulphonamide derivatives (2a-k). 
3.3.1. 1-(Benzylsulphonyl)-N,N-diethylpyrrolidine-2-carboxamide (2a). Yield 0.94 g 
(97.9%); mp 185-187 oC; Rf = 0.71 (CHCl3/CH3OH, 3:1, at RT). 1H-NMR (D2O) δ: 7.53 
(s, 5H, Ar-H), 4.54-4.50 (m, 1H, CH-CON), 4.28 (s, 2H, CH2-SO2), 3.56-3.54 (m, 2H, 
CH2-N), 3.19-3.14 (q, J = 7.28 Hz, 4H, 2 × CH2-CH3), 2.54-2.51 (m, 1H, CH), 2.28-2.24 
(m, 1H, CH), 2.16-2.14 (m, 2H, CH2), 1.39-1.35 (t, J = 7.28 Hz, 6H, 2 × CH3-CH2) ppm. 
13C-NMR (Dioxane) δ: 173.2 (C=O), 132.6, 131.1 (2 × CH aromatic), 129.4 (2 × CH 
aromatic), 128.8, 60.8, 57.7, 47.1, 43.3 (2 × CH2), 29.2, 24.2, 11.4 (2 × CH3) ppm. Anal. 
calcd. for C16H24N2O3S (324.45): C, 59.23; H, 7.46; N, 8.63. Found: C, 59.09; H, 7.46; N, 
8.48. 
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N
S
O
O N
O
1-(Benzylsulphonyl)-N,N-diethyl
(2a)
pyrrolidine-2-carboxamide
                               
3.3.2. 1-(Benzylsulphonyl)-N,N-diethylpiperidine-2-carboxamide (2b). Yield 0.99 g 
(99.0%); mp 210-211 oC; Rf = 0.72 (CHCl3/CH3OH, 3:1, at RT). 1H-NMR (D2O) δ: 7.54 
(s, 5H, Ar-H), 4.30 (s, 2H, CH2-SO2),  4.08-4.04 (dd, J1 = 3.52 Hz, J2 = 20.00 Hz, 1H, 
CH of CH2-N), 3.60-3.57 (m, 1H, CH-CON),  3.21-3.16 (q, J = 7.20 Hz, 4H, 2 × CH2-
CH3), 2.42-2.38 (dd, J1 = 3.32 Hz, J2 = 20.00 Hz, 1H, CH of CH2-N),  2.03-1.99 (m, 2H, 
3H, CH & CH2), 1.40-1.37 (t, J  CHCH2), 1.86-1.73 (m,  = 7.20 Hz, 6H, 2 × 3-CH2) ppm. 
13C-NMR (Dioxane) δ: 173.5 (C=O), 132.9, 131.1 (2 × CH aromatic), 129.8 (2 × CH 
aromatic), 128.6, 60.6, 57.8, 47.4, 43.4 (CH2), 29.4, 24.2, 18.1, 11.4 (CH3) ppm. IR (KBr) 
cm-1: 3028 (CH aromatic), 2951 (CH aliphatic), 1720 (C=O), 1593 (C=C), 1188, 1148 
(SO2 two bands), 696 (Ar-H). Anal. calcd. for C17H26N2O3S (338.47): C, 60.33; H, 7.74; 
N, 8.28. Found: C, 60.29; H, 6.94; N, 7.98. 
                                  
N
S
O
O
1-(Benzylsulphonyl)-N,N-
diethylpiperidine-2-carboxamide
N
O
(2b)
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3.3.3. N,N mide (2c). Yield 0.78 g 
(92.6%); mp 213-215 1H-NMR (D2O) δ: 7.53 
(s, 5H, Ar-H), 4.29 (s, 2H, 
-Diethyl-2-(phenylmethylsulphonamido)aceta
oC; Rf = 0.51 (CHCl3/CH3OH, 3:1, at RT). 
CH2-SO2),  4.01 (s, 2H, CH2-CON), 3.20-3.14 (q, J = 7.30 Hz, 
4H, 2 × CH2-CH3 CH), 1.39-1.36 (t, J = 7.30 Hz, 6H, 2 × 3-CH2) ppm. 13C-NMR 
(Dioxane) δ atic), 129.5 (2 × CH aromatic), 
1 (CH2), 11.4 (CH3) ppm. IR (KBr) cm-1: 3217 (N-H), 3036 (CH 
OS
: 174.1 (C=O), 133.4, 131.6 (2 × CH arom
128.6, 57.7, 49.8, 43.
aromatic), 2947 (CH aliphatic), 1712 (C=O), 1601 (C=C), 1219, 1194, (SO2 two bands), 
694 (Ar-H). Anal. calcd. for C13H20N2O3S (284.38): C, 54.91; H, 7.09; N, 9.85. Found: C, 
55.13; H, 6.94; N, 10.08. 
                                   
N
O
O HN
N,N-Diethyl-2-(phenylmethylsulph
onamido)acetamide
(2c)
 
3.3.4. N,N-Diethyl-2-(phenylmethylsulphonamido)propanamide (2d). Yield 0.87 g 
(98.5%); mp 238-240 oC; Rf = 0.56 (CHCl3/CH3OH, 3:1, at RT). 1H-NMR (D2O) δ: 7.50 
(s, 5H, Ar-H), 4.26 (s, 2H, CH2-SO2),  4.22-4.16 (q, J = 7.28 Hz, 1H, CH-CH3), 3.18-
3.12 (q, J = 7.32 Hz, 4H, 2 × CH2-CH3), 1.65-1.63 (d, J = 7.28 Hz, 3H, CH3-CH), 1.37-
1.33 (t, J = 7.32 Hz, 6H, 2 × CH3-CH2) ppm. 13C-NMR (Dioxane) δ: 173.8 (C=O), 132.7, 
ic), 129.5 (2 × CH aromatic), 128.9, 57.7, 49.8, 43.1 (CH2), 16.2, 131.2 (2 × CH aromat
11.4 (CH3) ppm. IR (KBr) cm-1: 3058 (N-H), 3036 (CH aromatic), 2951 (CH aliphatic), 
1719 (C=O), 1601 (C=C), 1219, 1196, 1148 (SO2 two bands), 696 (Ar-H). Anal. calcd. 
for C14H22N2O3S (298.41): C, 56.35; H, 7.43; N, 9.39. Found: C, 56.11; H, 7.33; N, 9.28. 
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N
O
O HN
OS
N,N-Dieth l-2-(phenylmethylsulphy
onamido)propanamide
(2d)
 
3.3.5. N,N-Diethyl-3-mercapto-2-(phenylmethylsulphonamido)propanamide (2e). 
Yield 0.87 g (89.0%); mp 198-200 oC; Rf = 0.71 (CHCl3/CH3OH, 3:1, at RT). 1H-NMR 
(D2O) δ: 7.46 (s, 5H, Ar-H), 4.54-4.51 (dd, J1 = 4.24 Hz, J2 = 7.92 Hz, 1H, CH2-CH-
COOH), 4.21 (s, 2H, CH2-SO2), 3.57-3.52 (dd, J1 = 4.24 Hz,  J2 = 20.00 Hz, 1H, CHa 
of CH2-CH), 3.41-3.36 (dd, J1 = 7.92 Hz, J2 = 20.00 Hz, 1H, CHb of CH2-CH), 3.18-3.12 
 2 × CH(q, J = 7.35 Hz, 4H, 2-CH3), 1.37-1.33 (t, J = 7.35 Hz, 6H, 2 × CH3-CH2) ppm. 
                                    
13C-NMR (Dioxane) δ: 173.5 (C=O), 132.7, 131.2 (2 × CH aromatic), 129.5 (2 × CH 
aromatic), 128.9, 57.4, 49.5, 43.1 (CH2), 35.5, 11.4 (CH3) ppm. IR (KBr) cm-1: 2997 (CH 
aromatic), 2911 (CH aliphatic), 1719 (C=O), 1591 (C=C), 1194, 1144 (SO2 two bands), 
696 (Ar-H). Anal. calcd. for C14H22N2O3S2 (330.47): C, 50.88; H, 6.71; N, 8.48. Found: C, 
50.71; H, 6.99; N, 7.97. 
N
O
O HN
OS
N,N-Diethyl-3-mercapto-2-(phenylmethyl
sulphonamido)propanamide
(2e)
SH
                               
ethylthio)-2-(phenylmethylsulphonamido)butanamide (2f). 
Yield 0.96 g (90.6%); mp 170-172 oC; Rf = 0.65 (CHCl3/CH3OH, 3:1, at RT). 1H-NMR 
3.3.6. N,N-Diethyl-4-(m
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J = 6.72 Hz, 1H, CH(D2O) δ: 7.49 (s, 5H, Ar-H), 4.24 (s, 2H, CH2-SO2),  4.23-4.20 (t, -
CH2), 3.16-3.10 (q, J = 7.32 Hz, 4H, 2 × CH2-CH3), 2.77-2.73 (t, J = 7.40 Hz, 2H, S-
CH2-CH2), 2.34-2.24 (m, 2H, CH-CH2-CH2-S), 2.19 (s, 3H, CH3-S), 1.35-1.31 (t, J = 
7.32 Hz, 6H, 2 × CH3-CH2) ppm. 13C-NMR (Dioxane) δ: 173.8, 132.7, 131.2 (2 × CH 
atic), 57.7, 49.8, 43.1 (CH2), 30.8, 29.5, 16.2, 11.4 (CH3) 
N
aromatic), 129.5, (2 × CH arom
ppm. IR (KBr) cm-1: 3028 (CH aromatic), 2945 (CH aliphatic), 1722 (C=O), 1620 (C=C), 
1200, 1126 (SO2 two bands) 698 (Ar-H). Anal. calcd. for C16H26N2O3S2 (358.53): C, 
53.60; H, 7.31; N, 7.81. Found: C, 53.55; H, 7.22; N, 7.69. 
                                 
OS
O
O HN
S
CH3
N,N-Diethyl-4-(methylthio)-2-(phenylmethyl
(2f)
sulphonamido)butanamide
 
3.3.7. N,N-Diethyl-3-methyl-2-(phenylmethylsulphonamido)butanamide (2g). Yield 
0.94 g (97.3%); mp 226-230 C; Rf = 0.69 (CHCl3/CH3OHo , 3:1, at RT). 1H-NMR (D2O) 
δ: 7.50 (s, 5H, Ar-H), 4.25 (s, 2H, CH2-SO2),  4.00-3.97 (d, J = 2.84 Hz, 1H, CH-CH-
CON), 3.17-3.11 (q, J = 7.32 Hz, 4H, 2 × CH2-CH3), 2.45-2.38 (m, 1H, CH), 1.36-1.32 (t, 
J = 7.32 Hz, 6H, 2 × CH3-CH2), 1.15-1.13 (d, J = 7.00 Hz, 3H, CH3-CH), 1.12-1.10 (d, J 
= 7.00 Hz, 3H, CH3-CH) ppm. 13C-NMR (Dioxane) δ: 173.8 (C=O), 132.7, 131.2 (2 × 
aromatic), 128.9, 60.8, 57.7, 49.8, 43.1 (CH2), 16.2, 15.5, CH aromatic), 129.5 (2 × CH 
11.4 (CH3) ppm. IR (KBr) cm-1: 3053 (CH aromatic), 2945 (CH aliphatic), 1718 (C=O), 
1611 (C=C), 1219, 1194 (SO2 two bands), 696 (Ar-H). Anal. calcd. for C16H26N2O3S 
(326.46): C, 58.87; H, 8.03; N, 8.58. Found: C, 59.01; H, 7.96; N, 8.61. 
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N
O
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N,N-Diethyl-3-methyl-2-(phenylmethyl
sulphonamido)butanamide
(2g)
 
3.3.8. N,N-Diethyl-3-hydroxy-2-(phenylmethylsulphonamido)butanamide (2h). Yield 
0.78 g (80.2%); mp 245 oC (dec); Rf = 0.53 (CHCl3/CH3OH, 3:1, at RT). 1H-NMR (D2O) 
δ: 7.55 (s, 5H, Ar-H), 4.54-4.52 (m, 1H, CH-CH-CH3), 4.31 (s, 2H, CH2-SO2), 4.09-4.08 
(d, J = 3.96 Hz, 1H, CH-CH-CON), 3.22-3.17 (q, J = 7.32 Hz, 4H, 2 × CH2-CH3), 2.85 (s, 
1H, OH), 1.49-1.47 (d, J = 6.60 Hz, 3H, CH3-CH), 1.41-1.37 (t, J = 7.32 Hz, 6H, 2 
× CH3-CH2) ppm. 13C-NMR (Dioxane) δ: 173.5 (C=O), 132.9, 131.3 (2 × CH aromatic), 
c), 128.9, 61.2, 58.1, 49.5, 42.5 (CH , 16.6, 11.1 (CH3) ppm. IR 129.5 (2 × CH aromati 2)
(KBr) cm-1: 3396 (OH), 3030 (CH aromatic), 2945 (CH aliphatic), 1720 (C=O), 1601 
(C=C), 1221, 1194 (SO2 two bands), 694 (Ar-H). Anal. calcd. for C15H24N2O4S (328.43): 
C, 54.86; H, 7.37; N, 8.53. Found: C, 54.71; H, 7.26; N, 8.65. 
                                    
N
O
O HN
HO
OS
N,N-Diethyl-3-hydroxy-2-(phenylmethyl
sulphonamido)butanamide
(2h)
  
3.3.9. N1,N1-Diethyl-2-(phenylmethylsulphonamido)pentanediamide (2i). Yield 0.98 
g (93.2%); mp 251-253 oC; Rf = 0.58 (CHCl3/CH3OH, 3:1, at RT). 1H-NMR (D2O) δ: 
7.51 (s, 5H, Ar-H), 4.52-4.48 (dd, J1 = 5 Hz, J2 = 14.32 Hz, 1H, NOC-CH-CH2a,b), 4.26 
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(s, 2H, CH2-SO2), 3.17-3.12 (q, J = 7.32 Hz, 4H, 2 × CH2-CH3), 2.67-2.60 (m, 1H, CHa 
of CH2), 2.53-2.48 (t, J = 8 Hz, 2H, CO-CH2-CH2), 2.30-2.24 (m
CH
, 1H, CHb of CH2), 1.37-
1.33 (t, J = 7.32 Hz, 6H, 2 × 3-CH2) ppm. 13C-NMR (Dioxane) 
atic), 129.5 (2 × CH arom
δ: 182.7 (C=O), 177.1 
(C=O), 132.6, 131.2 (2 × CH arom atic), 128.9, 57.7, 53.3, 43.1 
(CH3) ppm. IR (KBr) cm-1: 3075 (NH)
O S
(CH2), 30.1, 25.2, 11.4 , 3053 (CH aromatic), 2951 
(CH aliphatic), 1703 (C=O), 1659 (C=O of CON), 1601 (C=C), 1221, 1193 (SO2 two 
bands), 696 (Ar-H) ppm. Anal. calcd. for C16H25N3O4S (355.46): C, 54.06; H, 7.09; N, 
11.82. Found: C, 53.95; H, 6.88; N, 12.01. 
                                           
N
O NH2
O
ONH
N1,N1-Diethyl-2-(phenylmethyl
(2i)
sulphonamido)pentanediamide
 
3.3.10. N,N-Diethyl-3-phenyl-2-(phenylmethylsulphonamido)propanamide (2j). 
Yield 1.00 g (90.2%); mp 227-229 oC; Rf = 0.70 (CHCl3/CH3OH, 3:1, at RT). 1H-NMR 
(D2O) δ: 7.49 (s, 10H, 2 × Ar-H), 4.39-4.36 (dd, J1 = 5.60 Hz, J2 = 7.60 Hz, 1H, NOC-
CH-CH2a,b), 4.24 (s, 2H, CH2-SO2), 3.44-3.39 (dd, J1 = 5.60 Hz, J2 = 20.00 Hz, 1H, CHa 
of CH2a,b), 3.31-3.26 (dd, J1 = 7.60 Hz, J2 = 20.00 Hz, 1H, CHb of CH2a,b), 3.16-3.10 (q, J 
= 7.32 Hz, 4H, 2 × CH2-CH3), 2.78 (s, 2H, CH2), 1.35-1.31 (t, J = 7.32 Hz, 6H, 2 × CH3-
CH2) ppm. 13C-NMR (Dioxane) δ: 172.4 (C=O), 135.1, 132.7, 131.2 (2 × CH aromatic), 
atic), 129.5 (2 × CH aromatic), 128.9 (2 × 
CH aromatic), 57.8, 55.2, 43.1 (CH2), 36.5, 11.5 (CH3) ppm. IR (KBr) cm-1: 2976 (NH), 
130.3 (2 × CH aromatic), 130.1 (2 × CH arom
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2828 (CH aromatic), 2774 (CH aliphatic), 1736 (C=O), 1620 (C=C), 1206, 1153, 1148 
(SO2 two bands), 698 (Ar-H). Anal. calcd. for C20H26N2O3S (374.51): C, 64.14; H, 7.00; 
N, 7.48. Found: C, 64.00; H, 6.84; N, 7.29. 
O N
O
O HN
S
N,N-Diethyl-3-phenyl-2-(phenylmethyl
sulphonamido)propanamide
(2j)
                                              
f
3 3 2
= 8.00 Hz, 2H, Ar-H), 6.99-6.97 (d, J = 8.00 Hz, 2H, Ar-H), 4.37-4.33 (dd, J1 = 5.60 Hz, 
J2 = 7.60 Hz, 1H, NOC-CH
3.3.11. 4-(3-(Diethylamino)-3-oxo-2-(phenylmethylsulphonamido)propyl)phenyl phe 
nylmethanesulphonate (2k). Yield 1.44 g (89.3%); mp 265 oC (dec); R  = 0.69 
(CHCl /CH OH, 3:1, at RT). 1H-NMR (D O) δ: 7.50 (s, 10H, 2 × Ar-H), 7.29-7.27 (d, J 
-CH2a,b), 4.26 (s, 2H, CH2-SO2), 3.37-3.32 (dd, J1 = 5.60 Hz, 
J2 = 20.00 Hz, 1H, CHa of CH2a,b), 3.26-3.21 (dd, J1 = 7.60 Hz, J2 = 20.00 Hz, 1H, CHb 
of CH2a,b), 3.17-3.12 (q, J = 7.32 Hz, 4H, 2 × CH2-CH3), 1.37-1.33 (t, J = 7.32 Hz, 6H, 2 
× CH3-CH2) ppm. 13C-NMR (Dioxane) δ: 172.4 (C=O), 155.9, 141.3, 131.8 (2 × CH 
matic), 129.6 (2 × CH aromatic), 129.0 (2 × CH aromatic), aromatic), 131.3 (2 × CH aro
126.6, 123.0 (2 × CH aromatic), 116.9 (2 × CH aromatic), 111.6 (2 × CH aromatic), 57.8, 
55.2, 43.2 (CH2), 35.6, 11.6 (CH3) ppm. IR (KBr) cm-1: 3058 (NH), 3036 (CH aromatic), 
2951 (CH aliphatic), 1719 (C=O), 1601 (C=C), 1219, 1196, 1148 (SO2 two bands), 696 
(Ar-H). Anal. calcd. for C27H32N2O6S2 (544.69): C, 59.54; H, 5.92; N, 5.14. Found: C, 
59.43; H, 5.99; N, 4.98. 
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4-(3-(Diethylamino)-3-oxo-2-(phenylmethylsulphonamido)
propyl) phenyl phenylmethanesulphonate
(2k)
                                
3.3.12. General Procedure for Attempted Synthesis of Benzothiazepine (3a) 
Method A: A solution o
           
f 1-(benzylsulphonyl)-N,N-diethylpyrrolidine-2-carboxamide 2a 
(0.324 g, 1.0 mmol) in THF (5 mL) was added to a solution of Lithium diisopropylamide 
(LDA) (freshly prepared from diisopropyl amine [(0.57 mL, 4 mmol) and n-BuLi (1.82 
mL of 2.2 M, 4.0 mmol)] in THF (20 mL) at 0 oC in stream of N2 gas. The ice bath was 
immediately removed, the solution was stirred at room temperature until the reaction was 
completed (TLC monitored for ca 1 h) and quenched with saturated aq. NH4Cl (5 mL). 
2O (30 mL) was ad
hed with 
 
The reaction mixture was evaporated to dryness, H ded and the whole 
was extracted with DCM (3 x 15 mL). The combined organic extracts were was
brine (15 mL), dried over anhydrous Na2SO4 and concentrated in vacuo. Since, the 
starting material did not dissolve throughout the reaction it was observed that the bulky of
the product was in aqueous layer. Hence, the aqueous layer was worked up to obtain a 
solid which was not the expected benzothiazepine. However, both organic layer and 
aqueous layers product were not benzothiazepine according to the 1H-NMR spectrum of 
the product which showed the same spectral data with the starting material (2a).   
Method B: AlCl3-SiO2 (0.0232 g, 0.12 mmol) was added to a solution of 1-
(benzylsulphonyl)-N,N-diethylpyrrolidine-2-carboxamide (2a) (0.324 g, 1.0 mmol) in 
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DCM (20 mL). The reaction mixture was magnetically stirred at 80 oC until the reaction 
was completed 2 h. The catalyst was filtered off, washed with DCM and the filterate was 
concentrated on rotary evaporator to afford the solid expected to be benzothiazepine (3a). 
Nevertheless, there was no evidence of cyclization as the product gave the same 1H-NMR 
spectrum similar to that of the starting material (2a).    
Preparation of SiO2-AlCl3 
Anhydrous AlCl3 (5.1 g) was added to silica gel (Merck, grade 60, 230-400, washed with 
1 M HCl and dried under vacuum at 80 oC for 72 h, 10.2 g) in carbon tetrachloride (30 
mL). The mixture was stirred using a magnetic stirrer under reflux conditions for 2 days 
under N2 atmosphere, filtered and washed with 50 mL of dry CCl4, and then dried under 
vacuum at 60 oC for 3 h according to Boroujeni (2010).  
3.4. General Procedure for Synthesis of p-Toluenesulphonamides (4a-k) 
 Na2CO3 (2.785 g, 26.25 mmol) was added to a solution of amino acid (12.5 mmol) 
llowed by addition of p-toluenesulphonyl chloride, p-TsCl 
a suction filtration. The filtered 
60 oC for 12 
in H2O (15 mL) at 0 oC fo
(2.86 g, 15 mmol) in three portions over a period of 1 h. The slurry was then warmed to 
room temperature and allowed to stir for 4 h. Upon completion of the reaction which was 
TLC monitored using CHCl3/CH3OH solvent system (9:1), the reaction mixture was 
acidified with 20 % concentrated aqueous HCl solution to pH 2, after which 
crystallization occurred and the product was obtained vi
crude product was washed with pH 2.2 buffer and dried in a vacuum oven at 
h to afford p-toluenesulphonamides (4a-k) in good to excellent yields (60.5 – 99.0%).  
3.4.1. 1-Tosylpyrrolidine-2-carboxylic acid (4a). The amino acid was L-proline, yield 
3.23 g (95.9%), mp 41-43 oC, {Literature mp 42-44 oC (Zhang et al., 2005)}, Rf = 0.82 
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(CHCl3/CH3OH, 9:1, at RT). 1H-NMR (DMSO-d6) δ: 7.72-7.70 (d, J = 8 Hz, 2H, Ar-H), 
7.43-7.41 (d, J = 8 Hz, 2H, Ar-H), 4.08-4.05 (m, 1H, CH-COOH), 3.36-3.30 (m, 1H, 
CHb of CH2-N), 3.16-3.10 (m, 1H, CHa of CH2-N), 2.39 (s, 3H, CH3), 1.89-1.77 (m, 3H, 
CH & CH2), 1.56-1.50 (m, 1H, CH). 13C-NMR (DMSO-d6) δ: 173.2 (CO), 143.5, 134.7, 
129.9, 127.2, 67.1, 60.5, 48.5, 30.5, 25.2, 24.3, 21.1. IR (KBr) cm-1: 3217 (OH), 2939 
(CH aromatic), 2860 (CH aliphatic), 1734 (C=O of COOH), 1601 (C=C aromatic), 1184, 
1151 (SO2 two bands), 662 (Ar-H).  
                                        
S
O
O
N
(4a)
OHO
1-tosylpyrrolidine-2-carboxylic acid
 
3.4.2. 1-Tosylpiperidine-2-carboxylic acid (4b). The amino acid was pipecolic acid, 
yield 3.36 g (95%), Rf = 0.89 (CHCl3/CH3OH, 9:1, at RT). 1H-NMR (CDCl3) δ: 7.71-
7.63 (d, J = 8 Hz, 2H, Ar-H), 7.29-7.24 (d, J = 8 Hz, 2H, Ar-H), 4.74-4.73 (m, 1H, CH-
COOH), 3.72-3.69 (dd, J1 = 10.4 Hz, J2 = 20 Hz, 1H), 3.23-3.18 (dd, J1 = 12 Hz, J2 = 20 
Hz,  1H), 2.41 (s, 3H, CH3), 2.18-2.15 (dd, J1 = 3.7 Hz, J2 = 12.7 Hz, 1H), 1.74-1.55 (m, 
4H), 1.48-1.35 (m, 3H, CH2 & CH). 13C-NMR (DMSO-d6) δ: 171.8 (CO), 142.9, 137.4, 
129.6, 129.4, 126.9, 126.8, 54.6 (CH-CO), 42.1 (CH2-N), 27.0, 23.9, 19.7 (CH2), 21.0 
l. %]: 239.1 [M+ - CO2, 10%], 238.1 [M+ - COOH, 74%], 220.1 (CH3-Ph). MS: in m/z [re
[37%], 191.1 [M+ - PhCH2, 28%], 91.1 [PhCH2+, 100%]. Anal. calcd. for C13H17NO4S 
(283.35): C, 55.11; H, 6.05; N, 4.94. Found: C, 54.10; H, 6.08; N, 5.02.  
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3.4.3. 2-(4-Methylphenylsulphonamido)acetic acid (4c). The amino acid was glycine, 
yield 2.75 g (95.8%), mp 120-122 C, Rf = 0.47 (CHCl3/CH3OH, 9:1, at RT). 1H-NMR 
(DMSO-d6) δ: 12.63 (s-br, 1H, OH of -COOH), 7.95-7.92 (t, J = 6 Hz, 1H, NH-CH2), 
7.68-7.66 (d, J = 8 Hz, 2H, Ar-H), 7.38-7.36 (d, J = 8 Hz, 2H, Ar-H), 3.55-3.53 (d, J = 6 
Hz, 2H, CH2-NH), 2.37 (s, 3H, CH3). IR (KBr) cm-1: 3279 (N-H), 3102 (CH aromatic), 
=O of COOH), 1595 (C=C aroma
o
2980 (CH aliphatic), 1726 (C tic), 1234, 1161 (SO2 two 
bands), 669 (Ar-H). MS: in m/z [rel. %]: 238.1 [41%], 184.0 [55%], 155.0 [PhCH2SO2+, 
100%], 91.1 [PhCH2+, 65%], 65.0 [63%].    
                             
O
HO
SHN
O
O
2-(4-Methylphenylsulphonamido)acetic acid
(4c)
   
 3.4.4. 2-(4-Methylphenylsulphonamido)propanoic acid (4d). The amino acid was 
alanine, yield 2.51 g (82.6%), mp 116-118 oC, Rf = 0.78 (CHCl3/CH3OH, 9:1, at RT). 1H-
NMR (DMSO-d6) δ: 8.05-8.03 (d, J = 8.3 Hz, 1H, NH), 7.68-7.65 (d, J = 8 Hz, 2H, Ar-
H), 7.37-7.35 (d, J = 8 Hz, 2H, Ar-H), 3.74-3.71 (m, 1H, CH), 2.37 (s, 3H, CH3-Ph), 
1.13-1.12 (d, J = 7.2 Hz, 3H, CH3-CH). IR (KBr) cm-1: 3277 (N-H), 3084 (OH), 2934 
15 (C=O of COOH), 1595 (C=C aromatic), 1233, 1150 (SO2 two 
bands), 677 (Ar-H). MS: in m/z [rel. %]: 199.1 [M+ - CO2, 12%], 198.0 [M+ - CO2H, 
(CH aliphatic), 17
 98
89%], 156.0 [CH3PhSO2+, 21%], 155.0 [PhCH2SO2+, 97%], 91.1 [PhCH2+, 100%], 65.0 
[47%], 44.1 [27%].    
                                             
O
HO SHN
O
O
2-(4-Methylphenylsulphonamido)propanoic acid
(4d)
    
3.4.5. 3-Mercapto-2-(4-methylphenylsulphonamido)propanoic acid (4e). The amino 
acid was cysteine, yield 3.03 g (88.1%), mp 161-164 oC, Rf = 0.39 (CHCl3/CH3OH, 9:1, 
at RT). 1H-NMR (DMSO-d6) δ: 8.59-8.53 (s-br, 1H, SH), 8.29-8.27 (d, J = 8.4 Hz, 
1H, NH-CH), 7.71-7.69 (m, 1H, CH2-CH-NH), 7.65-7.58 (d, J = 8 Hz, 2H, Ar-H), 7.48-
7.46 (d, J = 7.6 Hz, 1H, CHb of CH2), 7.35-7.33 (d, J = 8 Hz, 2H, Ar-H), 7.12-7.10 (d, J 
= 7.6 Hz, 1H, CHa of CH2), 2.37 (s, 3H, CH3-Ph). IR (KBr) cm-1: 3445 (N-H), 3003 (CH 
c), 1736 (C=O of COOH), 1596 (C=C aromatic), 1221, 1152 aromatic), 2907 (CH aliphati
(SO2 two bands), 679 (Ar-H).   
                                  
O
O
O
HS
HO SHN
3-Mercapto-2-(4-methylphenylsulphonamido)propanoic acid
(4e)
 
3.4.6. 2-(4-Methylphenylsulphonamido)-4-(methylthio)butanoic acid (4f). The amino 
acid was methionine, yield 2.62 g (69.1%), Rf = 0.80 (CHCl3/CH3OH, 9:1, at RT). 1H-
NMR (CDCl3) δ: 7.75-7.73 (d, J = 8 Hz, 2H, Ar-H), 7.29-7.27 (d, J = 8 Hz, 2H, Ar-H), 
4.07 (s-br, 1H, NH), 2.50-2.48 (m, 1H, CH-NH), 2.45-2.33 (m, 2H, CH2-S), 2.40 (s, 3H, 
CH3-Ph), 2.10-2.03 (m, 1H, CH of CH2), 1.99 (s, 3H, CH3-S), 1.94-1.87 (m, 1H, CH of 
 99
CH2). IR (KBr) cm-1: 2997 (CH aromatic), 2911 (CH aliphatic), 1726 (C=O of COOH), 
1591 (C=C aromatic), 1220, 1144 (SO2 two bands), 696 (Ar-H).    
                                    
O
O
HO
S
S
O
HN
2-(4-Methylphenylsulphonamido)-4-(methylthio)butanoic acid
(4f)
 
3.4.7. 3-Methyl-2-(4-methylphenylsulphonamido)butanoic acid (4g). The amino acid 
was valine, yield 3.21 g (94.7%), mp 125-126 oC, Rf = 0.81 (CHCl3/CH3OH, 9:1, at RT). 
1H-NMR (CDCl3) δ: 7.73-7.71 (d, J = 8 Hz, 2H, Ar-H), 7.29-7.27 (d, J = 8 Hz, 2H, Ar-
H), 5.07-5.04 (d, J = 9.9 Hz, 1H, NH), 3.82-3.78 (dd, J1 = 4.6 Hz, J2 = 9.9 Hz, 1H, CH-
CH-NH), 2.41 (s, 3H, CH3-Ph), 2.13-2.08 (m, 1H, CH), 0.97-0.96 (d, J = 6.8 Hz, 3H, 
CH3), 0.88-0.86 (d, J = 6.8 Hz, 3H, CH3). IR (KBr) cm-1: 3289 (N-H), 2967 (CH 
aromatic), 2876 (CH aliphatic), 1711 (C=O of COOH), 1595 (C=C aromatic), 1335, 1163 
(SO2 two bands), 687 (Ar-H). MS: in m/z [rel. %]: 227.1 [M+ - CO2, 11%], 226.1 [M+ - 
CO2H, 100%], 155.0 [PhCH2SO2+, 98%], 92.1 [PhCH3+, 33%], 91.1 [PhCH2+, 92%], 65.0 
r C12H17NO4S (271.34): C, 53.12; H, 6.32; N, 5.16. Found: C, [48%]. Anal. calcd. fo
52.91; H, 6.33; N, 5.08. 
                                      
O
OH
S NH
O
O
3-Methyl-2-(4-methylphenylsulphonamido)
butanoic acid
(4g)
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3.4.8. 3-Hydroxy-2-(4-methylphenylsulphonamido)butanoic acid (4h). The amino 
acid was threonine, yield 3.22 g (94.4%), mp 90-92 oC, Rf = 0.62 (CHCl3/CH3OH, 9:1, at 
RT). 1H-NMR (DMSO-d6) δ: 7.68-7.66 (d, J = 8 Hz, 2H, Ar-H), 7.52-7.50 (d, J = 9.2 Hz, 
1H, NH-CH), 7.34-7.32 (d, J = 8 Hz, 2H, Ar-H), 3.95-3.91 (m, 1H, CH), 3.64-3.61 (dd, 
= 9.2 Hz, 1H, CH-CHJ1 = 3.6 Hz, J2 -NH), 2.36 (s, 3H, CH3-Ph), 2.08 (s, 1H, -OH), 1.01-
0.99 (d, J = 6.36 Hz, 3H, CH3-CH). IR (KBr) cm-1: 3501 (OH free), 3435 (N-H), 3360 
(OH of COOH), 3262 (N-H), 2976 (CH aliphatic), 1697 (C=O), 1595 (C=C aromatic), 
1167 (SO2), 673 (Ar-H).   
O
O
                                    
O
OH
S NH
OH
3-Hydroxy-2-(4-methylphenylsulphonamido)
butanoic acid
(4h)
 
3.4.9. 5-Amino-2-(4-methylphenylsulphonamido)-5-oxopentanoic acid (4i). The 
amino acid was glutamine, yield 3.10 g (82.7%), mp 145-146 oC, Rf = 0.14 
(CHCl3/CH3OH, 9:1, at RT). 1H-NMR (DMSO-d6) δ: 8.06-8.04 (d, J = 8.76 Hz, 1H, NH-
CH), 7.65-7.63 (d, J = 8 Hz, 2H, Ar-H), 7.36-7.34 (d, J = 8 Hz, 2H, Ar-H), 7.24 (s, 1H, 
NH of NH2), 6.73 (s, 1H, NH of NH2), 3.69-3.65 (dd, J1 = 8.76 Hz, J2 = 17.24 Hz, 
1H, CH-COOH), 2.37 (s, 3H, CH3-Ph), 2.08-2.04 (t, J = 7.68 Hz, 2H, CH2), 1.83-1.80 (t, 
J = 4 Hz, 1H, CH), 1.67-1.61 (q, J1 = 4 Hz, J2 = 7.6 Hz, CH). IR (KBr) cm-1: 3456 (N-H), 
3331 (OH of COOH), 3246 (N-H), 2955 (CH aliphatic), 1678 (C=O), 1640 (C=O), 1570 
 1167 (SO2 two bands), 685 (Ar-H). MS: in m/z [rel. %]: 246.0 
3 2 2 3 2
(C=C aromatic), 1321,
[97%], 238.1 [16%], 171.0 [CH PhSO NH +, 49%], 156.0 [CH PhSO +, 84%], 139.0 
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[52%], 123.0 [100%], 92.1 [PhCH3+, 38%], 44.0 [CONH2+, 32%]. Anal. calcd. for 
C12H16N2O5S (300.34): C, 47.99; H, 5.37; N, 9.33. Found: C, 47.77; H, 5.39; N, 9.04.  
                            
5-Amino-2-(4-methylphenylsulphonamido)-5-oxopentanoic acid
OHO
O
N
NH2
(4i)
O
H
S
O
 
3.4.10. 2-(4-Methylphenylsulphonamido)-3-phenylpropanoic acid (4j). The amino 
acid was phenylalanine, yield 3.95 g (99.0%), 139-140 oC, Rf = 0.76 (CHCl3/CH3OH, 9:1, 
at RT). 1H-NMR (CDCl ) δ: 7.61-7.59 (d, J = 8 Hz, 2H, Ar-H), 7.24-7.21 (m, 5H, Ar-H), 
7.10-7.08 (d, J = 8 Hz, 2H, Ar-H), 5.16-5.14 (d, J = 8.64 Hz, 1H, NH), 4.22-4.17 (ddd, 
3
J1 
= 5.6 Hz, J2 = 6.4 Hz, J3 = 8.64 Hz, 1H, CH-COOH), 3.12-3.08 (dd, J1 = 5.6 Hz, J2 = 20 
Hz, 1H), 3.03-2.98 (dd, J1 = 6.4 Hz, J2 = 20 Hz, 1H), 2.40 (s, 3H, CH3). 13C-NMR 
(CDCl3) δ: 175 (CO), 143.9, 136.6, 134.9, 129.8 (2CH aromatic), 129.6 (2CH aromatic), 
atic), 127.5, 127.2 (2CH aromatic), 56.5, 39.0 (CH2), 21.7 (CH3). IR 128.8 (2CH arom
(KBr) cm-1: 3350 (N-H), 3188 (OH), 3057 (CH aromatic), 2961 (CH aliphatic), 1736 
(C=O of COOH), 1350, 1171 (SO2 two bands), 675 (Ar-H).   
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2-(4-Methylphenylsulphonamido)-3-phenylpropanoic acid
(4j)
   
3.4.11. 2-(4-Methylphenylsulphonamido)-3-(4-(tosyloxy)phenyl)propanoic acid (4k). 
The amino acid was tyrosine, yield 3.70 g (60.5%), mp 101-103 oC, Rf = 0.76 
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(CHCl3/CH3OH, 9:1, at RT). 1H-NMR (CDCl3) δ: 7.69-7.67 (d, J = 8.26 Hz, 2H, Ar-H of 
OTs), 7.59-7.57 (d, J = 8.26 Hz, 2H, Ar-H of OTs), 7.32-7.30 (d, J 
= 8 Hz, 2H, Ar-H), 7.03-7.01 (d, J = 8.4 Hz, 2H, Ar-H of benzyl), 6.85-
= 8.4 Hz, 2H, Ar-H of benzyl), 5.14-5.12 (d, J = 8.5 Hz, 1H, 
= 8 Hz, 2H, Ar-H), 
7.24-7.22 (d, J 
6.83 (d, J NH-CH), 4.17-
4.12 (q, J = 6.8 Hz, 1H, NH-CH-CH2), 3.11-3.06 (dd, J1 = 5.2 Hz, J2 = 20 Hz, 1H, CH of 
CH2-Ar), 2.97-2.92 (dd, J1 = 6.8 Hz, J2 = 20 Hz, 1H, CH of CH2-Ar), 2.45 (s, 3H, CH3-
CH3-Ph). 13C-NMR (CDCl3) δ: 173.9 (CO), 148.9, 145.7, 144.2, 136.4, 
SNH
OTs), 2.41 (s, 3H, 
134.3, 132.4 (six benzylic aromatic carbon atoms), 130.9, 130.9, 130.0, 130.0, 129.9, 
129.9, 128.6, 128.6, 127.2, 127.2, 122.6, 122.6 (twelve sulphonyl aromatic carbon atoms), 
56.4 (CH), 38.3 (benzylic CH2), 21.9 (CH3 linked to SO3-Ar), 21.7 (CH3 linked to SO2-
Ar). IR (KBr) cm-1: 3561 (N-H), 3339 (OH of COOH), 2924 (CH aliphatic), 1717 (C=O), 
1559 (C=C aromatic), 1150, 1092 (SO2 two bands), 669 (Ar-H). MS: in m/z [rel. %]: 
443.1 [M+ - COOH, 23%], 171.0 [CH3PhSO2NH2+, 35%], 156.0 [CH3PhSO2+, 58%], 
155.0 [PhCH2SO2+, 90%], 134.1 [90%], 92.1 [PhCH3+, 64%], 65.0 [100%]. Anal. calcd. 
for C23H23NO7S2 (489.57): C, 56.43; H, 4.74; N, 2.86. Found: C, 54.16; H, 4.79; N, 5.31. 
                            
O
OH
O
O
OS
O
O
2-(4-Methylphenylsulphonamido)-3-(4-(tosyloxy)phenyl)
propanoic acid
(4k)
 
3.5. General Procedure for N,N-Diethylalkanamide of p-Toluenesulphonamide (5a-k) 
 A three-necked 250 mL flask equipped with magnetic stirring bar was charged 
with appropriate p-toluenesulphonamide (4a-k) (2.96 mmol) and dichloromethane (DCM) 
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(10 mL). The flask was stoppered, cooled to 0 oC and N2 was bubbled into it continuously. 
Oxalyl chloride (0.34 mL, 3.85 mmol, 1.3 equiv.) was added via dropping pipette to 
maintain the temperature below 10 oC followed by the addition of 2 drops of dimethyl 
formamide (DMF). The resulting mixture was stirred at room temperature until the 
conversion to acid chloride was completed (i.e. for about 1.5 h) and then concentrated to 
dryness with rotary evaporator (23 oC, 40 mmHg). Dichloromethane (DCM) (20 mL) was 
added to the resulting crude acid chloride and the solution was concentrated again.  
 In a separate 250 mL three-necked round bottom flask, equipped with a magnetic 
stirring bar, a N  inlet, a rubber septum, 125-mL pressure equalizing addition funnel and 
a temperature probe was charged with dichloromethane (DCM) (10 mL), triethylamine 
(0.62 mL, 4.44 mmol, 1.5 equiv.) and diethylamine (0.4 mL, 3.85 mmol, 1.3 equiv.) and 
the mixture was cooled to -10 oC (acetone/ice bath). The crude acid chloride was 
dissolved in dichloromethane (DCM) (10 mL) and this solution was transferred to the 
addition funnel. The acid chloride was then added dropwisely to the stirred diethylamine 
solution at such a rate that the internal temperature was maintained below 10 oC. Upon 
completion of the addition of the acid chloride solution (ca 30 min), the mixture was 
stirred at -10 to 0 oC for 1 h and at room temperarure for 1 h.  
 The mixture was then diluted with 2M HCl (6 mL) and was transferred into a 250 
mL separatory funnel and the layers separated. The organic layer was washed with brine 
(6 mL) and was then concentrated under reduced pressure (23 oC, 40 mmHg), diluted 
with methanol (6 mL) and re-concentrated to give a crude solid. The solid was slurried in 
methanol (7.5 mL) and water (15 mL) was added dropwise with continuous stirring for 
10 min. The slurry was stirred at room temperature for 1 h and allowed to crystallize 
2
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according to Kuethe and Beutner, (2009). It was filtered by suction and dried under 
vacuum/N2 sweep for 8 h to afford N,N-diethyl substituted p-tolylsulphonamides (5a-k). 
3.5.1. N,N-Diethyl-1-tosylpyrrolidine-2-carboxamide (5a). Yield 0.89 g (92.3%), mp 
114-116 oC, 1H-NMR (CDCl3) δ: 7.76-7.73 (m, 2H, Ar-H), 7.33-7.31 (d, J = 8.0 Hz, 1H, 
Ar-H), 7.28-7.26 (d, J = 8.0 Hz, 1H, Ar-H), 4.73-4.70 (m, 1H, CHa of CH2-N), 4.26-4.24 
(m, 1H, CHb of CH2-N), 3.50-3.41 (m, 2H, CH2-CH3), 3.34-3.29 (m, 2H, CH2-CH3), 
2.42-2.39 (d, J = 12.12 Hz, 3H, CH3), 2.11-2.09 (m, 2H, CH2 of pyrrolo), 1.94-1.71 (m, 
3H, CH2 & CH of pyrrolo), 1.27-1.23 (t, J = 7.2 Hz, 3H, CH3-CH2), 1.09-1.06 (t, J = 7.12 
Hz, 3H, CH3-CH2). IR (KBr) cm-1: 2974 (aromatic), 2866 (CH aliphatic), 1657 (C=O), 
1609 (C=C aromatic), 1149, 1107 (SO2 two bands), 673 (Ar-H). MS: in m/z [rel. %]: 
225.0 [MH+ - CON(CH2CH3)2, 62%], 224.0 [M+ - CON(CH2CH3)2, 100%], 169.1 [89%], 
155.0 [PhCH2SO2+, 93%], 100.1 [+CON(CH2CH3)2, 17%], 91.0 [PhCH2+, 82%], 72.0 
[45%], 65.0 [42%]. Anal. calcd. for C16H24N2O3S (324.45): C, 59.23; H, 7.46; N, 8.63. 
Found: C, 57.97; H, 7.20; N, 7.92. 
                            
N
O
S
N
O
O
N,N-Diethyl-1-tosylpyrrolidine-2-carboxamide
(5a)
 
o 1
3
3.5.2. N,N-Diethyl-1-tosylpiperidine-2-carboxamide (5b). Yield 0.94 g (94.1%), mp 
127-129 C, H-NMR (CDCl ) δ: 7.58-7.56 (d, J = 8.0 Hz, 2H, Ar-H), 7.21-7.19 (d, J = 
8.0 Hz, 2H, Ar-H), 4.86-4.85 (m, 1H, CH-COOH), 3.73-3.70 (q, J = 7.2 Hz, 2H, CH2-
CH3), 3.31-3.26 (q, J = 7.08 Hz, 2H, CH2-CH3), 3.15-3.14 (m, 1H, CHa of CH2-N), 3.09-
3.08 (m, 1H, CHb of CH2-N), 2.36 (s, 3H, CH3), 1.75-1.66 (m, 3H, CH & CH2 of 
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piperidine), 1.59-1.50 (m, 3H, CH & CH2 of piperidine), 1.26-1.23 (t, J = 7.2 Hz, 
3H, CH3-CH2), 0.96-0.93 (t, J = 7.02 Hz, 3H, CH3-CH2). Anal. calcd. for C17H26N2O3S 
(338.47): C, 60.33; H, 7.74; N, 8.28. Found: C, 60.27; H, 7.60; N, 8.32. 
N
ON
S
O
O
(5b)
N,N-Diethyl-1-tosylpiperidine-2-carboxamide
                             
3.5.3. N,N-Diethyl-2-(4-methylphenylsulphonamido)acetamide (5c). Yield 0.69 g 
(82.7%), mp 109-111 oC, 1H-NMR (CDCl3) δ: 7.75-7.73 (d, J = 8.0 Hz, 2H, Ar-H), 7.29-
7.27 (d, J = 8.0 Hz, 2H, Ar-H), 5.80 (s-br, 1H, NH), 3.73-3.72 (d, J = 4.12 Hz, 2H, CH2-
NH), 3.31-3.26 (q, J = 7.14 Hz, 2H, CH2-CH3), 3.17-3.11 (q, J = 7.18 Hz, 2H, CH2-CH3), 
2.40 (s, 3H, CH3-Ar), 1.12-1.08 (t, J = 7.18 Hz, 3H, CH3-CH2), 1.02-0.99 (t, J = 7.14 Hz, 
3H, CH3-CH2). IR (KBr) cm-1: 3034 (CH aromatic), 2946 (CH aliphatic), 1707 (C=O), 
1601 (C=C aromatic), 1191, 1145 (SO2 two bands), 694 (Ar-H). Anal. calcd. for 
C13H20N2O3S (284.38): C, 54.91; H, 7.09; N, 9.85. Found: C, 55.03; H, 7.13; N, 9.92. 
O
NS
O
O
NH
N,N-Diethyl-2-(4-methylphenylsulphonamido
(5c)
)acetamide
                            
3.5.4. N,N-Diethyl-2-(4-methylphenylsulphonamido)propanamide (5d). Yield 0.68 g 
(77.9%), mp 121-124 C, H-NMR (CDCl3) δ: 7.74-7.66 (m, 2H, Ar-H), 7.28-7.22 (m, 
2H, Ar-H), 5.46-5.44 (d, J = 8.48 Hz, 1H, 
o 1
NH-CH), 4.25-4.15 (m, 1H, NH-CH-CH3), 
3.99-3.92 (q, J = 7.12 Hz, 4H, 2 × CH2-CH3), 2.38 (s, 3H, CH3-Ar), 1.39-1.37 (d, J = 
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7.16 Hz, 3H, CH3-CH), 1.13-1.09 (t, J = 7.12 Hz, 6H, 2 × CH3-CH2). IR (KBr) cm-1: 
3279 (N-H), 3107 (CH aromatic), 1711 (C=O), 1620 (C=C aromatic), 1225, 1152 (SO2 
two bands), 677 (Ar-H). Anal. calcd. for C14H22N2O3S (298.41): C, 56.35; H, 7.43; N, 
9.39. Found: C, 56.42; H, 7.35; N, 9.44. 
O
NS
O
O
NH
N,N-Diethyl-2-(4-methylphenylsulphonamido)propanamide
(5d)
                            
3.5.5. N,N-Diethyl-3-methyl-2-(4-methylphenylsulphonamido)butanamide (5g). 
Yield 0.86 g (89.1%), mp 164-166 oC, 1H-NMR (CDCl3) δ: 7.68-7.66 (d, J = 8.0 Hz, 2H, 
Ar-H), 7.23-7.21 (d, J = 8.0 Hz, 2H, Ar-H), 5.78-5.75 (d, J = 9.24 Hz, 1H, NH-CH), 
3.81-3.78 (dd, J1 = 4.22 Hz, J2 = 9.24 Hz, 1H, NH-CH-CH), 3.15-3.02 (m, 4H, 2xCH2-
CH3), 2.37 (s, 3H, CH3-Ar), 1.83-1.78 (m, 1H, CH-CH(CH3)2), 1.03-1.01 (d, J = 6.8 Hz, 
3H, CH3-CH), 0.92-0.88 (t, J = 7.2 Hz, 3H, CH3-CH2), 0.84-0.82 (d, J = 6.0 Hz, 
3H, CH3-CH), 0.84-0.81 (t, J = 6.48 Hz, 3H, CH3-CH2). IR (KBr) cm-1: 3260 (N-H), 
2974 (CH aliphatic), 1668 (C=O), 1167, 1090 (SO2 two bands), 689 (Ar-H). Anal. calcd. 
for C16H26N2O3S (326.46): C, 58.87; H, 8.03; N, 8.58. Found: C, 58.79; H, 7.98; N, 8.59. 
                      
O
NS
O
O
NH
(5g)
N,N-diethyl-3-methyl-2-(4-methylphenylsulphonamido)butanamide
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3.5.6. N,N-Diethyl-2-(4-methylphenylsulphonamido)-3-phenylpropanamide (5j). 
Yield 0.99 g (89.4%), mp 164-166 oC, 1H-NMR (CDCl3) δ: 7.67-7.65 (d, J = 8.0 Hz, 2H, 
Ar-H), 7.24-7.19 (m, 5H, Ar-H), 7.13-7.09 (m, 2H, Ar-H), 5.88-5.86 (d, J = 9.48 Hz, 
1H, NH-CH), 4.31-4.25 (m, 1H, CH), 3.21-3.15 (m, 1H, CHa of CH2-Ph), 2.99-2.96 (m, 
1H, CHb of CH2-Ph), 2.94-2.90 (m, 2H, CH2-CH3), 2.80-2.74 (q, J = 7.2 Hz, 2H, CH2-
CH3), 2.37 (s, 3H, CH3-Ar), 0.88-0.84 (t, J = 7.14 Hz, 3H, CH3-CH2), 0.84-0.81 (t, J = 
7.2 Hz, 3H, CH3-CH2). IR (KBr) cm-1: 3306 (N-H), 2947 (CH aliphatic), 1710 (C=O), 
1601 (C=C aromatic), 1213, 1171 (SO2 two bands), 685 (Ar-H). Anal. calcd. for 
C20H26N2O3S (374.51): C, 64.14; H, 7.00; N, 7.48. Found: C, 64.07; H, 6.91; N, 7.63. 
                       
NS
O
NH
O
O
(5j)
N,N-Diethyl-2-(4-methylphenylsulphonamido)-3-phenylpropanamide
 
3.5.7. 8-Methyl-1a,1,2,3-tetrahydropyrrolo[1,2-b][1,2]benzothiazin-10-one-5,5-
dioxide (6a). A solution of N,N-Diethyl-1-tosylpyrrolidine-2-carboxamide (5a) (0.324 g, 
1.0 mmol) in tetrahydrofuran (THF) (5 mL) was added to a solution of lithium 
diisopropylamide (LDA) (freshly prepared from diisopropyl amine [(0.57 mL, 4 mmol) 
and n-BuLi (1.82 mL of 2.2 M, 4.0 mmol)] in THF (20 mL) at 0 C in stream of N2 gas. 
The ice bath was immediately removed, the solution was stirred at room temperature until 
the reaction was completed (TLC monitored for ca 1 h) and quenched with saturated aq. 
NH4Cl (5 mL). The reaction mixture was evaporated to dryness, H2O (30 mL) was added 
and the whole was extracted with DCM (3 x 15 mL). The combined organic extracts were 
o
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washed with brine (15 mL), dried over anhydrous Na2SO4 and concentrated in vacuo. 
The residue was chromatographed (SiO2: EtOAc/hexane 3:7 eluent, at RT) to afford 24% 
of 8-methyl-1a,1,2,3-tetrahydropyrrolo[1,2-b][1,2]benzothiazin-10-one 5,5-dioxide (6a). 
An analytically pure sample was obtained by recrystallization from i-Pr2O. Yield 0.06 g 
oC, 1H-NMR (CDCl3) δ: 7.9-7.7 (m, 3H, Ar-H(24.0%), mp 88-89 ), 5.01 (t, J = 3.7 Hz, 
1H, NCHCO), 3.72 (dt, J1 = 11.7 Hz, J2 = 3.6 Hz, 1H, NCH2), 2.8-2.5 (m, 2H, CH2), 1.9-
1.6 (m, 2H, CH2), 2.37 (s, 3H, CH3-Ar). 1C-NMR (CDCl3) δ: 192.9 (C=O), 138.2, 135.2, 
132.9, 129.1, 128.1, 125.1, 63.9, 46.1, 24.3, 24.1, 21.1 (CH3). IR (KBr) cm : 2928, 2842, 
1694, 1588, 1449, 1342, 1192, 1171, 1126, 1042, 1006, 927, 833, 770, 749. The melting 
point, other physical and spectroscopic data were identical with that of the authentic 
sample earlier reported (Bakker et al., 1997). 
(6a)
S
N
O
OO
-1
                                           
8-Methyl-1a,1,2,3-tetrahydropyrrolo[1,2-b][1,2]
benzothiazin-10-one 5,5-dioxide
 
3.6.    General Procedure for Synthesis of Benzenesulphonamides (7a-k) 
 Na2CO3 (5.565 g, 52.5 mmol) was added to a solution of amino acid (25 mmol) in 
H2O (30 mL) at 0 C, cooled to -5 C followed by addition of benzenesulphonyl chloride, 
BzCl (5.299 g, 3.84 mL, 30 mmol) in three portions over a period of 1 h. The reacting 
mixture was then warmed to room temperature and allowed to stir for 4 h. Upon 
completion of the reaction, 20 % concentrated aqueous HCl solution was added with 
continuous stirring to avoid foaming on the surface until the pH 2 was attained. The solid 
separated out and was allowed to settle down over night and the product isolated via 
o o
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suction filtration. The filtered crude product was washed with pH 2.2 buffer and dried in 
a vacuum oven at 60 oC for 12 h to afford benzenesulphonamides (7a-k) in good to 
excellent yields (73.2 – 96.6%).  
3.6.1. 1-(Phenylsulphonyl)pyrrolidine-2-carboxylic acid (7a). The amino acid was L-
proline, yield 6.11 g (95.7%), mp 75-77 oC, Rf = 0.77 (CHCl3/CH3OH, 9:1, at RT). 1H-
NMR (CDCl3) δ: 7.92-7.90 (d, J = 7.6 Hz, 2H, Ar-H), 7.68-7.60 (m, 3H, Ar-H), 4.32-
 12 Hz, 1H, CH4.30 (dd, J1 = 3.2 Hz, J2 = -COOH), 3.56-3.54 (m 1H, CHa of CH2-N), 
2 2), 1.83-
2 11 13 4
                                 
, 
3.33-3.27 (m, 1H, CHb of CH -N), 2.18-2.15 (m, 1H, CH), 1.97-1.95 (m, 2H, CH
1.79 (m, 1H, CH). IR (KBr) cm-1: 3065 (CH aromatic), 2957 (CH aliphatic), 1728 (C=O 
of COOH), 1157, 1094 (SO two bands), 689 (Ar-H). Anal. calcd. for C H NO S 
(255.29): C, 51.75; H, 5.13; N, 5.49. Found: C, 51.72; H, 4.92; N, 5.35. 
N
O OH
O
O
S
1-(Phenylsulphonyl)pyrrolidine-2-carboxylic acid
(7a)
  
3.6.2. 1-(Phenylsulphonyl)piperidine-2-carboxylic acid (7b). The amino acid was 
pipecolic acid, yield 6.50 g (96.6%), mp 81-82 C, Rf = 0.79 (CHCl3/CH3OH, 9:1, at RT). 
H-NMR (CDCl3) δ: 10.06-9.95 (s-br, 1H, OH of COOH), 7.81-7.78 (d, J = 8.76 Hz, 2H, 
Ar-H), 7.55-7.46 (m, 3H, Ar-H), 4.78-4.77 (d, J = 5 Hz, 1H, CH
o
1
-COOH), 3.77-3.74 (d, J 
= 10 Hz, 1H, CHa of CH2-N), 3.23-3.16 (dt, J1 = 2.8 Hz, J2 = 10 Hz, 1H, CHb of CH2-N), 
2.17-2.13 (m, 1H, CH), 1.71-1.66 (m, 3H, CH2 & CH), 1.46-1.41 (m, 1H, CH), 1.32-1.23 
(m, 1H, CH). Anal. calcd. for C12H15NO4S (269.32): C, 53.52; H, 5.61; N, 5.20. Found: C, 
53.71; H, 5.59; N, 5.31. 
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1-(Phenylsulphonyl)piperidine-2-carboxylic acid
(7b)
                                     
3.6.3. 2-(Phenylsulphonamido)acetic acid (7c). The amino acid was glycine, yield 3.94 
61 oC, Rf = 0.45 (CHCl3/CH3OH, 9:1, at RT). 1 -NMR (DMSO-d6) g (73.2%), mp 160-1 H
δ: 12.68 (s-br, 1H, OH of COOH), 8.07-8.04 (t, J = 6 Hz, 1H, NH-CH ), 7.80-7.78 (d, J = 
8 Hz, 2H, Ar-H), 7.65-7.55 (m, 3H, Ar-H), 3.58-3.57 (d, J = 6 Hz, 2H, 
2
CH2-NH). IR 
KBr) cm-1: 3314 (N-H), 3088 (C-H aromatic), 2974 (CH aliphatic), 1726 (C=O of 
COOH), 1157, 1128 (SO two bands), 691 (Ar-H). Anal. calcd. for C H NO S (215.23): 
C, 44.65; H, 4.21; N, 6.51. Found: C, 44.45; H, 4.32; N, 6.49. 
HO S
ON
(
2 8 9 4
                                           
O
O
H
2-(Phenylsulphonamido)acetic acid
(7c)
   
3.6.4. 2-(Phenylsulphonamido)propanoic acid (7d). The amino acid was alanine, yield 
4.72 g (82.4%), mp 118-119 oC, Rf = 0.70 (CHCl3/CH3OH, 9:1, at RT). 1H-NMR 
-br, 1H, OH of COOH), 8.16-8.14 (d, J = 8.36 Hz, 1H, NH(DMSO-d6) δ: 12.62 (s -CH), 
7.80-7.78 (d, J = 8.52 Hz, 2H, Ar-H), 7.64-7.54 (m, 3H, Ar-H), 3.78-3.73 (dt, J1 = 7.20 
Hz, J2 = 8.36 Hz, 1H, NH-CH-CH3), 1.14-1.12 (d, J = 7.20 Hz, 3H, CH3-CH). IR (KBr) 
cm-1: 3327, 3267 (N-H), 3065 (C-H aromatic), 2990 (CH aliphatic), 1721 (C=O of 
COOH), 1153, 1086 (SO2 two bands), 725 (Ar-H). Anal. calcd. for C9H11NO4S (229.26): 
C, 47.15; H, 4.84; N, 6.11. Found: C, 46.98; H, 4.82; N, 6.06. 
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2-(Phenylsulphonamido)propanoic acid
(7d)
                                         
3.6.5. 3-Mercapto-2-(phenylsulphonamido)propanoic acid (7e). The amino acid was 
%), 176-177 oC, Rf = 0.35 (CHCl H3OH, 9:1, at RT). 1H-cysteine, yield 2.75 g (84.1 3/C
NMR (DMSO-d6) δ: 12.95 (s-br, 1H, OH of COOH), 8.35-8.32 (d, J = 8.40 Hz, 1H, NH-
CH), 7.77-7.75 (d, J = 8.64 Hz, 2H, Ar-H), 7.64-7.53 (m, 3H, Ar-H), 3.93-3.88 (dd, J1 = 
8.40 Hz, J2 = 20.00 Hz, 1H, NH-CH-CHa), 2.92-2.87 (dd, J1 = 5.60 Hz, J2 = 20.00 Hz, 
1H, CHa of CH2-S), 2.62-2.56 (dd, J1 = 8.22 Hz, J2 = 20.00 Hz, 1H, CHb of CH2-SH). IR 
(KBr) cm-1: 3294 (N-H), 3057 (CH aromatic), 2922 (CH aliphatic), 1736 (C=O of 
COOH), 1582 (C=C), 1148, 1088 (SO2 two bands), 689 (Ar-H). Anal. calcd. for 
C9H11NO4S2 (261.32): C, 41.37; H, 4.24; N, 5.36. Found: C, 41.34; H, 4.06; N, 5.29. 
O
OHS
O
O
N
H
SH
3-Mercapto-2-(phenylsulphonamido)propanoic acid
(7e)
    
(phenylsulphonamido)butanoic acid (7f). The amino acid was 
                           
3.6.6.  4-(Methylthio)-2-
methionine, yield 2.98 g (82.3%), mp 128-130 oC, Rf = 0.77 (CHCl3/CH3OH, 9:1, at RT). 
1H-NMR (DMSO-d6) δ: 12.73 (s-br, 1H, OH of COOH), 8.21-8.19 (d, J = 8.8 Hz, 
1H, NH-CH), 7.78-7.76 (d, J = 8.52 Hz, 2H, Ar-H), 7.63-7.54 (m, 3H, Ar-H), 3.87-3.84 
(dt, J1 = 4.00 Hz, J2 = 8.80 Hz, 1H, NH-CH-CH2), 2.36-2.25 (m, 2H, CH2S), 1.91 (s, 3H, 
CH3), 1.82-1.73 (m, 2H, CH2-CH2-S). IR (KBr) cm-1: 3254 (N-H), 3001 (CH aromatic), 
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2914 (CH aliphatic), 1724 (C=O of COOH), 1159, 1094 (SO2 two bands), 691 (Ar-H). 
Anal. calcd. for C11H15NO4S2 (289.37): C, 45.66; H, 5.22; N, 4.84. Found: C, 45.54; H, 
5.19; N, 4.67. 
OH
O S
O
O
H
N
S
4-(Methylthio)-2-(phenylsulphonamido)butanoic acid
(7f)
                                  
l-2-(phenylsulphonamido)butanoic acid (7g). The amino acid was 3.6.7.  3-Methy
valine, yield 5.08 g (79.0%), mp 143-144 oC, Rf = 0.76 (CHCl3/CH3OH, 9:1, at RT). 1H-
NMR (CDCl3) δ: 7.85-7.83 (d, J = 8.68 Hz, 2H, Ar-H), 7.58-7.54 (m, 1H, Ar-H), 7.51-
7.47 (m, 2H, Ar-H), 5.15-5.13 (d, J = 12.00 Hz, 1H, NH-CH), 3.82-3.79 (dd, J1 = 4.80 
Hz, J2 = 12.00 Hz, 1H, NH-CH-CH), 2.12-2.07 (m, 1H, CH), 0.97-0.95 (d, J = 6.80 Hz, 
3H, CH3-CH), 0.88-0.86 (d, J = 6.88 Hz, 3H, CH3-CH). IR (KBr) cm-1: 3294 (N-H), 3090 
(CH aromatic), 2972 (CH aliphatic), 1715 (C=O of COOH), 1173, 1094 (SO2 two bands), 
687 (Ar-H). Anal. calcd. for C11H15NO4S (257.31): C, 51.35; H, 5.88; N, 5.44. Found: C, 
49.77; H, 5.70; N, 5.18. 
O
OHS
O
O
N
H
3-Methyl-2-(phenylsulphonamido)butanoic acid
(7g)
                                         
henylsulphonamido)butanoic acid (7h). The amino acid was 
 
3.6.8.  3-Hydroxy-2-(p
threonine, yield 2.88 g (88.9%), 144-146 oC, Rf = 0.55 (CHCl3/CH3OH, 9:1, at RT). 1H-
NMR (DMSO-d6) δ: 12.55 (s-br, 1H, OH of COOH), 7.81-7.79 (d, J = 8.6 Hz, 2H, Ar-H),
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7.68-7.65 (d, J = 9.2 Hz, 1H, NH-CH), 7.59-7.51 (m, 3H, Ar-H), 3.98-3.96 (dq, J1 = 3.60 
Hz, J2 = 6.40 Hz, 1H, CH-CH-CH3), 3.68-3.65 (dd, J1 = 3.60 Hz, J2 = 9.20 Hz, 1H, NH-
CH-CH), 2.08 (s, 1H, OH), 1.00-0.99 (d, J = 6.40 Hz, 3H, CH3-CH). IR (KBr) cm-1: 3445 
(OH free), 3296 (N-H), 3017 (CH aromatic), 2945 (CH aliphatic), 1726 (C=O of COOH), 
1167, 1078 (SO2 two bands), 669 (Ar-H). Anal. calcd. for C10H13NO5S (259.28): C, 46.32; 
H, 5.05; N, 5.40. Found: C, 46.47; H, 4.99; N, 5.59. 
                               
O
OHS
O
O
N
H
HO
3-Hydroxy-2-(phenylsulphonamido)butanoic acid
(7h)
    
-2-(phenylsulphonamido)pentanoic acid . The amino acid 3.6.9. 5-Amino-5-oxo (7i)
was glutamine, yield 3.25 g (90.8%), mp 173-174 oC, Rf = 0.34 (CHCl3/CH3OH, 9:1, at 
RT). 1H-NMR (DMSO-d6) δ: 12.61 (s-br, 1H, OH of COOH), 8.17-8.15 (d, J = 8.8 Hz, 
1H, NH-CH), 7.77-7.75 (d, J = 8.64 Hz, 2H, Ar-H), 7.61-7.53 (m, 3H, Ar-H), 7.25 (s, 1H, 
NHa of CO-NH2), 6.74 (s, 1H, NHb of CO-NH2), 3.74-3.68 (dt, J1 = 5.60 Hz, J2 = 8.80 
Hz, 1H, NH-CH-CH2), 2.08-2.04 (t, J = 7.6 Hz, CO-CH2-CH2), 1.84-1.82 (m, 1H, CHa 
of CH2-CH2CO), 1.65-1.63 (m, 1H, CHb of CH2-CH2CO). IR (KBr) cm-1: 3429, 3227 
(N-H), 2978 (CH aliphatic), 1740 (C=O of COOH), 1684 (CO of amide), 1541 (C=C), 
1171, 1092 (SO2 two bands), 604 (Ar-H). Anal. calcd. for C11H14N2O5S (286.31): C, 
46.15; H, 4.93; N, 9.78. Found: C, 46.03; H, 4.95; N, 9.84. 
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OOH
S
O
O
NH
O
NH2
5-Amino-5-oxo-2-(phenylsulphonamido)pentanoic acid
(7i)
                                
f 3 3
6
 3.6.10. 3-Phenyl-2-(phenylsulphonamido)propanoic acid (7j). The amino acid was 
phenylalanine, yield 3.03 g (79.3%), mp 124-125 oC, R  = 0.63 (CHCl /CH OH, 9:1, at 
RT). 1H-NMR (DMSO-d ) δ: 12.71 (s-br, 1H, OH of COOH), 8.30-8.28 (d, J = 9.00 Hz, 
1H, NH-CH), 7.57-7.53 (m, 3H, Ar-H), 7.45-7.41 (m, 2H, Ar-H), 7.23-7.13 (m, 3H, Ar-
H), 7.12-7.11 (m, 2H, Ar-H), 3.88-3.84 (ddd, J  = 5.76 Hz, J  = 8.96 Hz, J  = 9.00 Hz, 
1H, NH-CH
1 2 3
-CH -Ar), 2.96-2.91 (dd, J  = 5.76 Hz, J  = 20.00 Hz, 1H, CHa of CH2 1 2 2-Ar),
2.73-2.68 (dd, J  = 8.96 Hz, J  = 20.00 Hz, 1H, CHb of CH
 
1 2 2-Ar). IR (KBr) cm-1: 3341 
(N-H), 3173 (OH), 3059 (CH aromatic), 2964 (CH aliphatic), 1736 (C=O of COOH), 
1169, 1092 (SO two bands), 689 (Ar-H). Anal. calcd. for C2 15H15NO4S (305.36): C, 59.00; 
H, 4.95; N, 4.59. Found: C, 58.88; H, 4.83; N, 4.47. 
OHO
S
O
O
N
H
3-Phenyl-2-(phenylsulphonamido)propanoic acid
(7j)
                                 
3.6.11. 2-(Phenylsulphonamido)-3-(4-(phenylsulphonyloxy)phenyl)propanoic acid 
(7k). The amino acid was tyrosine, yield 4.23 g (73.3%), mp 109-110 oC, Rf = 0.61 
(CHCl3/CH3OH, 9:1, at RT). 1H-NMR (CDCl3) δ: 7.82-7.82 (d, J = 8.60 Hz, 2H, Ar-H), 
7.74-7.72 (d, J = 8.52 Hz, 2H, Ar-H), 7.70-7.68 (m, 1H, Ar-H), 7.56-7.53 (m, 3H, Ar-H), 
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7.48-7.46 (m, 2H, Ar-H), 7.05-7.03 (d, J = 8.40 Hz, 2H, Ar-H), 6.87-6.85 (d, J = 8.40 Hz, 
2H, Ar-H), 5.10-5.08 (d, J = 8.80 Hz, 1H, NH-CH), 4.19-4.18 (m, 1H, CH), 3.13-3.08 
(dd, J1 = 5.20 Hz, J2 = 20.00 Hz, 1H, CHa of CH2-Ar), 2.99-2.94 (dd, J1 = 6.60 Hz, J2 = 
20.00 Hz, 1H, CHb of CH2-Ar). IR (KBr) cm-1: 3225 (N-H), 3071 (CH aromatic), 2932 
(CH aliphatic), 1755 (C=O of COOH), 1625 (C=C), 1161, 1092 (SO2 two bands), 687 
(Ar-H). Anal. calcd. for C21H19NO7S2 (461.52): C, 54.65; H, 4.15; N, 3.03. Found: C, 
54.74; H, 4.25; N, 2.85. 
                      
O
HO
O
S
O
OS
O
O
NH
2-(Phenylsulphonamido)-3-(4-(phenylsulphonyloxy)phenyl)
propanoic acid
(7k)
 
3.7. General Procedure for N,N-Diethylalkanamide of Benzenesulphonamide (8a-k) 
 A three-necked 250 mL flask equipped with magnetic stirring bar was charged 
with (7a-k) (9.35 mmol) and DCM (30 mL). The flask was closed and N2 was bubbled 
into it continuously. Oxalyl chloride (1.0 mL, 12.16 mmol, 1.3 equiv.) was added via 
dropping pipette followed by the addition of 2 drops of DMF. The mixture was stirred at 
room temperature for 2 h and then concentrated to dryness with rotary evaporator (23 C, 
40 mmHg). Dichloromethane (DCM) (40 mL) was added to the resulting crude acid 
chloride and the solution was concentrated again. In a separate 250 mL three-necked 
round bottom flask, equipped with a magnetic stirring bar, a N2 inlet, a rubber septum, 
125-mL pressure equalizing addition funnel and a temperature probe was charged with 
DCM (20 mL), triethylamine (2.0 mL, 14.03 mmol, 1.5 equiv.) and diethylamine (1.3 mL, 
o
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12.16 mmol, 1.3 equiv.) and the mixture was cooled to -15 oC. The crude acid chloride 
was dissolved in DCM (20 mL) and this solution was transferred to the addition funnel. 
The acid chloride was then added dropwisely to the stirred diethylamine solution at such 
a rate that the internal temperature was maintained below 10 oC.  
 Upon completion of the addition of the acid chloride solution (ca 30 min), the 
mixture was stirred at -10 to 0 oC for 1 h and at room temperarure for 1 h. The mixture 
was then diluted with 2M HCl (18 mL) and was transferred into a 250 mL separatory 
funnel and the layers separated. The organic layer was washed with brine (18 mL) and 
was then concentrated under reduced pressure (23 C, 40 mmHg), diluted with methanol 
(18 mL) and re-concentrated to give a crude solid. The solid was slurried in methanol (20 
mL) and water (30 mL) was added dropwisely with continuous stirring for 10 min. The 
slurry was stirred at room temperature for 1 h and methanol was removed by rotary 
evaporator. The resulting solution was transferred into separatory funnel and extracted 
with DCM. The organic layer was and dried under vacuum/N  sweep for 12 h to afford 
N,N-diethyl alkanamide substituted benzenesulphonamides (8a-k) in 71.5% - 95.8%.  
3.7.1. N,N-Diethyl-1-(phenylsulphonyl)pyrrolidine-2-carboxamide (8a). Yield 2.20g 
(75.9%), mp 84-85 oC. 1H-NMR (CDCl ) δ: 7.92-7.90 (d, J = 7.12 Hz, 2H, Ar-H), 7.56-
7.48 (m, 3H, Ar-H), 4.81-4.78 (dd, J1 = 3.6 Hz, J2 = 11.6 Hz, 1H, CH
o
2
3
-CON), 3.58-3.50 
(m, 2H, N-CH2-CH ),  3.48-3.41 (m, 2H, CH -N of pyrrolo), 3.37-3.30 (m, 2H, N-CH3 2 2-
CH ), 2.15-2.07 (m, 2H, CH  of pyrrolo), 1.92-1.85 (m, 2H, CH  of pyrrolo), 1.29-1.26 (t, 
J = 7.08 Hz, 3H, CH
3 2 2
3-CH2N), 1.11-1.07 (t, J = 7.08 Hz, 3H, CH3-CH2N). IR (KBr) cm-1: 
2982 (CH aromatic), 2926 (CH aliphatic), 2860 (CH aliphatic), 1649 (C=O of amide), 
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1152, 1086 (SO2 two bands), 687 (Ar-H). Anal. calcd. for C15H22N2O3S (310.42): C, 
58.04; H, 7.14; N, 9.02. Found: C, 57.98; H, 7.25; N, 9.02. 
N
O
S
N
O
O
(8a)
N,N-Diethyl-1-(phenylsulphonyl)pyrrolidine-2-carboxamide
                              
3.7.2. N,N-Diethyl-1-(phenylsulphonyl)piperidine-2-carboxamide (8b). Yield 2.90 g 
(95.8%), mp 128-129 C. H-NMR (CDCl3) δ: 7.73-7.71 (d, J = 8.6 Hz, 2H, Ar-H), 7.54-
7.42 (m, 3H, Ar-H), 4.90-4.88 (dd, J1 = 2.0 Hz, J2 = 8.0 Hz, 1H, CH
o 1
-CON), 3.79-3.76 (m, 
2H, N-CH2-CH3),  3.33-3.28 (m, 2H, N-CH2-CH3), 3.18-3.15 (m, 1H, CHa of CH2-N 
piperidine), 3.10-3.07 (m, 1H, CHb of CH2-N piperidine), 1.78-1.65 (m, 3H, CH & CH2 
of piperidine), 1.61-1.47 (m, 3H, CH & CH2 of piperidine), 1.29-1.26 (t, J = 7.16 Hz, 
3H, CH3-CH2N), 0.98-0.94 (t, J = 7.12 Hz, 3H, CH3-CH2N). Anal. calcd. for 
C16H24N2O3S (324.45): C, 59.23; H, 7.46; N, 8.63. Found: C, 59.17; H, 7.29; N, 8.55. 
                            
N
ON
S
O
O
N,N-Diethyl-1-(phenylsulphonyl)piperidine-2-carboxamide
(8b)
 
3.7.3. N,N-Diethyl-2-(phenylsulphonamido)acetamide (8c). Yield 2.23 g (88.2%), mp 
NMR (CDCl3) δ: 7.89-7.85 (m, 2H, Ar-H), 7.64-7.48 (m, 3H, Ar-H), 201-202 oC. 1H-
5.92 (s-br, 1H, NH), 3.76-3.75 (d, J = 5.08 Hz, 2H, CH2-NH), 3.31-3.25 (q, J = 7.12 Hz, 
2H, N-CH2CH3), 3.18-3.12 (q, J = 7.16 Hz, 2H, N-CH2CH3), 1.12-1.09 (t, J = 7.16 Hz, 
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3H, CH3-CH2), 1.03-0.99 (t, J = 7.12 Hz, 3H, CH3-CH2). IR (KBr) cm-1: 3294 (N-H), 
3057 (CH aromatic), 2986 (CH aliphatic), 1726 (C=O of amide), 1625 (C=C), 1167, 
1092 (SO2 two bands), 689 (Ar-H). Anal. calcd. for C12H18N2O3S (270.35): C, 53.31; H, 
6.71; N, 10.36. Found: C, 53.19; H, 6.84; N, 10.51. 
OS
O N
                               
N
O
H
(8c)
N,N-Diethyl-2-(phenylsulphonamido)acetamide
 
3.7.4. N,N-Diethyl-3-methyl-2-(phenylsulphonamido)butanamide (8g). Yield 2.11 g 
(72.3%), mp 89-90 oC. 1H-NMR (CDCl3) δ: 7.82-7.79 (d, J = 8.72 Hz, 2H, Ar-H), 7.54-
J = 9.16 Hz, 1H, NH7.43 (m, 3H, Ar-H), 5.83-5.81 (d, -CH), 3.84-3.81 (dd, J1 = 4.16 Hz, 
J2 = 9.16 Hz, 1H, NH-CH-CH), 3.17-2.99 (m, 4H, 2 × CH2-CH3), 1.83-1.81 (m, 1H, CH), 
1.05-1.01 (d, J = 15.88 Hz, 3H, CH3-CH), 0.93-0.89 (t, J = 7.2 Hz, 3H, CH3-CH2), 0.87-
0.83 (t, J = 7.1 Hz, 3H, CH3-CH2), 0.87-0.83 (d, J = 14.2 Hz, 3H, CH3-CH). IR (KBr) 
cm : 3258 (N-H), 2967 (CH aliphatic), 1640 (C=O of amide), 1625 (C=C), 1165, 1092 
(SO2 two bands), 606 (Ar-H). Anal. calcd. for C15H24N2O3S (312.43): C, 57.67; H, 7.74; 
N, 8.97. Found: C, 57.44; H, 7.83; N, 9.09. 
                              
-1
O
O
N
S
O NH
N,N-Diethyl-3-methyl-2-(phenylsulphonamido)
butanamide
(8g)
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3.7.5. 4-(3-(Diethylamino)-3-oxo-2-(phenylsulphonamido)propyl)phenyl benzene 
sulphonate (8k). Yield 3.46 g (71.5%), mp 72-73 oC. 1H-NMR (CDCl3) δ: 7.81-7.79 (d, 
J = 7.4 Hz, 2H, Ar-H), 7.75-7.74 (d, J = 7.4 Hz, 2H, Ar-H), 7.68-7.64 (m, 1H, Ar-H), 
7.54-7.50 (m, 3H, Ar-H), 7.45-7.41 (m, 2H, Ar-H), 7.06-7.03 (d, J = 8.44 Hz, 2H, Ar-H), 
6.88-6.85 (d, J = 8.44 Hz, 2H, Ar-H), 4.23-4.21 (d, J = 9.2 Hz, 1H, NH-CH), 4.24-4.21 
(dd, J1 = 9.2 Hz, J2 = 13.6 Hz, 1H, NH-CH-CH), 3.17-3.14 (m, 1H, CHa of CH2-Ar), 
2.98-2.95 (m, 1H, CHb of CH2-Ar), 2.88-2.80 (m, 4H, 2 × CH2-CH3),  0.86-0.82 (t, J = 
7.1 Hz, 3H, CH3-CH2), 0.78-0.75 (t, J = 7.16 Hz, 3H, CH3-CH2). IR (KBr) cm-1: 3248 
(N-H), 3073 (CH aromatic), 2974 (CH aliphatic), 1690 (C=O of amide), 1625 (C=C), 
1161, 1088 (SO2 two bands), 687 (Ar-H). Anal. calcd. for C25H28N2O6S2 (516.64): C, 
58.12; H, 5.46; N, 5.42. Found: C, 57.97; H, 5.39; N, 5.31. 
                     
 
 
3.8. Antimicrobial Activity 
 
general sensitivity testing and MIC with respect to freshly cultured targeted organisms. 
aureus Escherichia coli
 
The antimicrobial properties of the sulphonamides were investigated in form of the 
The two organisms used in this present study are one Gram positive (Staphylococcus 
 ATCC 6538) and one Gram negative (  ATCC 25922) which are 
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associated with the gastrointestinal tract infections in man and animal (Nwinyi et al., 
2008).  
3.8.1. Preparation of the Inoculum 
The standard strains of S. aureus and E. coli used were obtained from Center for 
Antimicrobial Test, TIPC, Beijing. No clinically isolated organism was used based on in-
availablilty in this laboratory as at the time of this study. The strains were propagated on 
plates and maintained on the plate at 4 oC. The isolates were sub-cultured in 
utrient broth at 37oC for 8 h prior to antibacterial testing. 
vity Testing of Compounds 
7 8 -1
n filled with 0.3 mL of each sulphonamide solution in appropriate solvent at a 
of sulphonamide dissolved in 20 mL of solvent). It 
o
anisms was noticed. Zones of 
iameter of such zones were 
measured. The procedure was repeated for the streptomycin (standard). 
nutrient agar 
n
3.8.2.   Antibacterial Sensiti
Agar well diffusion technique as described by Adeniyi et al., (1996) was used to 
determine the antibacterial activity of the synthesized compounds. Sensitivity test agar 
plates were seeded with 0.1 ml of an overnight culture of each bacterial strain (equivalent 
to 10  – 10  CFU mL ). The seeded plates were allowed to set and a standard cork borer 
of 8 mm diameter was used to cut uniform wells on the surface of the agar. The wells 
were the
concentration of 1000 μg/mL (0.02 g 
should be noted that the solubilizing solvent for α-tolylsulphonamides was distilled water 
while the required solvent for p-tolylsulphonamides and benzenesulphonamides 
categories was DMSO). All the plates were incubated at 37 C for 24 h. The assay was 
conducted at regular intervals of 24 h until marked decline in the potency of the 
sulphonamide solution to inhibit the growth of the test org
clearance round each well means inhibition and the d
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3.8.3.  Minimum Inhibitory Concentration (MIC) Testing 
Agar well dilution method as described by Russell and Furr (1977) was used to determine 
the minimum inhibitory concentration (MIC) of the sulphonamides and streptomycin. 
Different dilutions of the sulphonamides were prepared first at ≤ 100 μg/mL to give final 
concentrations in the range of 100, 50, 25, 12.5, 6.25, and 1.8 μg/mL. The different 
dilution of sulphonamide derivatives that could not inhibit the microbial growth at ≤ 100 
μg/mL were later prepared at ≤ 1000 μg/mL to give final concentrations in the range of 
1000, 500, 250, 125, 62.5 μg/mL. Two milliliter (2 ml) of each dilution was mixed with 
Mueller Hinton agar (18 mL) (MHA, Difco, France) and poured into Petri-dishes and 
allowed to set. The agar was streaked with an overnight broth culture of the bacterial 
strains and incubated overnight. The plates were then examined for the presence or 
absence of growth. The minimum concentration that completely inhibited macroscopic 
growth was regarded as the minimum inhibitory concentration (MIC) of the respective 
sulphonamide. The procedure was repeated for streptomycin (standard). 
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CHAPTER FOUR 
 
RESULTS AND DISCUSSION 
ynthesis of various functionalized α-toluenesulphonamides and synthetic modification 
lylsulphonamide which was the targeted key intermediate for the synthesis of 
enzothiazepinone. In detail, for the first time, a successful approach to the synthesis of 
-toluenesulphonamides from the reaction of α-toluenesulphonyl chloride (α-TsCl) with 
me readily available amino acids was here-in described. Using L-proline as the 
presentative amino acid, which upon effective coupling with α-TsCl in basic medium 
fforded α-toluenesulphonamide, 1-(benzylsulphonyl)pyrrolidine-2-carboxylic acid (1a) 
hich was converted to the acid chloride intermediate and  subsequently amidated to 
btain 1-(benzylsulphonyl)-N,N-diethylpyrrolidine-2-carboxamide  (2a).  
The intramolecular cyclization of (2a) via either direct ortho metalation or 
eterogeneous catalytic approach was also attempted to see the possibility of achieving 
the corresponding benzothiazepinone (3a) (Scheme 4.1). This was based on the earlier 
port of direct ortho metalated conversion of some N,N-diethylamide of p-tolyl 
lphonamide to benzothiazinone heterocyclic templates (Bakker et al., 1997). It was 
very crucial to explore various reaction conditions for effective optimization study as 
 
4.1. Derivatives of α-Toluenesulphonamide 
 
S
of the derivatives were carried out towards achieving novel N,N-diethylamide of α-
to
b
α
so
re
a
w
o
 
h
re
su
regard reaction of α-TsCl with L-proline, since the present work has never been 
embarked upon to the best of our knowledge.   
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Scheme 4.1: Overall Pathway for Representative Derivative of α-Toluenesulphonamide 
 
Hence, preliminary optimization of reaction conditions for α-
toluenesulphonamide was carried out by comparing the sulphonylation of L-proline as 
the representative of amino acid for the synthesis of (1a) under two different cases 
namely: in the presence of (i) triethylamine base using THF solvent and (ii) Na2CO3 base 
using water as the solvent. It was discovered that although, in case i, proline was 
effectively converted to its ammonium salt as a way of protecting the carboxyl 
functionality by triethylamine nucleophilic attack on its acidic proton, but it failed to 
couple with α-TsCl as envisaged (Scheme 4.2). This was established through the 1H-
NMR spectrum of the product from case i which had no aromatic protons in the region 
around 6.0 to 8.0 ppm showing that there was no effective coupling with α-TsCl. The 
failure of the case (i) reaction condition may be as a result of poor solubility of L-proline 
in THF and possibility of steric hinderance exerted by the alkylated ammonium side 
chain. Therefore, the case (i) approach was discarded due to this disappointment.   
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Scheme 4.2: Mechanism for Formation of Sulphonamide (1a) using Case i  
 
 On the other hand, case (ii) condition using aqueous Na2CO3 gave the expected α-
toluenesulphonamide product named 1-(benzylsulphonyl)pyrrolidine-2-carboxylic acid 
(1a) via the modified procedure according to Zhang and co-workers (2005). Basifying of 
L-proline with Na2CO3 aqueous turned the carboxyl end to the sodium salt which did not 
only act as protecting group but also increased the solubility of the amino acid in aqueous 
medium. The amino group then attacked the sulphonyl chloride at the highly electrophilic 
sulphur site. After all, the sodium salt side chain of the sulphonamide was re-converted to 
the carboxylic functional group by acidifying with 2M HCl until pH 2.2 was attained 
(Scheme 4.3). It is important to note at this stage that the solid product could not 
crystallize out, even after being kept in refrigerator for several days. However, the TLC 
spotting indicated that the coupling was successful; hence, the clear liquid obtained was 
freeze-dried to obtain a bulky solid which upon purification with column chromatography 
materials 
specially the α-tolylsulphonyl chloride was overcome by increasing the duration of 
stirring at room temperature to 48 h. 
afforded (1a). Difficulty connected with the poor reactivity of some starting 
e
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 Scheme 4.3: Mechanism for Formation α-Toluenesulphonamide using aq. Na2CO3  
 
Meanwhile, after establishing case (ii) as the more acceptable working procedure, it is 
thoughtful to explore the thermodynamic potential in order to validate the best reaction 
temperature to afford maximum yield. Hence, the effect of variation in temperature was 
carefully studied by carrying out the coupling of proline with α-TsCl in aqueous Na2CO3 
at carefully controlled temperature of 0oC to room temperature, at 60 oC to 80 oC and at 
120 oC to 140 oC as shown in entries 1, 2 and 3 respectively (Table 4.1). It was observed 
that the synthesis at 0 oC followed by stirring at room temperature afforded (1a) at 
excellent yield 92%, while at an elevated temperature of 60 oC to 80 oC, majority of the 
reacting species reverted back to the starting material thereby resulting in poor (1a) yield 
of 37%.  
Table 4.1: Synthesis of 1-(Benzylsulphonyl)pyrrolidine-2-carboxylic acid (1a) at   
      Different Temperatures for Optimization Study 
Entry Reagent/Solvent Temperature oC Time h Yield % 
1 Na2CO3 / H2O 0 to rt 48  92 
2 Na2CO3 / H2O 60 - 80 48 37 
3 Na CO / H O 120 - 140 48 - 2 3 2
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At extremely high temperature (120 oC to 140 oC) as shown in entry 3, no isolable 
id, CH aromatic, CH aliphatic, C=O and C=C  at 3447-3404 cm-1, 2990-2974 
all 
exp d stre frequ s as t s near 6 
cm-1  1171-115  Ar-H band oticed at 810  cm-1 as expected.  
product was obtained. This was because of thermal decomposition of the proline 
precursor at this elevated reaction temperature. Based on this result, it could be seen that 
the best optimization condition was to couple proline with α-TsCl in aqueous Na2CO3 at 
0oC to room temperature. Hence, this protocol was repeated using ten other amino acids 
and it was established as an efficient procedure for accessing diverse highly 
functionalized α-toluenesulphonamide (1a-k) in excellent yield (87.7% - 98.8%) 
(Scheme 4.4). The structures of all these new compounds (1a-k) were confirmed using 
FT-IR, 1H- and 13C-NMR, Mass spectral and elemental analytical data. Generally, IR 
spectra of compounds (1a-k) showed absorption bands due to the stretching vibrations of 
O-H of ac
cm-1, 2878-2774 cm-1, 1751-1728 cm-1 and 1620-1590 cm-1 respectively. They 
erience tching vibrational ency of SO2 unit wo band 1238-120
and 1 cm-1 whereas s were n -698
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Scheme 4.4: Synthesis of Novel α-Toluenesulphonamide Derivatives (1a-k)  
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 In particular, the IR spectrum of (1a) as a representative of this group, exhibited 
the absorption band at 3441 cm-1 due to the presence of O-H of carboxylic acid while 
bands for the CH of both aromatic and aliphatic were noticed at 2980 cm-1  and 2828 cm-1 
respectively. The stretching vibrations at 1728 cm-1  and 1620 cm-1 depicted C=O of acid 
and C=C of aromatic ring respectively while the two bands at 1219 cm-1 and 1151 cm-1 
were as a result of the presence of SO2 functionality. The mass spectral data of (1a) 
showed the molecular ion peak at m/z 269.1 which correlated well with the molecular 
mass of the compound (269.32) while the base peak found at m/z 178.1 was as a result of 
loss of benzylic radical (PhCH2.). Other daughter peaks produced by some fragmentation 
patterns of (1a), were observed at m/z 179.1, 176.1, 122.0 and 105.0 with relative 
intensities of 18.4%, 32.4%, 49% and 32% respectively.   
 In addition, the chemical shifts and the multiplicity patterns of 1H- and 13C-NMR 
were consistent with that of the proposed structure for (1a). So, the 1H NMR spectrum of 
(1a) in D2O exhibited a five aromatic protons singlet at δ 7.47 and two protons singlet of 
benzylic methylene (i.e. Ph-CH2-SO2) at  4.24. All other signals observed upfield of 
TMS from  3.48-3.45 to  2.15-2.09 were due to the presence of six pyrrolo protons 
while that of the seventh pyrrolo proton (CH
δ
δ δ
-COO) resonated as a doublet-doublet at δ 
4.46-4.43 (J1 = 7.20 Hz, J2 = 15.76 Hz). The C-NMR spectrum of (1a) showed the 
presence of twelve different carbon atoms with the signals ranging from 173.1 (C=O) to 
24.3 (CH2) ppm. The six aromatic carbon of phenyl resonated downfield between 132.6 
and 128.9 ppm while benzylic CH2 linked to SO2 was observed at 57.7 ppm. The three 
sp  hybridized CH2 of proline nucleus appeared between 47.1 and 24.3 ppm while its CH 
linked to –COOH resonated at 67.4 ppm. The mass spectrum of (1a) showed the 
13
3
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molecular ion peak at m/z 269.1 which correlated well with molecular mass of the 
compound within precision limit of +0.2 while the base peak experienced at m/z 178.1 
was as a result of loss of benzylic radical. Other fragmentation patterns resulted in some 
other prominent daughter fragments at m/z of 179.1, 176.1, 122.0, and 105.0 with the 
intensities of 18.4%, 32.4%, 49% and 32% respectively.         
 Furthermore, the conversion of α-toluenesulphonamide (1a) (i.e. 1-(benzyl 
sulphonyl)pyrrolidine-2-carboxylic acid) to the target novel corresponding N,N-diethyl 
alkanamide of α-tolylsulphonamide (2a) (i.e. 1-(benzylsulphonyl)-N,N-diethyl 
pyrrolidine-2-carboxamide) was achieved via one pot two steps amidation technique 
(Kuethe and Beutner, 2009). This involved treatment of (1a) with oxalyl chloride in one 
drop of DMF. The chloride ion which was the reaction initiator and precedential species 
for the formation of acid chlorides, was generated by molecular interaction between 
oxalyl chloride and DMF via a proposed mechanism (Scheme 4.5a) similar to that of 
Swern oxidation (Kawaguchi et al., 2005). The nucleophilic attack of the –COOH by the 
chloride ion generated above led to the conversion of (1a) to the acid chloride reactive 
intermediate which upon further treatment with diethylamine in basic medium between 
controlled temperature of -10 oC and room temperature afforded the amide bearing 
sulphonamide (2a) according to a well established mechanism (Scheme 4.5).  
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Scheme 4.5: Mechanism for the Formation of Amide (2a)  
 
 In more elaborate terms, the protocol for the conversion of (1a) to the amide (2a) 
also worked successfully for other α-toluenesulphonamide derivatives. Thus, the 
treatment of α-toluenesulphonamides (1a-k) with oxalyl chloride in DMF generated the 
intermediate acid chloride which when subsequently treated with diethylamine in the 
presence of Na2CO3 in aqueous medium afforded N,N-diethyl alkanamide of α-tolyl 
sulphonamides (2a-k) in excellent yields (Scheme 4.6).  This medium was used as a 
result of high hydrophilic nature of the sulphonamides that were to be amidated which 
made them practically insoluble in every other solvent except water.  
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cheme 4.6: Synthesis of N,N-Diethylalkanamide Substituted α-Tolylsulphonamides (2a-k) 
Table 4.2: Physical Data of N,N-Diethyl Substituted α-Tolylsulphonamides (2a-k) 
Sample 
Code 
R R1 R2 Molecular 
Weight 
Mp oC Rfa Yield 
(2a) - - - 324.45 185-187 0.71 97.9 
(2b) - - - 338.47 210-211 0.72 99.0 
(2c) H - - 284.38 213-215 0.51 92.6 
(2d) CH3 - - 298.41 238-240 0.56 98.5 
(2e) CH2SH - - 330.47 198-200 0.71 89.0 
(2f) (CH2)2SCH3 - - 358.53 170-172 0.65 90.6 
(2g) - CH3 CH3 326.46 226-230 0.69 97.3 
(2h) - CH3 OH 328.43 240 (dec) 0.53 80.2 
(2i) - H CH2CONH2 355.46 251-253 0.58 93.2 
(2j) - H Ph 374.51 227-229 0.70 90.2 
(2k) - H PhCH OSO - 544.69 265 (dec) 0.69 2 2 89.3 
a Solvent system. Chloroform: Methanol (3:1)  
 The result of the physical parameters in terms of the molecular weights, melting 
f valu as well the perc ge yields of the synthesized N,N thyl
alkanamide substituted α-tolylsulphonami s (2a-k) is as shown in Table 4.2. Hence, the
molecular weights of (2a-k) anged from 284.38 to whi lting points
ranged from 170 - 172 oC to 251 - 253 oC cept that o d (2 ec sed
at 240 oC and 265 C respectively. The inability of ( (2k) ven at high
points, R es as enta -die  
de  
 r   544.69 le the me  
ex f (2h) an k) which d ompo  
o 2h) and  to melt e  
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te ture might be as a result of inte cular hy bond en the
molecule. It was also observ spotting actio e s ch
 with the Rf values varying between 0.51 
R, mass 
 
mpera rmole drogen ing occurr ce in  
ed that upon TLC , each re n gave on pot ea  
in chloroform: methanol (3:1) solvent system
and 0.72. It should be noted that the Rf values were reported at 23oC and 1 atm.  
 Moreover, from the high polar nature of the eluting solvent system and the Rf 
values obtained, it could be easily seen that these compounds were very polar. This may 
be responsible for the complete solubility in water and failure to crystallize from water 
even after several days. Hence, this may explain why the only method by which the solid 
(2a-k) were obtained from the solution was lyophilization technique. It was worthy of 
note that the entire solid (2a-k) were obtained in excellent yields ranging between a 
minimum of 80.2% for (2h) to a maximum of 99.0% for (2b) according to Table 4. The 
spectroscopic properties of the synthesized N,N-diethyl substituted α-tolylsulphonamides 
(2a-k) were studied and the structural characterization using FT-IR, 1H-, 13C-NM
sprectra data as well as elemental analyses were carried out. It was discovered that all the 
spectroscopic parameters were consistent with the proposed structures for (2a-k).  
 
Attempted Cyclization of the Amide (2a) 
 Intramolecular cyclization of N,N-diethylalkanamide of α-tolylsulphonamide (2a) 
to the corresponding benzothiazepinone (3a) was attempted with (a) ortho-metalation 
procedure via lithiation technique and (b) heterogeneous catalytic approach with silica-
mediated aluminium chloride as solid acid catalyst. 
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(a) Using Ortho-Metalation Technique:  
 Lithium dialkylamides are generally used as bases to generate lithio species due to 
eir strength and low nucleophilicity, especially when they are derived from sterically 
ni et al., 1997). Based on this discovery, the 
ue earlier reported in literature as a 
ccessful tool for the conversion of benzenesulphonamide counterpart to the 
enzothiazinone equivalent (Bakker et al., 1997). The excess LDA-promoted cyclization 
enzothiazepinone (3a) and relative ease of 
thiatio
  
th
hindered amines (Parra et al., 2003; Familo
reaction of n-butyllithium (n-BuLi) with diisopropylamine in THF at -78 oC afforded 
lithium diisopropylamide (LDA) which was subsequently used in attempting the 
intramolecular cyclization of amide (2a) to obtain the benzothiazepinone (3a). This was 
attempted by taking clue from the lithiation techniq
su
b
of α-tolylsulphonamide amide (2a) to b
li n was attributed to a prelithiation phenomenon called Complex Induced 
Proximity Effect (CIPE) which occurred in the transition state before deprotonation.  
 Mechanistically, the comparable intramolecular information transfer was effected 
by formation of a prelithiation complex which brought reactive groups into proximity for 
directed deprotonation (Scheme 4.7). This process utilized the shape of one part of a 
molecule to control the stereoselectivity of reactions occurring some distance away 
(Clayden et al., 2004). The mechanism of this reaction involved a complexing between 
LDA and the amide of interest (2a) in the prelithiation process which facilitated the 
deprotonation of hydrogen in the ortho position of the ring to achieve the lithio species. 
The carbanion generated from the lithio species exerted a nucleophilic attack on the sp2 
hybridized carbon center of C=O for effective cyclization. The driving force for the ring 
closure was the loss of a stable molecule of NEt2 as a good leaving group (Scheme 7).
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Scheme 4.7: Mechanism for Attempted Cyclization to (3a) using Ortho-Metalation  
 
 The representative equation for this reaction involved lithation of the ortho 
position with 4 equivalent of LDA in THF to form an intermediate at 0 oC which upon 
stirring at room temperature and quenching with NH4Cl (aq), was expected to afford the 
fused benzothiazepinone (3a) (Scheme 4.8). In contrast to the observation made in 
successful synthesis of benzothiazinone (Bakker et al., 1997), a directed metalation group 
did not dictate the expected regiochemistry even in the presence of excess LDA, hence, 
the effort of the intramolecular cyclization towards obtaining (3a) here-in proved abortive. 
The failure observed in using metalation as means of intramolecular cyclization here 
 
lphonamide (2a) precursor which made it practically difficult for it to dissolve in either 
might be as a result of high polar nature of the N,N-diethyl substituted α-tolyl
su
THF or DCM or any other solvent except water alone. However, water that was the only 
friendly solvent for solubilizing the amide (2a) was not acceptable solvent in ortho-
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metelation approach as it destroyed the n-BuLi used to generate the LDA that was 
required as the metalating agent. It could be deduced that methylene insertion has led to 
decrease in lipophilicity of the sulphonamide and also increase hydrophilicity thereof 
(Shoji et al., 2009). 
S N
OO
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O
(2a)
    4 equiv LDA
in THF at 0 oC
S N
OO
N
N
SO2
O
?
(3a)
O
   NH4Cl (aq)
Li in THF at rt for 3 h
X
Scheme 4.8: Attempted Synthesis of Benzothiazepinone (3a) using Ortho-Metalation 
 
(b) Using Heterogenous Catalytic Approach: 
 An attempt to carry out the intramolecular cyclization of (1a) toward formation of 
benzothiazepinone (3a) via heterogeneous catalytic approach with the aid of silica 
mediated aluminium chloride was also examined. This was carried out by refluxing (1a) 
in catalytic amount of SiO2-AlCl3 at 80 oC for 3 h using DCM solvent (Scheme 4.9). This 
was based on the earlier literature finding that reported SiO2-AlCl3 as heterogeneous 
catalyst of choice for intramolecular cyclization of the -COOH side chain of 4-
phenylbutanoic acid to achieving the cyclic ketone product, tetralone (Boroujeni, 2010). 
osition of benzene as a result of intermediate Friedel-Craft anionic equivalent generated  
icant advantages of this methodology are 
ild r
Thus, it was envisaged that the –COOH side chain of the (1a) might cyclized at the ortho-
p
by the effect of the solid acid catalyst. The signif
m eaction conditions, high to excellent yields, short reaction times, solvent-free 
conditions, low cost, simple reaction work-up, easy preparation and handling of the 
catalyst. In addition, the use of SiO2-AlCl3 resulted in a reduction of the unwanted and 
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hazardous waste that is produced during conventional homogeneous processes. Despite 
all the merits and wide acceptability of this approach, it was not successful in the 
intramolecular cyclization of (1a) in this study. The failure observed, just like in the case 
of ortho-metalation technique, may be as a result of high hydrophilic character of α-
toluenesulphonamide (1a) precursor which made it insoluble in DCM through the course 
of reaction. The only good solvent that dissolved (1a) was water which was indeed not 
compatible with AlCl3 used in preparing the solid acid catalyst (SiO2-AlCl3).   
S N
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Scheme 4.9: Attempted Synthesis of Benzothiazepinone (3a) using SiO2-AlCl3  
 
4.2.   Derivatives of p-Toluenesulphonamide 
 p-Toluenesulphonyl chloride (p-TsCl) and various amino acids were readily 
available; they were found as convenient starting materials in this present work. The 
reaction started with arylsulphonylation of various amino acids to afford the p-
toluenesulphonamide (4a-k) in good to excellent yields (60.5 – 99.0%) using a known 
procedure (Zhang et al., 2005). To show the overall reaction under this class, it was 
conceivable to use proline as the representative amino acid. Hence, the coupling of L-
proline with p-toluenesulphonyl chloride, p-TsCl in basic medium within 4 h at room 
uethe 
nd Beutner methodology (2009) to obtain N,N-diethylsubstituted amide of p-
temperature gave arylsulphonamide, (4a) which was subsequently amidated by K
a
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tolylsulphonamide (5a) in excellent yield (92.3%). Metalation of the amide (5a) using 
excess LDA-promoted cyclization gave the benzothiazinone (6a) (Scheme 4.10), 
although in a low yield (24%). This result authenticated the synthesis earlier reported by 
Bakker and co-workers in (1997).    
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Scheme 4.10: Overall Pathway for Representative Derivative of p-Toluenesulphonamide  
  
The mechanism of the reaction started with conversion of –COOH end of proline 
to the sodium salt of the acid through electrophilic substitution of H+ with Na+ released 
from the base. This served as a protection for –COOH functionality and enhanced the 
solubility of proline better in aqueous medium. The cross coupling with p-TsCl occurred 
by nucleophilic attack of the electrophilic sulphur by the amino group of proline to from 
ammonium ion where chloride ion was the leaving group. The abstraction of the 
ammonium proton by the chloride ion led to the formation of sodium salt of the amide 
which subsequently underwent acidification with 2M HCl to afford the expected p-
of ten other amino acids apart from L-proline to obtain corresponding p-
toluenesulphonamide derivatives (4b-k) (Scheme 4.12).   
toluenesulphonamide (4a) as shown in Scheme 4.11. This procedure was repeated with 
sulphonylation 
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Scheme 4.11: Mechanism for Formation p-Toluenesulphonamide using aq. Na2CO3 
 
 
 
Scheme 4.12: Synthesis of a Series of p-Toluenesulphonamides (4a-k) 
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 However, tyrosine required double molar proportion of p-TsCl for complete 
reaction to give (4k) in 80.5% yield (Scheme 4.13a). This is due to the fact that in 
addition to the sulphonylation, tyrosine also underwent tosylation on the phenolic
hydroxyl group at the para position of the phenyl ring to give (4k) whose structure was 
consistent with the assigned 1H- and 13C-NMR spectra (Experimental). This double 
sulphonylation in (4k) was as a result of the resonant stabilization of the phenolate anion 
conjugate base as shown by the reaction path in Scheme 4.13b. This resonant 
stabilization caused the equilibrium to shift forward; hence, tosylation is highly favoured. 
The spectroscopic study was investigated for the structural elucidation using IR, 1H- and 
13C-NMR, mass spectral and elemental analytical data. The data correlated well with the 
proposed structures for the synthesized p-toluenesulphonamide derivatives (4a-k).  
 
Scheme 4.13: Mechanistic Justification for the Chain End Tosylation of (4k) 
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 Meanwhile, (4k) was used as representative compound for the spectroscopic 
explanation for this group. The 1H-NMR spectrum of (4k) in deuterated chloroform 
showed -CH3 attached to phenyl and tosylate as singlet at 2.41 and 2.45 ppm respectively 
while the two benzylic protons (-CH2-Ar) resonated upfield of TMS as two separate 
doublet of doublet at δ 2.97-2.92 (J1 = 6.8 Hz, J2 = 20 Hz) and 3.11-3.06 (J1 = 5.2 Hz, J2 
= 20 Hz) ppm. This was as a result of shield effect in the sp3 hybridized carbon atoms 
which required higher external magnetic field to bring it to resonance. The -NH and its 
neighboring –CH, resonated as a doublet and a quartet at δ 5.14-5.12 (J = 8.5 Hz) and 
4.17-4.12 (J = 6.8 Hz) ppm respectively. All the twelve aromatic protons were found as 
expected between δ 6.85-6.83 ppm and 7.69-7.67 ppm. 13C-NMR spectrum confirmed 
(4k) to have twenty three carbon atoms ranging from δ 21.7 ppm (CH3) to 173.9 ppm 
.6 ppm (C=O) as envisaged. All the eighteen aromatic carbons resonated between δ 122
and 148.9 ppm while the three remaining signals which depicted -CH3 linked to tosylate, 
-CH2 linked to phenyl and -CH linked to -NH were observed at δ 21.9, 38.3 and 56.4 
ppm respectively.  
 The IR spectrum of (4k) exhibited the absorption bands at 1717 cm-1 and 1559 
cm-1 due to the presence of C=O (acid) and C=C respectively while SO2 functionality was 
observed as two bands at 1150 and 1092 cm-1. In addition, -NH vibrational mode was 
responsible for the absorption band noticed at 3339 cm-1. Mass spectrum of (4k) showed 
the base peak at m/z 65.0. Although, molecular ion peak was not observed, however; 
there was an appearance of a fragment m/z 443.1 which was as a result of loss of -COOH. 
Other fragmentation patterns resulted in some other prominent daughter fragments at m/z 
of 171.0, 156.0, 155.0, 134.1 and 92.1 with the intensities of 35%, 58%, 90%, 90% and 
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64% respectively. The result of elemental analysis was consistent with that of the 
proposed structure, showing not more than a maximum different of +0.30 between % 
calculated and % found for the carbon, hydrogen and nitrogen of the prepared 
sulphonamides.                      
 Secondly, the intermediate arylsulphonamides (4a-k) subsequently underwent one 
pot two steps amination procedure to afford N,N-diethylsubstituted amide (5a-k). The 
mechanism behind this amidation was given by using amidation of (4a) to produce N,N-
diethyl-1-tosylpyrrolidine-2-carboxamide (5a) as a representative for this group. It 
entailed initial conversion of (4a) to its acid chloride with the aid of (COCl)2/DMF earlier 
discussed (Scheme 4.5a). The acid chloride intermediate was then treated with 
diethylamine in the presence of TEA base to obtain N,N-diethyl-1-tosylpyrrolidine-2-
carboxamide (5a) where hydrogen chloride gas was eliminated as the byproduct (Scheme 
4.14). In order to compare the stereochemical assignment and yield improvement of N,N-
disubstituted amide, we deviated from conventional method of using thionyl chloride for 
the conversion of –COOH functionality to acid chloride before subsequent amination.  
Scheme 4.14: Mechanism for N,N-Diethyl-1-tosylpyrrolidine-2-carboxamide (5a).  
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 In a nutshell, N,N-diethylsubstituted amide (5a-k) was obtained from (4a-k) by 
one pot two steps amination protocol according to a recently used procedure (Kuethe and 
Beutner, 2009) (Scheme 4.15). Although, some of the N,N-diethylsubstituted amides (5a), 
(5b), (5d) had been reported by using conventional method of thionyl chloride for 
conversion to acid chloride (Bakker et al., 1997), but it is interesting to note that the 
procedural route used here-in afforded N,N-diethylsubstituted amides which showed 
improvement over the previous method. These include higher yields, easy work up, 
shorter synthetic route because each of the crude intermediates required no purification 
before further usage of such intermediate; thus, providing a quick and efficient synthetic 
route. In addition, although some of p-toluenesulphonamide group had been synthesized, 
the antimicrobial activities of those compounds have not been evaluated to the best of our 
n knowledge. Hence, there was need for repeating the synthesis of such categories, even i
this work, in order to investigate their antimicrobial potential.  
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Scheme 4.15: Conversion of p-Tolylsulphonamides to N,N-Diethylsulphonamides   
 
-
lylsulphonamide (5a) was attempted, by direct metalating approach with lithium 
  Thirdly, further synthetic utility of N,N-diethylalkanamide substituted p
to
diisopropylamide (LDA), to evaluate the possibility of getting benzothiazinone (6a). The 
preparation of (6a) was successfully achieved by first lithiating the THF solution of 
amide (5a) in 4 eqivalent of LDA at 0 oC, which was followed by stirring at room 
temperature for 30 mins. The reaction was quenched by addition of aqueous ammonium 
chloride and worked up accordingly (Scheme 4.16). The product (6a) was in comformity 
with the benzothiazinone of an earlier report (Bakker et al., 1997). The mechanism is 
shown in Scheme 4.17.  
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inone 
amework (6a) was preceded by a prelithiation complex formation via the Complex 
 
 The mechanism for the regiospecific construction of the targeted benzothiaz
fr
Induced Proximity Effect (CIPE) and followed by subsequent deprotonation by electronic 
effect to generate Friedel-Craft anionic equivalent. The nucleophilic attack of the ortho 
carbanion of benzene ring on sp2 hybridized carbonyl of amide resulted in the effective 
intramolecular cyclization which was driven by the departure of a good leaving group, 
NEt2 (Scheme 4.17).  
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4.3.   Derivatives of Benzenesulphonamide 
 Benzenesulphonyl chloride and its para-substituted counterparts were earlier used 
 the protection of amino functional group, identification of amino acid and 
e. However, we have here-in successfully 
n
in
distinguishing between three classes of amin
used benzenesulphonyl chloride as the cost effective and highly efficient main precursor 
in order to synthesize our targeted substituted benzenesulphonamide derivatives (7a-k) in 
this present work. Benzenesulphonyl chloride underwent condensation reaction with 
secondary amine of two different amino acids to afford N,N-disubstituted 
benzenesulphonamides (7a) and (7b), while its treatment with primary amine 
functionality of nine other amino acids in alkaline medium generated N-substituted 
benzenesulphonamide (7c-k) according to Scheme 4.18. It is important to note that amide 
formation is a fundame tal reaction of great interest in organic chemistry (Naik et al., 
2004; Katritzky et al., 2000). The development of efficient methods for the synthesis of 
amides remains good tools because of their importance in chemistry and biology, with a 
wide range of industrial and pharmaceutical applications and as valuable intermediates in 
organic synthesis (Theodorou et al., 2009; Katritzky et al., 2006).   
Scheme 4.18: Synthesis of Benzenesulphonamide Derivatives (7a-k) 
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 The carboxylic acid end of the benzenesulphonamide (7a-k) prepared was 
converted to the corresponding diethylsubstituted alkanamide of benzenesulphonamide 
(8a-k). Thus, some selected benzenesulphonamides containing free carboxyl side chain 
was further treated via two steps one pot mechanism to produce some selected new and
known series of N,N-diethylated alkanamido benzene sulphonamides (8a), (8b), (8c), (8g) 
and (8k) in good to excellent yield (Scheme 4.19). This involved, first reacting the 
arylsulphonamide with oxalyl chloride in presence of one drop of DMF catalyst to 
produce the acid chloride. This acid chloride was then converted to N,N-diethyl 
substituted arylsulphonamide by treating it with diethylamine in the presence of 
triethylamine base using dichloromethane (DCM) solvent.  
 
Scheme 4.19: Conversion of Benzenesulphonamides to N,N-Diethylamides  
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4.4.   Antimicrobial Activity 
 The antibacterial general sensitivity testing (inhibition zone, mm) of all the series 
of fifty five synthesized sulphonamides (twenty two α-tolylsulphonamides, seventeen p-
tolylsulphonamides and sixteen benzenesulphonamides) along side with that of 
streptomycin clinical standard were assayed on test organisms (Escherichia coli and 
Staphylococcus aureus) using agar diffusion technique (Adeniyi et al., 1996). The choice 
of E. coli as the Gram –ve organism is because it is easily transmissible through food, 
water, soil, animal and man (Nwinyi et al., 2008). E. coli is a normal flora of human body 
which causes a lot of vancomycin-resistant Enterococci and methicillin-resistant 
Staphylococcus aureus (MRSA) (Dyatkina et al., 2002).   
 Based on our previous report (Ajani et al., 2010), the choice of streptomycin as 
bits 
growth of the bacteria through induction of prokaryotic ribosomes to misread mRNA 
 also possesses broad spectrum of antibacterial activity. 
clinical standards is due to the fact that at low concentrations, streptomycin only inhi
(Voet and Voet, 2004) and it
There were reported cases of E. coli and Staphylococcus aureus being susceptible to 
streptomycin (Eshghi et al., 2011; Ajani and Nwinyi, 2009). The biological relevance of 
the synthesized sulphonamides here-in was authenticated by screening them in vitro 
against Staphylococcus aureus ATCC 6538 (S. aureus) and Escherichia coli ATCC 
25922 (E. coli) with the reported selectivity index (S.I.) duly calculated by comparing 
zones of inhibition (Z.O.I) of compound to that of streptomycin (i.e. ZO.I of 
compound/Z.O.I. of streptomycin standard  
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(a) Antimicrobial Activity of α-Tolylsulphonamides: The result of sensitivity testing 
revealed that the probable activities of α-tolylsulphonamide family on the test organisms 
were categorized based on the size of zone of inhibition (Table 4.3). Interestingly, it was 
observed that some of the compounds exhibited probable significant activities based on 
the large zone of inhibition reported. For instance, compounds (1f), (1g), (2b), (2c) and 
(2k) were highly active on E. coli while compounds (1a), (1b), (1d), (1e), (1j), (1k), (2e) 
and (2i) exhibited moderate activities on the same organism. All other compounds 
showed low activities on E. coli except (1c) and (2e) which were inactive on the E. coli 
even at 1000 μg/mL. The scenario of comparative study of effect of the sulphonamides 
and streptomycin on E. coli could be vividly understood by observing the selectivity 
index (S.I.). All the sulphonamides have selectivity indices ranging from 0.29 for 
ompound (2g) to 0.96 for compound (2k) (i.e. less than 1). This implies that c
streptomycin (S.I. = 1) was probably more active than any of the sulphonamide scaffolds 
as regarding the inhibition of E. coli growth. In the same vein, looking through the effect 
on S. aureus, compounds (1a), (1e), (2f), (2j) and (2k) were highly active; (1d), (1f), (1h), 
(1j), (1k), (2b), (2c) and (2h) were moderately active; (1b), (1c), (1g), (1i), (2a), (2d), (2g) 
and (2i) exhibited low activity while (2e) was inactive on S. aureus (Table 4.3).  
 The comparative study of α-toluenesulphonamides to streptomycin on S. aureus 
growth inhibition is worthy of commendation. The S.I. values indicated that compounds 
(1i), (2b), (2g) and (2i) competed favourably with streptomycin while (1a), (1d), (1e), 
(1f), (1h), (2a), (2c), (2f), (2h), (2j) and (2k) (S.I. = 1.08 - 2.31) showed even a better 
activity than streptomycin on S. aureus. All other compounds exhibited lesser activity 
than streptomycin (S.I. = 0.46 - 0.92) on S. aureus except (2e) which was inactive.  
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Table 4.3: General Sensitivity Testing with of Organisms with Zones of Inhibition 
Organisms 
Compd. No 
In vitro antibacterial activity  
 E. coli  S. aureus  
Z.O.I (mm) S.I. Z.O.I. (mm) S.I. 
(1a) ++ 0.54 +++ 2.31 
(1b) ++ 0.61 + 0.92 
(1c) - - + 0.69 
(1d) ++ 0.57 ++ 1.08 
(1e) ++ 0.57 +++ 2.15 
(1f) +++ 0.86 ++ 1.15 
(1g) +++ 0.89 + 0.46 
(1h) + 0.46 ++ 1.15 
(1i) + 0.36 + 1.00 
(1j) ++ 0.57 ++ 0.92 
(1k) ++ 0.75 ++ 0.92 
(2a) + 0.43 + 1.08 
+++ 0.84 ++ 1.00 (2b) 
+++ 0.82 1.38 (2c) ++ 
(2d) + 0.36 + 0.92 
(2e) - - - - 
(2f) ++ 0.57 +++ 2.23 
(2g) + 0.29 + 1.00 
(2h) + 0  +.43 + 1.08 
(2i) ++ 0.54 + 1.00 
(2j) + 0.39 +++ 2.00 
(2k) +++ 0.96 +++ 2.00 
Str. +++ 1.00 ++ 1.00 
+ = active 5-12 ++ = mode ; +++ = hi ctive 20-
31m  resistance; str. = streptomycin clinical reference; Z.O.I. = zone of inhibition; 
S.I. ective index tained by com pound to that of 
strep cin standard . coli = Escherichia coli (ATCC 25922)G- aureus = 
Staphylococcus aureus CC 6538)G+  Gram negative; G+ = Gram
 
Less mm; rately active 13-19mm ghly a
m; - =
= sel ob
; E
paring inhibition zone of com
tomy ; S. 
 (AT ; G- =  positive.    
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 e to high z of inhibition obtained during general sensitiv sting, the 
Min  Inhibitory ntration was conducted, first at 100 μg/mL using Russell and 
Furr m  those compounds that could not effect 
the inhibition of micro growth at thi tration were further repeated for MIC test 
at 10 E. co S. aureus 
was as shown in Table 4.4. 
Interestingly all the sulphonamides teste wed a conc ion-depende ibitory 
effect on the in vitro m ial growth a (Andrighet hner et al., 2009).  
nds 
ere ac
μg/mL for (1b) and (1k); 125 μg/mL for (1a), (1d), (1e), (1j), (2f) and (2i); 250 μg/mL 
for (1h), (1i), (2a), (2d), (2h) and (2j).   
 Although the most active sulphonamide on E. coli were (1f), (1g) and (2k) with 
MIC values of 25, 25 and 12.5 μg/mL respectively, but none of them could compete with 
streptomycin (with MIC value of 6.25 μg/mL) in term of activity. The two rings presenct 
in 2k and their π-character might be resposible for the high for it being the most active as 
deduced from the finding of Aissaoui et al. (2008). To face the stark reality, eight 
sulphonamides (1a), (1e), (1f), (1h), (2c), (2f), (2j) and (2k) inhibited the S. aureus 
growth at concentration ranging from 1.8 and 100 μg/mL. All others compounds were 
Du ones ity te
imum Conce
ethod (Russell and Furr, 1977). However,
bial s concen
00 μg/mL. The result of the MIC of this class of compounds on li and 
d sho entrat nt inh
icrob ssays ti-Frö
 Considering the MIC testing on the gram negative organism (E. coli), it was 
observed that compounds (1b), (1f), (1g), (1k), (2b), (2c) and (2k) inhibited the microbial 
rowth at varying values less than or equal to 100 μg/mL; whereas, all other compoug
w tive on E. coli at higher concentration (between 125 and 1000 μg/mL) except (1c) 
and (2e) which had no activity even at 1000 μg/mL. Specifically speaking, MIC values of 
the synthesized compounds on E. coli was reported to be 50 μg/mL for (2b) and (2c); 100 
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able to effect the expected inhibition from 125 μg/mL to 1000 μg/mL except (2e) which 
was inactive even at 1000 μg/mL. The significant antibacterial activity of the synthesized 
compounds may be explained as earlier documented in literatures (Shei, 2010; Levin et 
al., 2007), by the ability of its sulphonamide binding site to mimic p-aminobenzoic acid 
 
 
Minimum Inhibitory Concentration (μg/mL) 
(PABA) which is an essential growth factor in the targeted organisms.  
Table 4.4: MIC Test of α-Tolylsulphonamides on Targeted Organisms (μg/mL)  
Organisms 
Compd. No 
E. coli ATCC 25922 S. aureus ATCC 6538 
@100μg/mL @1000μg/mL @100μg/mL @1000μg/mL 
(1a) >100 125 1.8 <1000 
(1b) 100 <1000 >100 250 
(1c) >100 - >100 250 
(1d) >100 125 >100 125 
(1e) >100 125 50 <1000 
(1f) 25 <1000 100 <1000 
(1g) 25 <1000 >100 500 
(1h) >100 250 100 <1000 
(1i) >100 1000 >100 250 
(1j) >100 125 >100 125 
(1k) 100 <1000 >100 125 
(2a) >100 250 >100 250 
(2b) 50 <1000 >100 125 
(2c) 50 00 <1000 62.5 <10
(2d) >100 200 >100 1000 
(2e) >100 - >100 - 
(2f) >100 125 25 <1000 
(2g) >100 500 >100 1000 
(2h) >100 250 >100 125 
(2i) >100 125 >100 250 
(2j) >100 200 25 <1000 
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(2k) 12.5 <1000 25 <1000 
Str. 6.25 <1000 >100 125 
>100 s that if there was no gr  inhibition at g/mL, it was repeated at 1000 
μg/mL , <1000 μ has already been exp ced at 
lower concentration less than or equal to 100 μg/mL;  there is n d to repeat the 
test at 1000 μg/mL. – means no activity was observed even at 1000 μg/mL. Str. means 
Streptom
 
 
(b) Antimicrobial Activity of p-T honamid  the sake o vity and better 
understanding, the selectivity ind e synthesi tolylsulpho  derivatives 
on E i is as shown in Fig. x, which was evaluated by 
comp  the z  inhibition ( h of the synt compounds 
with of cli tandard (str ycin), gave a clearer picture of the antibacterial 
activ f this of sulphona on the targeted organisms. Although majority of 
the p supho es have mod  to high activity, but none of them could compete 
with the streptom E. coli growth inhibition efficacy. It was observable that the S.I. 
 
on the inhibition of E. coli growth. The highest activity 
as observed in (5j) with S.I. of 0.98. This improved activity might be as a result of 
additional conjugation which occurred in (5j), other compounds that showed high activity 
include (4d), (4e), (4k), (5a), (5b), (5c), (5d) and (5g) (S.I. > 0.8). Within the class, it 
was noticeable that only seven compounds showed moderate activity, in a decreasing 
order (4f) ≈ (4g) > (4h) > (4j) > (4a) ≈ (4i) > (4b) (0.6 < S.I. < 0.8) while the least 
activity which was categorized by S.I. < 0.6, was experienced in one compound (4c) with 
S.I. value of 0.5 to be precised.  
 mean owth 100 μ
g/mL means that growth inhibition erien
o nee hence,
ycin clinical reference.  
olylsulp es: For f bre
ex of th zed p- namide
. col 4.1. The selectivity inde
aring one of mm) obtained from eac hesized 
 that nical s eptom
ity o group mide 
-tolyl namid erate
ycin in 
of p-tolylsulphonamide varied from 0.5 for (4c) to 0.98 for (5j). Unequivocally speaking,
streptomycin, with S.I. value of 1, demonstrated high level of superiority to all the 
synthesized p-tolylsulphonamide 
w
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 In like manner, the antib
Fig. 4.1: Antibacterial Activity of p-Tolylsulphonamides against Escherichia coli 
 
acterial activity of p-tolylsulphonamides with respect to 
reptomycin antibiotic on the S. aureus clinical isolate was also evaluated and pictorially 
presented as shown in Fig. 4.2. Based on the intensity of the selectivity index, (5j) could 
be considered as the most active (S.I. value = 1.6) while (4a) and (5g) were the least 
active having S.I. value of 0.47. It is worthy to note that two compounds (4f) and (5j) 
were more active than the streptomycin as far as S. aureus screening was concerned. All 
other p-tolylsulphonamides were less active than streptomycin except (4i), which in this 
case, competed favourably with the streptomycin standard. Hence, ten p-
tolylsulphonamides exhibited moderate activity on S. aureus in a decreasing order as 
(4k) > (4g) > (4d) ≈ (4e) ≈ (4h) ≈ (5a) > (4j) > (5c) ≈ (5b) > (5d) (0.5 < S.I. < 0.8)
hereas lesser activity was exhibited by compounds (4c) > (4b) > (4a) ≈ (5g) (S.I. < 0.5). 
 
st
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Fig. 4.2: Antibacterial Activity of p-Tolylsulphonamides against Staphylococcus aureus 
 
Furthermore, in order to establish the lowest concentration at which the growth of 
E. coli and S. aureus was inhibited by p-tolylsulphonamide scaffolds, the MIC test was 
carried out and the result is as shown in Table 4.5. From the point of view of E. coli, the 
MIC values ranged from 12.5 μg/mL (5j) to 1000 μg/mL (4c) while the MIC value for 
streptomycin under similar condition was 6.25 μg/mL. Although, streptomycin was more 
active than any of the p-tolylsulphonamides, it was apparent that different p-
tolylsulphonamides exhibited varying MIC values against the strain of E. coli. Thus, the 
MIC values ranging from 12.5 μg/mL to 50 μg/mL was observable among (5j), (5d), (4k), 
(4d), (4e), (5a) and (5c); between 62.5 μg/mL and 100 μg/mL for (5b), (5g), (4f) and (4g)
etween 125 μg/mL and 500 μg/mL for (4a), (4b), (4i), (4h) and (4j) and the least 
 
; 
b
activity was observed in compound (4c) with an MIC value of 1000 μg/mL.  
 In addition, the MIC test for the series of p-tolylsulphonamides was carried out on 
S. aureus (Table 4.5) and it should be noted that the lowest MIC value culminated into 
highest potency (Sepandj et al., 2004). It is therefore paramount to note that the highest 
potency was observed in (5j) (MIC = 25 μg/mL) while compound (5g) exhibited the least 
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potency (MIC = 1000 μg/mL) on S. aureus. This is higher activity than one reported by 
Ghorab et al., (2004). From comparative study, many members of this group such as (4d), 
(4e), (4f), (4g), (4h), (4i), (4j), (4k), (5a) and (5j) (MIC = 25 μg/mL – 100 μg/mL) were 
more active than streptomycin (MIC = 125 μg/mL) using the MIC test involving S. 
aureus. Under the same condition, (5b) (MIC = 125 μg/mL) competed favorably with 
streptomycin in its inhibitory potential on S. aureus. Seven compounds (4d), (4e), (4g), 
h), (4(4 j), (4k) and (5a) had MIC value 100 μg/mL and other seven p-tolylsulphonamides 
(5b), (5c), (5d), (4a), (4b), (4c) and (5g) had MIC values between 125 μg/mL and 1000 
μg/mL.  
   
Table 4.5: MIC Test of p-Tolylsulphonamides on Targeted Organisms (μg/mL) 
rganisms 
ompd. No 
Minimum Inhibitory Concentration (μg/mL)  
O
 
C
E. coli ATCC 25922 S. aureus ATCC 6538 
@100μg/mL @1000μg/mL @100μg/mL @1000μg/mL 
(4a) > 100 125 > 100 250 
(4b) > 100 250 > 100 250 
(4c) > 100 1000 > 100 500 
(4d) 25 < 1000  100 < 1000 
(4e) 50 < 1000 100 < 1000 
(4f) 100 < 1000 50 < 1000 
(4g) 100 < 1000 100 < 1000 
(4h) > 100 500 100 < 1000 
(4i) > 100 250 62.5 < 1000 
(4j) > 100 500 100 < 1000 
(4k) 25 < 1000 0 100 < 100
(5a) 50 < 1000 100 < 1000 
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(5b) 62.5 < 1000 > 100 125 
(5c) 50 < 1000 > 100 250 
(5d) 25 < 1000 > 100 250 
(5g) 62.5  < 1000 > 100 1000 
(5j) 12.5 < 1000 25 < 1000 
Str. 6.25 < 1000 > 100 125 
>100 means that if there was no growth inhibition at 100 
μg/mL , <1000 μg/mL means that growth inhibition ha ady been ex d at 
lower concentration less than or equal to 100 μg/mL; h  there is no epeat the 
test at 1000 μg/mL. – means no activity was observed even at 1000 μg/mL. Str. means 
Strepto n clinical ce.  
 
(c) An robial vity of B lphonam p study of 
activity of the benzenesulphonam ith that streptomycin standard was 
commensurated using selectivity index on both E. coli and S. aureus. The selectivity 
index of benzenesulphonamide derivatives along side with that of streptomycin was 
evaluated on E. coli ( .3). The s y index o ries of sul ide varied 
from 0.97 to 0.31; hence, streptomy re active than all the benzenesulphonamide. 
tive 
he 
o extremists as shown in Fig. 4.3. They were categorized into most active (S.I. > 0.8), 
μg/mL, it was repeated at 1000 
s alre perience
ence, need to r
myci  referen
timic Acti enzenesu ides: The com arative 
ides w  of 
Fig. 4 electivit f this se phonam
cin is mo
Since increasing intensity of selectivity index connotes improved antibacterial activity; 
thus, the most active compound of this class was (7b) (S.I. = 0.97) while the least ac
was (8c) (S.I. = 0.31). The activities of other benzenesulphonamides were between t
tw
moderately active (0.6 < S.I. < 0.8) and least active (S.I. < 0.6). Bearing this classification 
in mind, it was noticeable that the occurrence of the most active scaffolds in a decreasing 
order of activity was (7b) ≈ (7k) > (7d) > (8a) ≈ (8g) > (8k) > 7i ≈ 8b > 7j; that of 
moderate activity was (7c) ≈ (7e) ≈ (7f) > (7g) whereas the least activity was in order of 
(7a) ≈ (7h) > (8c).  
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Fig. 4.3: Antibacterial Activity of Benzenesulphonamides against Escherichia coli 
 
 
 
Furthermore, the selectivity index of benzenesulphonamides was also investigated 
on S. aureus and the values varied from 1.6 to 0.28 (Fig. 4.4). In comparing with the 
activity of streptomycin, five compounds (7b), (7j), (7k), (8b) and (8k) were more active; 
one compound (7a) had invariably similar activity with the standard while all other 
compounds were less potent than streptomycin. Nevertheless, by comparing the trend of 
activity within the series, the highly active compounds in order of priority of potency 
were (7k) ≈ (8b) ≈ (8k) > (7b) ≈ (7j) > (7a) > (7f) > (7g) (0.95 < S.I. < 1.6); the moderate 
ve 
benzenesulphonamides (7e) > (7d) > (7c) ≈ (7i) > (7h) (0.28 < S.I. < 0.48) were the 
 activity.                   
 
 
activity was found in (8a) ≈ (8c) ≈ (8g) (S.I. = 0.62) while the remaining fi
series with least
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Fig. 4.4: Antibacterial Activity of Benzenesulphonamides against Staphylococcus aureus 
The minimum inhibitory concentration was determined in order to authenticate 
the actual concentration responsible for the benzenesulphonamide activity observed on 
both E. coli and S. aureus (Masunari et al., 2007). The result was as shown in Table 4.6. 
Thus, to start with, the lowest concentration of these sulphonamides that inhibited the 
growth of E. coli varied from 25 μg/mL to 1000 μg/mL. Hence, the compound that had 
highest potency was (8b) with MIC value of 25 μg/mL while the least active ones were 
(7e) and (7h) with MIC of 1000 μg/mL. Other sulphonamides exhibited the potency at 
diverse ranges. They were compounds (7b), (7d), (8a), (8g), (8k) and (7i) with MIC 
ulphonamide followed a peculiar trend in activity, as it was noticed that all the N,N-
disubst
 
value between 50 μg/mL and 100 μg/mL; (7a), (7f), (7g), (8c) and (7c). This class of 
s
ituted sulphonamides (8a), (8b), (8c), (8g) and (8k) showed better activity than 
their corresponding non-subsituted sulphonamides (7a), (7b), (7c), (7g) and (7k) 
according to Table 4.6. This was in line with earlier work of Dobek et al., (1980) which 
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reported that N,N-disubstituted thiosemicarbazone were more active than the non- and 
mono-substituted analogs.  
Considering the MIC test of benzenesulphonamides on the gram positive 
organism (S. aureus), it was observed that compounds (8k), (8b), (7j), (7k), (7f) and (7b) 
inhibited the microbial growth at varying MIC values ≤ 100 μg/mL; whereas, all other 
compounds were active on S. aureus at higher concentrations (between 125 μg/mL and 
1000 μg/mL). Specifically speaking, MIC value of the most potent in this series (8b) and 
(8k) on S. aureus was reported to be 25 μg/mL which were two fold more active than (7j), 
with MIC value of 50 μg/mL and four times more active than (7b) (100 μg/mL). The 
MIC value (7j) was reported to be 50 μg/mL which established it to be ten times more 
active than (7d), (7h) and (7i) with MIC value of 500 μg/mL. The compound with least 
activity was (7c) (1000 μg/mL). 
 
Table 4.6: MIC Test of Benzenesulphonamides on Targeted Organisms (μg/mL) 
 
Organisms 
 
Compd. No 
Minimum Inhibitory Concentration (μg/mL) 
E. coli S. aureus  ATCC 25922 ATCC 6538 
@100 g/mL @1000 g/mL @100 g/mL @1000 g/mL μ μ μ μ
(7a) >100 125 >100 125 
(7b) 50 < 1000 100 < 1000 
(7c) >100 500 >100 1000 
(7d) 50 < 1000 >100 500 
(7e) >100 1000 >100 250 
(7f) >100 125 62.5 < 1000 
(7g) >100 250 >100 250 
(7h) >100 500 >100 1000 
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(7i) 100 < 1000 >100 500 
(7j) 250 0 < 1000 50 < 100
(7k) 125 62.5 < 1000 < 1000 
(8a) 50 < 1000 >100 125 
(8b) 25 < 1000 25 < 1000 
(8c) >100 250 >100 250 
(8g) 50 < 1000 >100 125 
(8k) 
  0 62.5 < 1000 25 < 100
Str. 12.5 < 1000 >100 125 
>100 s that if there was no th inhibition at g/mL, it was repeated at 1000 
μg/mL , <1000 μg/mL means that growth inhibition has already been experienced at 
lower concentration less than or equal to 100 μg/mL , there is n d to repeat the 
test at 1000 μg/mL. – means no activity was observed even at 1000 μg/mL. Str. means 
Strep
 
 
 
 
 
 
 
 
 mean grow  100 μ
; hence o nee
tomycin clinical reference.  
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CHAPTER FIVE 
CONCLUSIONS AND RECOMMENDATIONS 
.1. Conclusions 
 summary, it was discovered that α-toluenesulphonamide derivatives had a reverse 
rder of behaviour in terms of solubility properties as compared with p-
luenesulphonamide and benzenesulphonamide derivatives. The α-toluenesulphonamide 
erivatives were perfectly soluble in water thereby making it difficult to isolate. This was 
n abnormal behaviour as it contradicted the long standing hydrophobic pattern of normal 
lphonamides which made them crystallizable from water by acidifying to low pH (2.2). 
Hence, of all the sulphonamides, th -toluenesulphonamide framework 
has always been a 
the synthesis of this targeted novel α-toluenesulphonamide derivatives 
namide derivatives (4a-k) via 
simple 
5
In
o
to
d
a
su
e one that involves α
great challenge to synthetic Chemists.  
However, 
(1a-k) in excellent yields was obtained for the first time to the best of our knowledge, by 
introducing freeze drying at the work-up stage in order to obtain the α-
toluenesulphonamide crystals since the acidification resulted in water-soluble 
sulphonamides. The proferred solution in this present work made the α-
toluenesulphonamide derivatives available in crystalline form for further work. The 
reaction of N,N-diethyl amine with α-toluenesulphonamides in the preparation of N,N-
diethylalkanamide substituted sulphonamides (2a-k) was carried out successfully. 
Furthermore, a convenient synthesis of p-toluenesulpho
and cheap sulphonylation technique was developed. In this research work, the 
design and development of p-toluenesulphonamide pharmacophores bearing amide that 
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has been disubstituted with ethyl group (N,N-diethylamido substituted sulphonamide) 
(5a-k) has been obtained in improved yields using variation of the amidation approach.  
 The synthesis of benzenesulphonamide derivatives (7a-k) was obtained from 
benzenesulphonyl chloride as the sulphonylation agent. Some of the 
benzenesulphonamide derivatives were already known, but the protocol used in this work 
gave better yields and simplified the procedure. The subsequent amidation of some 
benzenesulphonamide intermediates using diethyl amine, afforded the diethyl substituted 
amide bearing benzenesulphonamide scaffolds (8a), (8b), (8c), (8g)and (8k) as envisaged. 
The purification of the synthesized compounds was carried out using recrystallization and 
column chromatography, while characterization was carried out using elemental analysis 
ial activity 
and spectroscopic means, especially FT-IR, Mass Spectra, 1H- and 13C-NMR. 
 The compounds that were prepared were tested for their antimicrobial activity. 
The result of the antimicrobial activity of the series of sulphonamides revealed that they 
were very active on E. coli and S. aureus as the targeted organisms and some of them 
also competed favourable with a standard antibiotic (streptomycin) which was used as the 
clinical reference. The general sensitivity testing was evaluated using selectivity index 
which was obtainable from the zone of inhibition (Z O I) while the actual lowest 
concentration at which the inhibition took place was determined using MIC test. The 
results indicated the series of sulphonamide has broad spectrum of antimicrob
(against both gram positive and negative bacteria) with majority having moderate activity. 
The most active of all sulphonamides on S. aureus was (1a) (MIC = 1.8 (μg/mL) while 
the most active sulphonamide on E. coli was (2k) and (5j) (12.5 μg/mL). Interestingly, 
both compounds were from the α-toluenesulphonamide series. It is also interesting to 
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note that compound (1a) reported above was more active than streptomycin standard as 
far as potency against S. aureus was concerned. 
 
5.2. Recommendations 
 It is hereby recommended that further study should be carried out in order to 
establish and identify a new and facile approach toward achieving the benzofused 
heterocycle such as benzothiazepinone from intramolecular cyclization of the amide of 
various α-toluene sulphonamide. Due to abnormally high hydrophilicity of the α-
toluenesulphonamide derivatives, it is recommended that the work-up stage should be 
effected via lyophilization.  
The quest to getting the desired approach to obtain the cyclized compounds is a 
because it will lead to achieving new functionalized 
itude could not have been achieved without the help of latest 
spectro
worthwhile adventure 
benzothiazepinone which are heterocyclic framework of great interest in drug discovery 
and therapeutic agents design. This is so because it is known that cyclized compounds 
most time are more active that the acyclic ones. The new α-toluenesulphonamide 
derivatives are also good candidates for further study in terms of toxicological and other 
pharmacological screening.  
A work of this magn
scopic method for structural characterization which were not available in the 
home University. Hence, it is recommended that the University Management should help 
the Central instrumentation laboratory to purchase some of these instruments such as 
NMR and mass spectrometer in order to take α-toluenesulphonamide research and other 
scientific research to the next level. 
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APPENDICES 
e Derivatives 
ig. 5.1: H-NMR Spectrum of 1a 
 
1H-NMR Spectral Data of α-Tolylsulphonamid
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Fig. 5.2: 1H-NMR Spectrum of 1b 
 
 192
 
Fig. 5.3: 1H-NMR Spectrum of 1c 
 
 
 
 
 
 
Fig. 5.4: 1H-NMR Spectrum of 1d 
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Fig. 5.5: 1H-NMR Spectrum of 1e 
 
 
 
 
Fig. 5.6: 1H-NMR Spectrum of 1f 
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Fig. 5.7: 1H-NMR Spectrum of 1g 
 
 
 
 
 
Fig. 5.8: 1H-NMR Spectrum of 1h 
 
 
 
 
 
 
 195
Fig. 5.9: 1H-NMR Spectrum of 1i 
 
 
 
 
 
 
 
Fig. 5.10: 1H-NMR Spectrum of 1j 
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Fig. 5.11: 1H-NMR Spectrum of 1k 
 
 
 
 
Fig. 5.12: 1H-NMR Spectrum of 2a 
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Fig. 5.13: 1H-NMR Spectrum of 2b 
 
 
 
 
Fig. 5.14: 1H-NMR Spectrum of 2c 
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Fig. 5.15: 1H-NMR Spectrum of 2d 
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Fig. 5.16: 1H-NMR Spectrum of 2e 
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Fig. 5.17: 1H-NMR Spectrum of 2f 
 
 
 
 
Fig. 5.18: 1H-NMR Spectrum of 2g 
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Fig. 5.19: 1H-NMR Spectrum of 2h 
 
 
1H-NMR Spectrum of 2i 
 
 
 
 
Fig. 5.20: 
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Fig. 5.21: 1H-NMR Spectrum of 2j 
 
 
 
 
 
Fig. 5.22: 1H-NMR Spectrum of 2k 
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13C-NMR Spectral Data of α-Tolylsulphonamide Derivatives 
Fig. 5.23: 13C-NMR Spectrum of 1a 
 
 
Fig. 5.24: 13C-NMR Spectrum of 1b 
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Fig. 5.25: 13C-NMR Spectrum of 1c 
 
 
 
Fig. 5.26: 13C-NMR Spectrum of 1d 
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Fig. 5.27: 13C-NMR Spectrum of 1e 
 
 
 
Fig. 5.28: 13C-NMR Spectrum of 1f 
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Fig. 5.29: 13C-NMR Spectrum of 1g 
 
 
 
 
 
 
Fig. 5.30: 13C-NMR Spectrum of 1h 
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Fig. 5.31: 13C-NMR Spectrum of 1i 
 
 
 
Fig. 5.32: 13C-NMR Spectrum of 1j 
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Fig. 5.33: 13C-NMR Spectrum of 1j (Expanded in Aromatic Region) 
 
 
 
 
Fig. 5.34: 13C-NMR Spectrum of 1k 
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Fig. 5.35: 13C-NMR Spectrum of 2a 
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Fig. 5.36: 13C-NMR Spectrum of 2b 
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Fig. 5.37: 13C-NMR Spectrum of 2c 
 
 
 
 
 
Fig. 5.38: 13C-NMR Spectrum of 2d 
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Fig. 5.39: 13C-NMR Spectrum of 2e 
 
 
Fig. 5.40: 13C-NMR Spectrum of 2f 
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Fig. 5.41: 13C-NMR Spectrum of 2g 
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Fig. 5.42: 13C-NMR Spectrum of 2h 
 
 
 212
ig. 5.43: 13C-NMR Spectrum of 2i F
 
 
ig. 5.44: 13C-NMR Spectrum of 2j 
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Fig. 5.45: 13C-NMR Spectrum of 2j (Expanded in Aromatic Region) 
 
 
 
 
Fig. 5.46: 13C-NMR Spectrum of 2k 
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Infrared Spectral Data of α-Tolylsulphonamide Derivatives 
 
Fig. 5.47: IR Spectrum of 1a 
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ig. 5.48: IR Spectrum of 1b F
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Fig. 5.49: IR Spectrum of 1c 
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Fig. 5.50: IR Spectrum of 1d 
500 1000 1500 2000 2500 3000 3500 4000
20
30
40
50
60
70
15
98
.7
56
3.
2
69
8.
2
79
4.
7
10
37
.7
11
68
.9
12
13
.2
14
54
.3
17
51
.4
24
86
.2
28
21
.9
29
74
.2
34
23
.6
Tr
an
sm
itt
an
ce
 (%
)
W ave Num ber (cm -1)
 
 216
Fig. 5.51: IR Spectrum of 1e 
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Fig. 5.52: IR Spectrum of 1f 
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Fig. 5.53: IR Spectrum of 1g 
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Fig. 5.54: IR Spectrum of 1h 
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Fig. 5.55: IR Spectrum of 1i 
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Fig. 5.56: IR Spectrum of 1j 
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Fig. 5.57: IR Spectrum of 1k 
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Fig. 5.58: IR Spectrum of 2b 
500 1000 1500 2000 2500 3000 3500 4000
0
10
20
30
40
50
60
52
2.
7
69
6.
3
10
58
.9
11
47
.6
11
88
.1
14
08
.0
15
93
.2
17
19
.8
29
51
.1
30
28
.2
Tr
an
sm
itt
an
ce
 (%
)
Wave Number (cm -1)
 
 220
Fig. 5.59: IR Spectrum of 2c 
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ig. 5.60: IR Spectrum of 2d F
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Fig. 5.61: IR Spectrum of 2e 
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Fig. 5.62: IR Spectrum of 2f 
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Fig. 5.63: IR Spectrum of 2g 
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Fig. 5.64: IR Spectrum of 2h 
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Fig. 5.65: IR Spectrum of 2i 
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Fig. 5.66: IR Spectrum of 2j 
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Fig. 5.67: IR Spectrum of 2k 
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Mass Spectral Data of α-Tolylsulphonamide Derivatives 
 
Fig. 5.68: Mass Spectrum of 1a 
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Fig. 5.69: Mass Spectrum of 1b 
 
 
 
 
 
Fig. 5.70: Mass Spectrum of 1c 
 
 
 226
 
Fig. 5.71: Mass Spectrum of 1e 
 
 
 
Fig. 5.72: Mass Spectrum of 1g 
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Fig. 5.73: Mass Spectrum of 1j 
 
 
 
Fig. 5.74: Mass Spectrum of 1k 
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1H-NMR Spectral Data of p-Tolylsulphonamide Derivatives 
Fig. 5.75: 1H-NMR Spectrum of 4a 
 
 
Fig. 5.76: 1H-NMR Spectrum of 4b 
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Fig. 5.77: 1H-NMR Spectrum of 4c 
 
 
 
Fig. 5.78: 1H-NMR Spectrum of 4d 
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Fig. 5.79: 1H-NMR Spectrum of 4f 
 
 
 
 
Fig. 5.80: 1H-NMR Spectrum of 4g 
 
 231
Fig. 5.81: 1H-NMR Spectrum of 4h 
 
 
 
 
Fig. 5.82: 1H-NMR Spectrum of 4i 
 232
 
Fig. 5.83: 1H-NMR Spectrum of 4j 
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Fig. 5.84: 1H-NMR Spectrum of 4k 
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Fig. 5.85: 1H-NMR Spectrum of 5a 
 
 
 
 
Fig. 5.86: 1H-NMR Spectrum of 5b 
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Fig. 5.87: 1H-NMR Spectrum of 5c 
 
 
 
 
Fig. 5.88: 1H-NMR Spectrum of 5d 
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Fig. 5.89: 1H-NMR Spectrum of 5g 
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Fig. 5.90: 1H-NMR Spectrum of 5j 
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Fig. 5.91: 13C-NMR Spectrum of 4b 
 
 
Fig. 5.92: 13C-NMR Spectrum of 4j 
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Fig. 5.93: 13C-NMR Spectrum of 4k 
 
 
 
Infrared Spectral Data of p-Tolylsulphonamide Derivatives 
Fig. 5.94: IR Spectrum of 4a 
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Fig. 5.95: IR Spectrum of 4c 
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Fig. 5.96: IR Spectrum of 4d 
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Fig. 5.97: IR Spectrum of 4e 
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Fig. 5.98: IR Spectrum of 4f 
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Fig. 5.99: IR Spectrum of 4g 
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Fig. 5.100: IR Spectrum of 4h
500 1000 1500 2000 2500 3000 3500 4000
45
50
55
60
65
70
10
31
.9
82
3.
6
54
3.
9
67
3.
2
91
0.
4
10
89
.8
11
66
.9
12
73
.0
13
42
.5
14
54
.3 15
95
.1
16
97
.4
19
55
.8
24
78
.5
29
76
.2
32
61
.6
33
60
.0
34
35
.2
35
00
.8
Tr
an
sm
itt
an
ce
 (%
)
W ave  N um ber (cm -1)
 
 241
Fig. 5.101: IR Spectrum of 4i 
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Fig. 5.102: IR Spectrum of 4j 
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Fig. 5.103: IR Spectrum of 4k 
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Fig. 5.104: IR Spectrum of 5a   
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Fig. 5.105: IR Spectrum of 5c 
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Fig. 5.106: IR Spectrum of 5d 
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 Fig. 5.107: IR Spectrum of 5j 
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(a) Calculation of Selectivity Index 
 
 
(b) Preparation of 20% HCl (v/v) 
20 mL of conc. HCl was added to small amount of distilled water and made up to mark in 
100 mL standard flask with distlled water. 
 
(c) Preparation of Buffer Solution (pH 2.2) 
25 mL of 0.2 M potassium hydrogen phthalate (KHP) was mixed with 20.35 mL of 0.2 M 
HCl  and the mixture was made up to mark in 100 mL standard flask with distilled water. 
 
(d) Preparation of Lithium Diisopropylamide (LDA) 
Disopropyl amine, i-Pr2NH (0.57 mL, 4 mmol) was added to dry THF (20 mL) in an air-
tighted quick fit flask with continuous stirring at room temperature. It was allowed to 
ool to -78oC and n-BuLi (1.82 mL of a 2.2 M solution, 4 mmol) was added with the aid 
perature for 20 mins. prior to use.  
c
of cannula and stirred at same tem
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